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ABSTRACT 
This thesis is an in-depth case study of an interdisciplinary, paradigm breaking, 
research team who are seeking to develop cultured red blood cells (RBCs) for 
transfusion using stem cells (known as the BloodPharma project). It answers the 
research question: What can an in-depth case study of the BloodPharma project 
reveal about everyday scientific practice and the project management of a large 
research programme? The BloodPharma project occupies a unique position within 
the stem cell arena due to the size and multi-disciplinary nature of the project team, 
and the unique risk profile of cultured RBCs. The historical significance of blood 
donation is combined with the modern innovation of stem cell usage, to create a 
product which is both novel but also highly emotive.  
 
The case study comprises interviews with a range of stakeholders, laboratory 
observation, and participant observation of public outreach activities. In addition 
presence at team meetings and teleconferences has allowed an in-depth analysis of 
the project progression. The thesis has also drawn heavily on science and technology 
studies and scientific literature, as well as on information gathered from a wide 
variety of conferences and workshops.  
 
Key findings indicate that early stage laboratory work in this interdisciplinary project 
is achieved through the standardisation of work across different research spaces, with 
training and visual aids used to overcome the hurdle of tacit knowledge associated 
with the development of stem cell technologies. In designing early stage laboratory 
work the team looked to the human body as a benchmark of in vivo RBC production, 
using in vivo cells as a dual standard for which the team must aim, but cannot fall 
short of. Scale-up and standardisation were identified as the key challenges to the 
translation of this early stage laboratory work into a clinically useable product. These 
challenges require new expertise and innovation, and are an example of the 
translational obstacles of tacit knowledge and visual techniques which are found in 
the wider stem cell field. The use of target markets was identified by the team as a 
stepping stone to larger scale production, although in common with other stem cell 
therapies the clinical trials route to first-in-human use is still unclear. The uncertainty 
of regulation for stem cell products, and specifically how this relates to the 
BloodPharma project, is also a key finding of this thesis. Interactions with the 
regulatory system are seen as a necessity but also represent an area of confusion for 
laboratory researchers, requiring much specialist knowledge to understand and 
navigate regulatory documents. Regulatory expertise is brought to the BloodPharma 
project through reliance on particular members of staff. Public outreach has formed 
an important part of the BloodPharma project and shows the scientists stepping 
outside their primary area of expertise, a reflection of the broader trend amongst 
academic research to demonstrate ‘broader impact criteria’. Public outreach for the 
BloodPharma team was found to occupy a unique niche, given that the team must 
balance the promotion of a future product with the preservation of the current 
donation system.  
 
This research is of a case study which goes beyond the boundaries of the laboratory, 
to look not only at early stage laboratory work, but also at the way in which the team 
envisions future translation and regulatory hurdles, and the public outreach which 
must combine to develop a novel stem cell therapy. The thesis is the first in-depth 
case study to follow a large, interdisciplinary, stem cell team through the work they 
carry out both within the laboratory space, and outside it; challenging the idea of 
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CHAPTER 1: INTRODUCTION 
INTRODUCTION 
This thesis is an in-depth case study of a paradigm breaking, multi-sited, 
interdisciplinary research team carrying out innovation in an area of high uncertainty, 
where control over biological processes, team-work, regulatory and public interest 
issues are intrinsically connected with the laboratory science. It is a case study of a 
team of scientists who are carrying out laboratory work which has the potential for 
new product development, but whose work also takes them outside the laboratory. 
The key research question of the thesis is: What can an in-depth case study of the 
BloodPharma project reveal about everyday scientific practice and the project 
management of a large research programme?  
 
Many years of investment in basic stem cell research has yet to yield more than a 
small number of clinical therapies. As such the innovation and regulatory pathways 
(for example the clinical trials template) are still uncertain, and concrete examples of 
everyday innovation practices are lacking. An in-depth case study of a particular 
case, in this instance the BloodPharma project, will contribute to an understanding of 
the hurdles and challenges faced by a research team. This thesis will analyse the 
practices of this visionary research team as it seeks to develop a stem cell therapy 
from basic research to clinical use, providing an in-depth case study of a real team 
and the implications for its everyday actions. 
 
The case study for this thesis is a multi-centre, interdisciplinary, collaborative team 
that is undertaking a scientific research project to develop cultured red blood cells 
(RBCs) from stem cells, known as the BloodPharma project. RBC transfusions in the 
UK are currently obtained from altruistic donors, however supply is limited and there 
is an ongoing risk of infection transmission. Previous attempts to create alternative 
blood sources have mostly been unsuccessful and there is currently no clinical 
substitute for RBCs. In 2009 the BloodPharma project was awarded £3million 
funding by the Wellcome Trust to develop an alternative method of blood 
production. If successful the technology will allow an unlimited number of RBCs to 


be produced, free of infection and of a blood type suitable for the majority of the 
recipient population. It is hoped that cultured RBCs may negate the need for human 
blood donation, or provide an enhanced treatment for patients with certain blood 
disorders. 
 
Blood transfusion as a medical technique in its current form has been practised for 
around 100 years and has become a vital component of modern medicine. It is 
therefore necessary to situate the new technique of culturing RBCs as both a 
continuation and reformation of a widely used and accepted practice. This case study 
is about the important period of transition from an existing, well used and publicly 
accepted technology to a new technology that may have huge consequences. It is also 
the story of a team seeking to develop a clinical stem cell therapy in the face of 
uncertainty about future scale-up and regulation. Blood is currently donated 
altruistically and tested, processed, fractionated and supplied to those who need it. In 
the future blood may be a stem cell product that reduces reliance on blood donors 
and supplies a continuous source of safe, standardised blood that is cultured in the 
laboratory. Cultured RBCs could potentially lead to a revolutionary change in the 
way that blood is produced, stored and distributed, as well as bringing additional 
benefits to patients. Currently these cultured cells are produced from stem cells, a 
technique which could also have a disruptive effect on public attitudes towards future 
blood transfusion technologies.  
 
The empirical data for this thesis have been gathered over three years and comprise 
interview, laboratory observation and participant observation data. I have been 
allowed access to all stages of the project and this thesis brings insight into the world 
of clinical stem cell therapy development. The BloodPharma project represents a 
unique example in the wider arena of stem cell therapy development. The team is 
attempting to replace a product which already has an accepted alternative in 
conventional blood donation. This gives the team a benchmark for their work, and 
also a regulatory hurdle in having to justify the replacement of an established 
practice. The project comprises teams in multiple laboratories across the UK and 
Ireland. The structure of the team is therefore unusual, for example there are six 

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principal investigators named on the project grant. Finally, unlike other stem cell 
therapies, which are designed for small numbers of recipients or which use relatively 
small numbers of cells, the BloodPharma project must anticipate an enormous 
challenge of production and scale-up. Each unit of blood requires around two trillion 
RBCs, and the UK alone uses two million units of blood a year.  
 
The Key Research Questions  
This thesis provides an analysis of the Project team as it navigates the early stage 
development of the cultured blood product, and is driven by five key research 
questions. These will be explained in more detail along with the sub-questions 
identified.  
1. How is early stage laboratory work achieved through interdisciplinary, 
multi-lab working, where standardisation of methods is difficult and where 
there exists an accepted technology?   
The BloodPharma team is spread across different laboratories within the UK and 
Ireland, and with a mix of primary disciplines within the team. This question seeks to 
explore how these smaller teams co-ordinate the production of a novel therapy. By 
their very nature stem cells can form different tissues types and control is difficult. 
Tacit knowledge and expertise is therefore a vital part of standardising work across 
different laboratory spaces. The BloodPharma team has an existing product in the 
form of donated blood, which acts as a benchmark for early stage laboratory work.  
• What are the challenges of working across multiple sites and different 
disciplinary areas? 
• How important is tacit knowledge in early stage laboratory practices?  
• What role does a natural/synthetic distinction play and how does the team use the 
human body as an exemplar? 
• To what extent does the team envision future product development pathways at 
an early stage of the research? 
 
2. What does the Team see as the key challenges associated with translating 




The scale-up and automation associated with the BloodPharma project makes this a 
unique case amongst stem cell derived products. Uncertainties exist in the potential 
clinical trial regime for stem cell products, which can impact on the ability of 
researchers to forward plan. Nevertheless suitable target populations have had to be 
identified and uses imagined beyond the production of the initial product.  
• What are the particular challenges of scale-up and automation within the 
BloodPharma Project? 
• How do uncertainties in the clinical trial regime for stem cells impact on the 
planning of potential trials for the BloodPharma product? 
• What are the markets for this product and to what extent does the team think 
beyond this initial product goal? 
 
3. How does the regulatory system, and perceptions of risk, shape the activities 
of the BloodPharma team and the development of the cultured blood 
product, and what can this case study tell us more generally about the 
regulatory system for stem cell products? 
The regulatory system for stem cell research in the UK is complex and has been built 
on previous legislation designed in the wake of particular historical events. The 
BloodPharma team must navigate this system which requires its own particular set of 
knowledge and expertise. The BloodPharma product will bring specific risks, which 
will impact on how it is perceived by the regulators, and on the specific hurdles 
which the team must overcome. Studying this example will provide more 
information about how the regulatory system for stem cells is working in practice 
across the wider regenerative medicine arena.   
• What can the history of regulation for stem cells tell us about the regulation of 
the BloodPharma product?  
• How does the BloodPharma team navigate the regulatory system, and what 
particular knowledge and expertise does it have to acquire? 
• How do the anticipated risks associated with this cultured blood product impact 




4. What are the main drivers and motivators behind the BloodPharma team 
engaging with public outreach, and how do the scientists respond to their 
own role as public communicators?  
Public communication is becoming an integral part of the modern day research 
community and a requirement of many funding awards. For many basic laboratory 
scientists this represents a new area of expertise with which they must engage. The 
BloodPharma project brings with it unique challenges to downstream engagement, 
whilst also balancing the current needs of the Blood Transfusion Services.  
• What expectations do the team have in undertaking public outreach and what are 
the different reasons for them performing this activity? 
• What specific activities were carried out and how did the results of these impact 
on the team’s thinking about its product?  
• How do the scientists experience their own role as public communicators? 
• What are the specific challenges for up-stream engagement in this project?  
 
The rest of this chapter will provide a background to the work of the BloodPharma 
team, situating it within the context of current clinical usage of donor blood 
transfusion. It will provide an overview of the historical development of blood 
donation and will show that the current practice of blood transfusion has changed 
little since the method entered everyday clinical usage. A synopsis of each chapter 
will then be provided.  
 
SITUATING THE BLOODPHARMA PROJECT WITHIN THE HISTORICAL 
CONTEXT OF DONOR BLOOD TRANSFUSION  
Blood has been revered for thousands of years and has come over the last century to 
be associated with the practice of human blood donation and transfusion. The 
BloodPharma project, if successful, has the ability to change society’s relationship 
with human blood in the space of a decade. In fifty years time it may seem 
inconceivable that our medical system once relied on human donors to supply such a 
vital product. Blood has often been attributed cultural and symbolic significance, as 
is the colour red with which blood is often associated. Greek mythology tells of the 
red rose growing from the blood of Adonis, whilst the Christian religion brought 

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with it a strong association with blood as a ‘life-giving force’. Conversely stories of 
vampires portray creatures who seek to drain the blood of humans. On a couple of 
occasions I have heard clinicians talk of phlebotomists as ‘vampires’, in the context 
of calculating how much blood would be required from critically ill patients 
undergoing tests. In more modern times the colour red has been associated with the 
ribbons worn in support of HIV/AIDS victims.  
 
The practice of draining blood from a patient, bloodletting, was first recorded in 
430BC and remained a common practice until the nineteenth century (Giangrande, 
2000). Bloodletting was considered to relieve many conditions, including fevers, 
back pain, madness, headaches, hypertension and ‘going into decline’ (Starr, 1999, 
pg.17). Although bloodletting was carried out by skilled professionals a greater 
knowledge of the vascular system was required for blood transfusions. The 
publication of William Harvey’s book ‘De Motu Cordis’ (‘On the motion of the heart 
and blood’) in 1628 represented a step forward in the understanding of the 
circulatory system, and led to the first transfusion experiments. It is generally 
accepted that Richard Lower carried out the first transfusion from animal to animal 
in 1665, which appears to mark the beginning of a trend in transfusion experiments 
(Brown, 1948). Thomas Coxe’s (1666-1667) paper describes his experiment to bleed 
a mangy dog into a healthy dog. The result being no difference in the healthy dog but 
the mangy dog was cured within two weeks (apparently due to being drained of ‘14 
or 16 ounces’ of blood). Coxe writes that the considerable loss of blood the dog 
underwent was “perhaps the quickest and surest remedy for the cure of that sort of 
disease, he was infected with, both in man and beast” (Coxe, 1666-1667, pg.3).  
 
Although this experiment demonstrated the transfer of blood from one animal to 
another its outcome appears to focus on supporting the long held idea that blood loss 
could affect a cure, showing that the old views on bloodletting would take time to be 
abandoned. It was also widely accepted that characteristics were contained within the 
blood; so many experiments took place transfusing the blood of docile animals (such 
as lambs) into humans, with the hope of curing madness (Brown, 1948). In many 
cases this appeared to succeed, probably because the subsequent shock reaction left 

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the patients too ill to move. Jean Denis published a series of pamphlets giving details 
of experiments in which the blood of lambs cured lethargy and fever. Unfortunately 
at the end of 1667 it transpired that one of the men mentioned in Denis’ accounts had 
subsequently died as a result of the transfusion experiment, and the public outcry 
effectively put a stop to this fledgling technology for the next 100 years (Brown, 
1948, pg.7). Denis was eventually exonerated of any wrongdoing, reports suggesting 
that the patient’s wife had found his recovery rather irritating and so poisoned him. 
 
The start of modern transfusion medicine is credited to James Blundell in 1818, who 
recognised the need to transfuse humans only with human blood. It was not, 
however, until the work of Karl Landsteiner in 1901 that the first published results of 
blood types were made (Landsteiner, 1901) and routine blood typing was not 
practised until the 1920’s (with the Rhesus positive and negative blood identified in 
1941) (Landsteiner and Wiener, 1941). Without anticoagulants transfusion of large 
quantities of blood was difficult and early techniques relied on connecting the vein of 
the donor to the artery of the recipient or stirring the blood to prevent clotting. 
Richard Lewinsohn is accredited with first introducing sodium citrate to medical 
transfusions in 1915 (Giangrande, 2000), and citrate-phosphate-dextrose is now the 
normal anticoagulant used for long term blood storage. In 1921 the first blood bank 
was set up in London by Percy Oliver, after the branch of the Red Cross for which he 
was secretary received a call for blood donors. He had the idea of setting up a list of 
donors who could be called upon at short notice, as anticoagulant use was not 
widespread so donors were required to attend the hospital and often be in the same 
room as the recipient. (Giangrande, 2000). In 1937 Bernard Fantus set up the blood 
bank as we now know it, with blood refrigerated for up to ten days.  
 
Other donation centres sprung up but most of these paid donors for their blood, a 
donation model which spread across most of the world. The Second World War 
provided the catalyst for many improvements in the collection, storage and 
transportation of blood (Edwards and Davie, 1940), with the British army 
abandoning the practice of extracting blood from soldiers at the front and instead 
supplying fighting units with stored blood transfusions. It was also around this time 
	
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that work started on obtaining products from fractionated blood, such as albumin, 
used to treat burns victims, and immunoglobulins used to treat infectious diseases. 
The war provided not just the need for such products but also the urgency that 
allowed many experimental products to be used without being rigorously tested. 
Although some adverse effects were reported it is likely this saved many lives, with 
one such product developed being factor VIII, which became vital in the treatment of 
haemophilia. 
 
Today blood is one of medicines’ ‘most vital commodities’ with a price many 
hundred times that of crude oil (Starr, 1999, pg.x). It is used in many forms, from 
whole blood transfusions to direct infusion of RBCs, white blood cells, antibodies, 
clotting factors, and plasma. Blood transfusions allow surgeons to overcome the 
inevitable blood loss during surgery and blood fractionation products are used to 
treat a range of blood based diseases such as haemophilia (Schneider, 2003). Many 
surgical techniques, such as open heart surgery, require large amounts of blood and 
could not have been developed without a reliable blood supply. The modern day 
process for blood collection and distribution is an extremely streamlined and efficient 
process, with donor and recipient safety the priority. Despite improvements in 
machinery, testing techniques, and storage times the basic process of transfusion 
remains the same, with blood collected from donors, processed, stored and then 
transfused to the recipient. Preventing the spread of transmissible diseases (often 
known as Transfusion-Transmissible Infections, TTIs) from donor to recipient is a 
priority and the UK system operates a self-selection policy, ensuring many 
unsuitable donors do not present themselves at a donation centre. If a donor is 
considered suitable they will donate a unit of whole blood1 (about 470ml, roughly the 
same as the old ‘pint’ of blood). After donation the blood is processed, with whole 
blood donations being separated into their constituent parts. RBCs are subsequently 
tested for blood type and infection and are then packaged and stored for use. Whole 
                                            
1 There is also the option for donors to give component donations, although the vast majority 
of donations collected in the UK are still of whole blood. These component donors are 
connected to machines similar to a kidney dialysis machine. Components (plasma, platelets, 
red cells or white cells) are removed as needed and the remainder of the blood is retuned to 





blood transfusions are very rare in the UK, with most ‘blood’ transfusions being 
composed of red cells re-suspended in a carrying liquid.  
 
For the purposes of this study donated blood technology is seen as the conventional 
and established technology, well defined, familiar and publicly acceptable. However 
blood transfusion could still be considered a technology in its infancy. Documented 
evidence has shown bloodletting to have been practised for almost two millennia, 
whilst a working knowledge of the human vascular system is barely 400 years old. 
The ‘established’ technology of clinical blood transfusion has actually been 
developed during living memory, although knowledge has advanced rapidly during 
this time. In less than 100 years it has moved from a very basic knowledge of blood 
typing to a system supplying millions of units every year, and blood transfusion has 
become publicly acceptable, with donors developing great attachment to the altruistic 
donation model employed in the UK. The current transfusion technology presented 
here may yet be replaced with the anticipated technology of cultured RBCs, negating 
the need for the vast majority of blood donors. The need for an alternative blood 
donation source is now more pressing, as the transfusion services are approaching a 
crisis point in their ability to provide the huge amount of blood required in current 
clinical practice. For example the SNBTS 2008 consultation (NHS, 2008) stated 
“[The] SNBTS currently has a shortfall of 16,000 active blood donors required to 
support the current targets for blood collection, resulting in an increasing reliance 
on existing donors coming more frequently”.  
 
The UK has an established and effective blood donation system but there are still 
challenges, both to the UK blood transfusion services and in the rest of the world, 
which highlight the need for the new cultured blood product being developed by the 
BloodPharma team. Contamination of donated blood with transferable diseases is 
one of the biggest hurdles to be faced by the blood transfusion services. The transfer 
of hepatitis from donor to recipient was an ongoing problem for many years (Starr, 
1999, pg.216), however more widely publicised was the HIV contamination of 
plasma products, which was first recognised in the early 1980’s and affected many 
haemophiliacs (Starr, 1999, pg.262). The authorities were slow to inform patients or 
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withdraw infected batches, which Starr (1999, pg.130) attributes to the reverence 
given to blood and its symbolic nature as a social gift, rather than a pharmaceutical 
product. In 2011 the public hearings for the Penrose Inquiry took place in Edinburgh. 
The Penrose Inquiry is the ‘Scottish Public Inquiry into Hepatitis C/HIV acquired 
infection from NHS treatment in Scotland with blood and blood products’ (The 
Penrose Inquiry, 2010). The inquiry sought to investigate the systems in place for 
collecting, testing and processing blood and blood products in Scotland, and for 
informing patients of possible contaminations. A large amount of blood testing is 
currently required to prevent future outbreaks of transmissible infections. Even in 
established blood donation systems the price of blood continues to rise as more 
extensive testing is implemented, at America’s Blood Centres the price of a unit 
trebled between 1994 and 2004 (Ferguson, Prowse et al., 2008).  
 
Acquiring adequate donors is another major hurdle faced by the transfusion services, 
with donor numbers falling and the UK transfusion services appearing to be heading 
towards a recruitment crisis. Currently only 4% of the UK population are registered 
blood donors (National Health Service, n.d). The Scottish National Blood 
Transfusion Service expressed a need to raise the donor levels from 175,000 in 2008 
to 210,000 in 2010, in order to safeguard the transfusion service (NHS, 2008). 
Fluctuations in donor numbers do occur throughout the year and these fall into two 
categories - those that can be prepared for (such as the drop in donors during the 
summer and around Christmas) which to some extent can be minimised by donor 
campaigns, and those that cannot be avoided, such as a major flu outbreak. Various 
proposals have been made in an attempt to raise donor numbers, with donor 
recruitment campaigns often used in an effort to overcome the donor shortage. 
Members of the Scottish Government have also called for workers to be given paid 
leave in order to donate blood (Unknown, 2010). Currently there is a lifetime ban on 
donation for men who have sex with men, a situation that is likely to change in the 
near future, with  studies showing that in Australia changing the deferral time from 5 
years to 1 year after male-to-male sexual intercourse did not result in an increase in 
HIV in blood donations (Seed, Kiely et al., 2010). In recent years there has been 
debate over the accuracy of the haemoglobin finger-prick tests that are used to 
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determine if a donor has an acceptable haemoglobin level. Some researchers argue 
that the haemoglobin in the peripheral blood is not an accurate representation of the 
levels present in the venous blood (Morris, Ruel et al., 1999; Radtke, Polat et al., 
2005). The SNBTS Consultation Document of 2008 states that implementation of 
new safety guidelines raising the acceptable haemoglobin count resulted in a loss of 
10,000 donors per year (NHS, 2008).  
 
Patients with certain blood conditions, including sickle cell anaemia and thalassemia 
require regular blood transfusions (Wayne, Kevy et al., 1993) and represent a 
different type of challenge to the blood transfusion system. Regularly transfused 
patients need blood that is a well matched as possible to the patient’s blood type, in 
order to prevent immune rejection (Cox, Steane et al., 1988). Finding such blood can 
be challenging, as sickle cell anaemia is prevalent in groups from sub-Saharan 
Africa, India and the Middle East (Aidoo, Terlouw et al., 2002) and thalassemia from 
Mediterranean areas (Al-Awamy, 2000). The highest chance of matching blood 
correctly comes from donors with a similar genetic background, yet such donors are 
not only a minority in the UK population but are underrepresented in the UK 
transfusion services, both on blood, cord blood, and organ donation registers (NHS 
Blood and Transplant, 2010). The website of the UK Blood Transfusion Service 
(www.blood.co.uk) specifically appeals for blood donors from Black and Minority 
Ethnic groups (BME). The potential impact of the BloodPharma cultured blood on 
such user groups is discussed further in Chapter Four.  
 
A number of innovations have been proposed to overcome the dual challenges of 
donor recruitment and possible infection risk. Few of these potential solutions have 
made it into mainstream medical practice and there still remain hurdles to overcome. 
There have been previous developments in the blood products industry, such as the 
use of recombinant DNA technology to provide Factor VIII, which show that an 
appropriate alternative technology can quickly become assimilated into mainstream 
practice. Therefore one focus has been on alternative methods that may replace, or 
lessen the need for, products acquired from conventional blood donations. These 
include temporary oxygen carriers (either based on processed haemoglobin or using 
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perflurocarbons), growth factors, clotting agents, thrombolysis inhibitors (which 
prevent the breakdown of blood clots), and autologous donation (through cell salvage 
or pre-operative donation) (Ferguson et al., 2008). Epoetin is also used to boost the 
RBC count of patients before surgery (Martyn, Farmer et al., 2002). Haemoglobin-
Based Oxygen Carriers (HBOCs), derived from human or animal blood (Silverman, 
Weiskopf et al., 2009) and Perfluorocarbons (PFCs), which are synthetic oxygen 
carriers (Cohn and Cushing, 2009), were heralded as an alternative to RBC 
transfusion. Unfortunately neither product performed well in clinical trials and are 
not licensed for use in the UK or USA, although Hemopure is licensed for use in 
South Africa (Henkel-Honke and Oleck, 2007; Grethlein and Rajan, 2012).  
 
These alternative methods of replacing blood have other drawbacks; one is that 
agents such as haemoglobin-based oxygen carriers still require donated blood and the 
second is a more social issue that the public perceive the use of ‘blood substitutes’ to 
be more risky. Ferguson et al. (2008) found that the public viewed blood substitutes 
as a ‘substandard replacement’ for actual blood, an unnatural and synthetic 
alternative, although the writers argue that this view may be changed by a more 
effective ‘marketing’ of alternative blood products. Other research on blood and 
blood substitutes has identified a greater acceptability of blood substitutes amongst 
medical professionals, when compared to journalists or blood donors (Lowe, Farrell 
et al., 2001). There was also a marked difference between the risk levels perceived 
by these groups concerning the infection rates through donation. 
 
The historical significance of blood donation and the present challenges facing the 
supply of donated blood have been discussed here, so that the BloodPharma project 
can be viewed within the context of the wider blood transfusion field. The 
BloodPharma project was originally set up in response to a funding call from the 
American Defence Advanced Research Projects Agency (DARPA), which was 
seeking to develop a method of producing blood in battlefield situations. The British 
team was not successful but realised that the expertise available would allow it to 
carry out the proposed project in the UK, which was then developed into the 
Wellcome Trust funded BloodPharma project. The project is a collaboration between 
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a variety of research teams and centres, including Roslin Cells, The Universities of 
Edinburgh and Glasgow, the Scottish National Blood Transfusion Service (SNBTS), 
the Medical Research Council (MRC) Centre for Regenerative Medicine, NHS 
Blood and Transplant, and the Irish Transfusion Service. The researchers are based at 
various locations around Edinburgh, as well as in Glasgow, Bristol and Dublin, and 
more recently Dundee. This collaborative approach makes the BloodPharma project 
an interesting study of not just how research is carried out within one scientific team, 
but how different teams collaborate to overcome the challenges associated with 
working across multiple research spaces. The BloodPharma project is officially titled 
‘Proof of principle: human embryonic stem cell derived red cell concentrates for 
clinical transfusion’. The project goal is to develop a technology that will allow 
RBCs to be cultured in the laboratory, eventually providing a limitless and infection 
free source of blood for transfusion. The project was awarded £2.9million by the 
Wellcome Trust between 2009 and 2012, with an additional injection of £2.5million 
from the Scottish Funding Council, from 2011-2016. It is hoped that by the time the 
project finishes it will be possible to generate small quantities of blood that may be 
suitable for initial animal and human safety tests.  
Objectives of the BloodPharma Project 
The project brings together three research components, the generation of embryonic 
stem cells to good manufacturing practice (GMP) standards, the generation of blood 
(haematopoietic) stem cells and the generation of RBCs from human haematopoietic 
stem cells (Mountford, 2008). Each of these three individual components have been 
generated previously to research grade but the Wellcome Trust Funding will allow 
further research to combine these three areas - deriving human embryonic stem cells, 
driving them to produce haematopoietic stem cells and finally scaling up and 
producing RBCs. These cells will also have to be derived at clinical level, which 
means meeting requirements for scale, quality and safety to allow initial clinical 
trials to proceed. The goal of this work over a longer time span is to produce O 
negative RBCs, the universal donor. For this to be achieved an O negative stem cell 
line would be required. Initial work on any blood group is possible but would restrict 
the blood types into which this cultured blood could be safely transfused.  
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The overall goals of the BloodPharma project are split between the various teams and 
locations. For example Roslin Cells are deriving the GMP embryos needed, and also 
converting protocols from each team into protocols that will hold up to GMP 
standards. The Edinburgh and Glasgow teams are working on converting the 
embryonic stem cells into RBCs and doing this at optimal levels. The NHS Blood 
and Transplant team are experts in RBC classification and the Dublin team is 
working towards the scale-up processes. In contrast to many big research projects the 
Wellcome Trust insisted on a milestone led project plan, which sets out clear goals 
and deadlines for each of the research stages. Although it is different to their normal 
way of working the scientists interviewed welcomed this structure as a way of 
motivating and coordinating the team. Many also felt that the Wellcome Trust had 
taken a big gamble giving the project the funding it needed, for which they were 
extremely grateful, and saw the milestones as a way of the Wellcome Trust ensuring 
that scientific progress was made.  
 
Cultured blood work has been attempted by others (Olsen, Stachura et al., 2006; Lu, 
Feng et al., 2008). The creation of a stem cell line possessing an O negative blood 
type has been slow because this genotype is reasonably uncommon in the human 
population (The National Blood Service puts the proportion of people with an O 
negative blood type in the UK population at around 7%. National Blood Service 
(date unknown)), and therefore also uncommon in the embryos used for research. 
The ultimate result of this work could be the generation of haematopoietic stem cells 
with the capacity for extensive proliferation, which in theory could repopulate the 
whole haematopoietic system from the injection of a single cell (Olsen et al., 2006). 
This is because haematopoietic cells have the ability to form all the different cell 
types present in the human blood system; therefore, if a single cell had the potential 
to both replicate and differentiate (the definition of a stem cell) it could repopulate 
the entire blood system. This work has been referred to as a ‘donorless source of 
cells’ (Lu et al., 2008), meaning that it will negate the need for human blood 
donations. However donations in the form of tissue from embryos are required in the 
initial creation of the stem cell line. One of the biggest competitors to the 
BloodPharma research team is the Paris based team headed by Prof. Luc Douay, 
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which is also developing stem cell derived RBCs and have shown that they can 
survive in mouse models (Giarratana, Kobari et al., 2005). Other relevant RBC 
research projects include teams attempting to mask RBC antigens, making any 
donation universal and able to be given to any recipient (Hortin, Lok et al., 1997; 
Nacharaju, Boctor et al., 2005).  
 
Cultured RBCs are seen to overcome some of the challenges introduced in the 
previous section of this chapter:  
• Removing reliance on donors – reducing the requirement for altruistic donations 
and the potential for Transfusion-Transmissible Infections which are a risk with 
these types of transfusion.   
• Reducing the need for blood typing – if cultured blood of the ‘universal donor’ 
blood type could be produced then this would minimise the requirement to 
bloodtype patients.  
• Improving storage – it is expected that the cultured blood will keep for longer 
than current donated blood.  
• Benefiting target populations – certain blood disorders are expected to benefit 
from the cultuRBCs, over and above the general population. These target groups 
will be discussed in Chapter Four. 
  
The BloodPharma team is seeking to develop blood that is safe, cost effective and 
publicly acceptable. The scientific research needed to bring this product to market 
necessitates forward thinking and imagining a development pathway for a product 
that does not yet exist. Brown and Kraft (2006) talk of ‘promissory pasts’ of blood 
stem cells, whereas here we see instead ‘promissory futures’. Target markets and 
potential funding are being considered some years before there is even a product to 
market. Much of this forward thinking is necessitated both by the programme of 
research work that must be identified, planned and undertaken, and also by the future 
impacts of current work. Throughout the early stage lab work the team is looking 
ahead to the requirements of the regulatory system for future animal and human 
clinical trials. This brings with it huge challenges for scale-up and uncertainty about 
the potential target markets, a few of which have been identified. Cultured RBCs are 
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expected to be identical to in vivo RBCs, and promise in many ways to be better. The 
BloodPharma team has identified a number of advantages to cultured RBCs, 
including eradicating the risk of infection and improving patient specificity. The 
BloodPharma case study allows us to follow a single substance, blood, and the work 
of a research team as they seek to develop a viable stem cell therapy in the context of 
over a hundred years of blood regulation and thousands of years of blood use.  
 
Introducing the Substantive Research Chapters 
Chapter Two - Methodology and Analytical Framework 
This chapter discusses the methodological and theoretical approaches used during 
this thesis and the collection of empirical data. A mixed method approach was used 
during empirical data collection, comprising interviews, desk based research, 
laboratory observation, and participant observation.  
 
Chapter Three - Early Stage Laboratory Work  
This chapter looks at the work achieved by the BloodPharma team in the early stages 
of product development. Blood as a biological entity is introduced, as well as the 
properties which make cultured RBCs a good target for stem cell research. Interview 
and observation data are drawn upon to discuss the biological challenges which are 
identified by the project team. Tacit knowledge is seen to play an important role in 
the work conducted by the team across multiple laboratory sites. The use of the 
human body as an examplar is introduced and the distinction between the ‘synthetic’ 
blood produced in the laboratory and ‘natural’ blood is discussed. The important role 
of expectation and vision is shown in the context of the BloodPharma team 
imagining a product goal which may be twenty years down the line.  
 
Chapter Four - Imaging and Shaping Final Products and Future Markets 
Challenges exist in the scale-up and automation of the cultured blood product, 
requiring large amounts of forward planning even before the basic product has been 
developed. The clinical trials for pharmaceuticals and stem cells will be discussed 
more broadly, showing why the biological properties of stem cells may make 
traditional clinical trial methods inadequate. This uncertainty is felt by the 
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BloodPharma team as it must look ahead to plan trials, a suitable paradigm for which 
does not yet exist. Target populations which have been identified are discussed as a 
potential first step towards the long-term goal of replacing the blood transfusion 
service, and because the cultured blood product may benefit these groups above 
others. The long-term goal is to replace the blood donation required by the current 
transfusion services, but already the project team are looking beyond this to other 
potential innovations.  
 
Chapter Five - Regulation in the BloodPharma Project 
The UK has a well developed system for the regulation of stem cell research and this 
chapter addresses historical events which have been instrumental in shaping this 
current system. Drawing on interviews with regulators and scientists outside the 
BloodPharma team, both the benefits and constraints of the regulatory system are 
identified. The chapter then focuses more specifically on the impact of regulations on 
the BloodPharma team, addressing specifically the knowledge and expertise required 
to navigate the regulatory system. The cultured blood product will bring with it 
specific risks which will impact on the way it is perceived by regulators and the 
future hurdles which the team will have to overcome to bring their product to clinical 
use. In the face of uncertainty the scientists often seek to anticipate future concerns 
before they have been articulated by the regulatory system.  
 
Chapter Six - Public Engagement in the BloodPharma Project 
Throughout the BloodPharma project the team has engaged in public outreach, which 
was a stipulation of the Wellcome Trust grant. The role of funding bodies in the 
motivation for scientists to do public outreach will be discussed more widely, before 
the specific motivations and expectations of the BloodPharma team are introduced. 
The outreach events attended and my role as a participant observer are discussed, as 
well as drawing on the experiences of the scientists stepping outside their normal 
area of expertise to engage with the lay public. The BloodPharma team has the 
difficult role of balancing current downstream engagement with current technology, 
specifically the need to promote the cultured blood project without undermining the 




Chapter 7 - Conclusion 
The concluding chapter of this thesis draws together the main themes from the 
substantive chapters and reviews the overarching research questions. The relevance 
of this work to the innovation/regulation/policy triangle is discussed and suggestions 
















CHAPTER 2: METHODOLOGY AND 
ANALYTICAL FRAMEWORK 
In this chapter I provide a description and justification of the methods and analytical 
framework used for this study, and outline some of the key literature relevant to the 
themes in each chapter. I also reflect on some of the opportunities and challenges of 
working closely with a scientific project team, whilst at the same time studying them.  
RESEARCH STRATEGY 
This thesis comprises an in-depth case study of the development of a cultured RBC 
product which is being undertaken by the BloodPharma team. In designing my 
research I drew upon previous work involving case studies and laboratories, 
particularly Latour and Woolgar (1986), Pfeffer and Kent (2006) and Collins and 
Kusch (1995). I was particularly interested in becoming immersed in the work of the 
team through a mixed method approach. Mixed method or multi-strategy research is 
often assumed to imply a mixture of qualitative and quantitative research. In this 
project, however, I will use the term to refer to the use of a variety of qualitative 
methods including desk based research, interviews, lab observation, public outreach, 
conference data and a dedicated case study.  
 
It must be acknowledged that there is some contention over the use of multiple 
methodologies, which is summarised by Bryman (2004) as resting on the idea that 
different methodologies come from different epistemological positions. In choosing 
to employ a particular method the researcher is not just choosing the practical 
undertakings of that method but the epistemological assumptions that come with it, 
and these assumptions may not be the same for different methods. I accept the idea 
that different methods will bring with them different epistemological assumptions, 
but this does not mean that mixed methods should necessarily be avoided.  
 
The area of stem cell research is extremely complex, involving many actors and 
stakeholders, and it would be a serious error to assume that one methodology has any 
hope of capturing all relevant data. Although interviews and desk based analysis 
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alone would have enabled a good, general assessment of the work of the 
BloodPharma team it would have lacked sufficient depth and failed to capture the 
full range of alternative perspectives. Like most professions, the important 
discussions in science are as likely to occur informally over lunch at a conference as 
they are in a formal team meeting, and it was this additional subset of information 
that this research set out to capture.  
 
Another reason for a multi-method approach was as much for my own benefit as it 
was for the quality and range of data. Using laboratory observation, for example, 
allowed me to see the tools used and the stem cell lines developed, which contributed 
to a greater understanding of techniques mentioned in interviews and journal papers. 
An important point to mention when discussing this use of multi-methods is that the 
entire data collection process was highly iterative. All the methodologies were used 
over the whole data collection period, rather than in discrete blocks. This allowed the 
experience of one data collection method to inform another and made for more in-
depth data collection. For this reason particular methods are not associated with 
particular research questions, as the project was designed to use an inductive 
approach allowing the data to inform the conclusions, rather than working to a pre-
supposed hypothesis.  
 
THE METHODS USED 
Below I explain in turn the different methods employed during the data collection 
period, although as mentioned above they were used in a highly iterative way and are 
grouped into discrete subheadings for presentational purposes only. After an 
explanation of each method I shall discuss issues of reflexivity and ethics which are 









The Case Study 
The Wellcome Trust BloodPharma project forms the case study for this project. This 
is a basic research project seeking to develop cultured RBCs (RBCs) from human 
embryonic stem cells, for the purpose of transfusion. It is a multi-lab project led by 
the SNBTS and involves research teams in Bristol, Edinburgh, Glasgow and Dublin, 
as described in detail in Chapter One. This particular case study was chosen for a 
number of reasons. On a practical level the co-sponsorship of the PhD by the SNBTS 
allowed a level of access to the project team that would not have been possible 
without this gate keeping role. As an example of a stem cell therapy project it was 
also unusual, involving many researchers from different backgrounds and 
geographical areas. It represented a full circle, from the earliest blood transfusion 
experiments to the development of blood as a cultured product, the dawning of a new 
era in potential stem cell therapies, and the attending public reactions to this. The 
timing of the project was also an important consideration as the BloodPharma project 
was at the beginning of its funding when this PhD started, meaning the case study 
allowed a stem cell therapy to be followed through the initial biological hurdles, 
whilst looking forward to the future regulatory challenges. Finally RBCs are short 
lived in the body and contain no DNA, but yet are required in enormous quantities, 
posing interesting challenges for future scale-up, clinical trials and regulation.   
 
In accordance with the iterative mixed-method setup of this PhD the case study was 
considered from a number of methodological angles.  
• Interviews with the heads of laboratories elicited in-depth information on the role 
of each laboratory, the biological hurdles faced and their experiences of the 
regulatory system.  
• Laboratory observation allowed further discussion with other researchers, 
including technicians and PhD students. They also allowed me to see first hand 
the workings of the laboratory.  
• Public outreach allowed me to witness the BloodPharma team projecting their 
‘public front’ and representing their work to wider audiences.  
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• Meetings/conferences allowed discussion with the BloodPharma team about new 
ideas, and revealed the methods and strategies used by researchers to disseminate 
their work to others within the team.  
 
The use of the case study provided in-depth data about the BloodPharma project. The 
project itself is ongoing and so the aim of this study has been to provide a ‘snapshot’ 
of the project over a three year time period, from the autumn of 2009 until the end of 
2012. As the BloodPharma project is still ongoing I may occasionally use the present 
tense to refer to work being undertaken by the team. This case study set out not to 
produce an example of experiences which can be extrapolated to all research teams, 
but instead to embrace the phenomological approach, to ‘seek to discover some of 
the underlying structure or essence of that experience through the intensive study of 
individual cases’ (Thorne, 2000). In other words my aim was to unpick the mystery 
which often surrounds the development of stem cell therapies by focusing on the 
individual case of the BloodPharma project. The single case study method is also 
recommended by Yin (1994, pg.40) where a case study represents an ‘extreme or 
unique case’ or a ‘revelatory case’. The BloodPharma project is unique amongst 
other stem cell research projects due to the biological properties of RBCs, the 
presence of an established donation system, and the large scale-up challenges. For 
this reason it not only represents a unique case study but also a revelatory case as it 
challenges the current ideas of appropriate regulation for stem cells.  
 
Interviews 
It was decided that semi-structured interviews (Fontana and Frey, 1994) with key 
participants would be beneficial in eliciting information that it would not be possible 
to obtain through desk based analysis alone. Interviews took place both with primary 
members of the BloodPharma team and also with persons involved in the regulatory 
system, plus other stem cell scientists and relevant stakeholders. In total there were 
18 interviews, one of which included two participants. Three interviews took place 
via the telephone, the rest were conducted face-to-face. On average each interview 
lasted for around one hour, with a recording time of around 50 minutes. The shortest 
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recording time was 33 minutes, the longest 86 minutes. A table of interviews and the 
relevant stakeholders is shown in Figure 1.  
 
The SNBTS co-sponsorship of this project was instrumental in allowing access to the 
researchers. All those who were involved in the BloodPharma project were willing to  
be interviewed, the only difficulty being arranging a convenient time. Other potential 
interviewees were identified at conferences, meetings or through recommendations  
from other participants and colleagues. In this way most interviewees were first 
approached in person to see if they would be willing to consider taking part in an 
interview. This initial meeting was then followed by an email explaining more about 
the project, explained their rights to confidentiality and included a copy of the 
consent form for them to study at their leisure. Two digital voice recorders were used 
for most of the interviews, apart from the three telephone interviews which relied on  
Figure 1: Interviews. Showing the interviews undertaken during data collection 
No. Affiliation Type Background 
1 Alternative stem cell project Interview 1 O Med 
2 Alternative stem cell project Interview 2 O Med 
3 Blood Expert O Med 
4 Blood Pharma Regulatory CS/R Reg 
5 BloodPharma PI CS Lab 
6 BloodPharma PI CS Lab 
7 BloodPharma PI CS Lab 
8 BloodPharma PI CS Lab 
9 BloodPharma PI (Double interview) CS Med 
10 BloodPharma PI Interview 1 CS Med 
11 BloodPharma PI Interview 2 CS Med 
12 Consultancy R Reg 
13 Regulatory R Reg 
14 Regulatory R Reg 
15 Regulatory R Reg 
16 Regulatory R Reg 
17 Regulatory  R Reg 
18 Regulatory  R Reg 
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hardware to connect the digital recorders to the phone line. Recording interviews 
allowed the interviewer to listen to the participants without the added difficulty of 
trying to take notes, and made for a more responsive interviewing technique. One 
respondent did not wish to be recorded and so notes were taken during the interview, 
which were subsequently emailed to the interviewee for clarification. Another 
interview was not recorded due to some unknown background interference which 
caused both Dictaphones not to work, so notes were taken instead. Recorders were 
turned on with the interviewee’s permission and after the consent form had been 
signed. They were turned off at the last possible minute, as interviewees had a habit 
of mentioning something important the moment that recording had stopped. Any 
points mentioned at the end of the meeting were noted down and added to the bottom 
of the transcribed interview.  
 
The interviews for this project were all with ‘elite’ participants, but what constitutes 
an elite is often hard to pin down from the literature. For the purposes of this project 
all the interviewees were considered to be ‘elites’ – men and women who were 
chosen because they are experts in their field. Interviews with elites do not pose the 
same methodological challenges that are experienced when interviewing lay or 
vulnerable people. They are distinct from the ‘caring interview dialogue’ discussed 
by Kvale (2006) for example, that gives a voice to the marginalised and empowers 
participants. But interviews with elites pose unique challenges that can be just as 
difficult to overcome and deserve consideration here. The interviews did not pose 
great challenges in terms of consent, ethics or safety. The interviewees were highly 
educated and capable of understanding and questioning the consent forms given, they 
were also in positions of responsibility that left them unlikely to be coerced into 
taking part against their will. The interviews generally took place in work situations, 
with the interviewees well known to the scientific and research community. One 
interview took place at the researcher’s home and in that instance a safety telephone 
call was arranged between the researcher and somebody back in the department.    
 
Smith (2006) talks of her surprise when realising how easily two groups of 
researchers could categorise their participants into those who ‘possessed power’ and 
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those who were ‘disempowered’. To somebody who has almost exclusively 
interviewed elites this does not seem so surprising, and those who were interviewed 
for this project definitely fell into the ‘possessing power’ category. The main 
methodological challenge to interviews with elites is identified by Desmond (2004) 
as stemming from ‘the power differentials between the researcher and the 
researched’. She identifies the power relationship between researcher and researched 
as ‘inevitably asymmetrical’. This was certainly evident when interviewing those 
who took part in this project – they projected the image of the confident interviewee 
entirely secure in their knowledge of the subject and not in the least bit intimidated 
by being faced with an interviewer and a tape recorder. Smith (2006) mentions that 
another problem of ‘interviewing up’ is the ability of elite interview participants to 
protect themselves and to manipulate data. Throughout the interviews I was alert to 
this, especially as at the time interviews were commencing the BloodPharma team 
had received a large amount of unplanned media attention when the details of the 
project had been accidentally leaked. This resulted in a press release being put 
together at short notice and the team therefore had a good coherent ‘story’ to use.  
 
Although on the lookout for this skewing of data I did not feel that it ever happened, 
all the interviewees appeared to be extremely open with me about their views, even if 
that meant going against the established or publicly articulated view. The power 
imbalance between myself and the interviewees also led me to place greater 
emphasis on my own scientific background as a way of demonstrating my credibility. 
However, there were instances when the greater power held by the interviewee could 
be put to good use, often ‘playing ignorant’ elicited more of a response as they 
attempted to explain their work to me as a lay person. Elite interviews are generally 
conducted with people who are extremely busy and coordinating timings of 
interviews can be problematic, in addition most elites are non-replaceable. With 
elites it is possible that only one person in the country may be able to answer your 
questions, which leaves little room for manoeuvre. Meeting people face-to-face 
before following up with emails did help the response rate, and nobody that was 
approached turned down the request for an interview, although setting a convenient 




Interview data were transcribed by myself using Express Scribe transcription 
software. Respondent’s replies were transcribed verbatim, but with the removal of 
hesitations, filler words, and non-verbal sounds (Roberts Powers, 2005, pg.67) unless 
they gave added meaning to the sentence. Grammatical inconsistencies were kept. 
Questions and general ‘chat’ that were not relevant to the interview were shortened 
or tidied. Transcripts were analysed using the inductive approach described by 
Bryman (2004, pg. 8-10), allowing the data to drive the conclusions rather than a 
reliance on pre-prepared hypotheses. Initial reading and re-reading of the interview 
transcripts allowed the main themes of the interviews to be identified (Strauss, 1987, 
pg.35). Transcripts were then loaded into NVivo and coded more systematically 
using thirteen nodes: 
• Clinical trials – information on clinical trials related to the BloodPharma product 
or stem cell research more generally.  
• Clinical trials (ReNeuron) – information specifically related to the clinical trial 
phase of the ReNeuron project. 
• Changes after use – proposed changes to the BloodPharma product after initial 
use. 
• Imagined regulation – potential regulatory concerns for the BloodPharma 
product and other stem cell research. 
• Interdisciplinary – incidences of interviewees referring to the interdisciplinary 
nature of the BloodPharma project or working together with other members of 
the team. 
• Product – information regarding the BloodPharma product, including references 
to who will produce and pay for the eventual product.  
• Scale-up and production – information from interviewees regarding the scale-
up and production challenges for the BloodPharma product. 
• Tacit knowledge – incidences where interviewees mentioned the use of tacit 
knowledge.  
• Public – mention of ethics, public understanding, requirement to carry out public 
engagement etc.  
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• Naturalness – where interviewees referred to the natural/unnatural/synethitic 
distinction of the BloodPharma product and other stem cell therapies.  
• Regulation (Case Study) – information about interactions between the 
BloodPharma product and the regulators. 
• Regulation (Other) – information from other interviewees about interactions 
with the regulatory system.  
• Regulation (Regulators) – views from interviewees involved in the regulatory 
system regarding the regulation of stem cell products.  
 
Transcripts were also categorised depending on the background of the interviewee 
(as shown in Figure 1.), which allowed for easier cross-referencing. These groupings 
were: 
Case Study (CS) – individuals directly involved in the BloodPharma project 
Regulatory (R) – individuals involved in the regulatory system 
Other (O) – interviewees with other backgrounds, for example blood specialists not 
related to the BloodPharma project, clinicians and consultants 
 
Within these three groupings the interviewees were also divided further into 
laboratory (Lab), regulatory (Reg), or medical (Med), to reflect the occupation of the 
individual. Throughout the thesis these groupings are used to reflect the background 
of the individual from whom quotations are taken, for example (CS/Med) indicates 
and individual involved in the BloodPharma case study but who has a medical 
background.  
  
 Laboratory observation 
The importance of visiting laboratories is becoming widely acknowledged as 
contributing to robust data collection methods for projects involving the study of any 
scientific innovation. The decision to use lab observation for this project stemmed 
initially from Pfeffer and Law’s (2006) paper on blood tests. This paper raised a 
number of issues which were important in the study of biological innovations, as 
well as having the added bonus of also being about the study of blood. The writers 
had made the decision to follow the blood tests through the laboratory process to get 
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an understanding of what happens in the translation of physical blood to 
computerised data. I felt this opened up new ways of understanding the scientific 
process, by focusing on the product as much as the researchers. Visiting the 
laboratories involved in the BloodPharma project was an important part of the data 
collection. The labs in Bristol, Glasgow and Edinburgh were chosen because of their 
role in the basic research component of the project. The visit to Bristol had to be 
combined with a morning of interviews, whilst the Glasgow and Edinburgh visits 
comprised a whole day each.  
 
Not only did these visits provide me with a fuller understanding of the laboratory 
environment but it also helped with the analysis of interview data. When an 
interviewee is miming cutting up a batch of cells (for example) they often assume 
that you can visualise that mime too, that you are familiar with the tools they would 
be holding and the environment that they would be in. This is only possible if you 
have at some point been there with them. It is also only through seeing the 
researchers in action that a fuller picture emerges of just how much of this 
technology relies on tacit knowledge and human observation, and how this is such a 
huge hurdle to overcome when discussing the automation of these techniques. 
Access was not problematic due to the good working relationship with the 
BloodPharma team, however the impression given was that the basic researchers 
were unsure about what I would be looking for and how they could help. It was 
difficult for them to understand that what was completely obvious to them (because 
they worked in that situation every day) might be interesting to outsiders.  
 
Observation in the laboratory was considered a casual data collection activity (Yin, 
1994, pg.86), and data collected was treated as supplementary evidence to interview 
data. Notes were taken as often as possible during visits to laboratories or during 
meetings. Care was taken to minimise disturbance to staff, especially when they were 
carrying out laboratory based work. Notes were kept of initial impressions of the 
laboratory space and my own reflexive feelings regarding the laboratory visit. A 
folder of loose paper was collected, which comprised notes taken during visits or 




conference information etc. This was considered a supplementary data source and 
was referred to using an iterative process (Thorne, 2000),in order to develop a 
comprehensive understanding of laboratory practices, how researchers organised 
themselves within the laboratory space, and presented their work to others. As in 
Okely (1994, pg.21) the material collected during this observation was used as a 
‘trigger’ to remember experiences which are impossible to commit to paper.  The use 
of drawings and images by the BloodPharma team in early stage laboratory work is 
discussed in more detail in Chapter Three. These images were collected during time 
spent with the team during meetings and one-to-one interviews. 
 
Documentary Analysis 
This project necessitated a large amount of desk based analysis above and beyond the 
normal academic journals. For example the official reports of the governmental 
bodies were extremely helpful, especially the Human Tissue Act and Human 
Fertilisation and Embryology Act reports. The official websites of the regulatory 
bodies also contain information on their remits and links to many of their official 
documentation, such as financial reviews and occasionally publicly available 
inspection reports. Both the scientific and the social science literature were drawn 
upon during this work. Such documents provided additional insight as they are 
considered artefacts, they were written in order to ‘do something’ (Hodder, 1994), 
and in this case often represented the ‘public face’ of an organisation.   
 
Conference and Meeting Data  
Attending a wide variety of conferences, talks and workshops on relevant subjects 
has been an important part of this project. Although the presentations themselves are 
clearly important in keeping up to-date with the current research field it has often 
been networking that provides much of the interesting data. Most researchers appear 
to be more open in their frustrations when in a more informal setting. Very often the 
same researchers would talk at different conferences throughout the year, and it was 
interesting to see how their work progressed throughout the course of this project. 
Smaller meetings were also attended, such as those organised by the Scottish Stem 
Cell Network, which were often focused on a smaller area of research. I also sat in 
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on one day of the Penrose Enquiry public hearings, which took place in Edinburgh. 
This enquiry is looking at the events which led to a number of patients being infected 
with Hepatitis C and HIV from blood and blood products. Notes were taken during 
conferences and meetings and a record made of any interesting points or 
observations made by those in the research or regulatory community.  
 
Public Outreach  
The BloodPharma project has been committed to public outreach since its inception 
and was chosen to exhibit at the prestigious Royal Society 350th Anniversary in 
London in 2010. The team also took their exhibit to the Big Bang Science festival 
and the Glasgow and Edinburgh 2011 Science Festivals. More information on the 
public outreach ventures is discussed in Chapter Six. Throughout these outreach 
activities I took the role of a participant observer, both studying the team and being 
directly involved as a member of the outreach team (Atkinson and Hammersley, 
1994). Joining the team for these outreach activities benefited the PhD data 
collection in a number of ways. Firstly it allowed me to talk with members of the 
general public regarding the BloodPharma project and their reactions to the proposed 
technology. Secondly, it helped to establish a better relationship between myself and 
the rest of the BloodPharma team, not only in working together as a team during the 
exhibitions but also because there was the necessity for meals and socialising 
together. Thirdly, it provided the opportunity to hear the researchers themselves talk 
about their work to others. This included members of the general public and those 
with more scientific backgrounds who came from other stands at the exhibition. At 
many of the public outreach events I was given the task of taking photographs and 
asking visitors to the stand to fill out photography consent forms and feedback forms. 
I would also talk about the project to members of the public if there were no 
members of the scientific team available. This worked well because it allowed me to 
chat to visitors after they had seen some of the information available and to ask them 





Guilemin and Gillam (2004) quote Bourdieu in explaining the process of reflexivity 
as taking two steps back from the research subject, to question not just what one 
knows but how one knows it, and what shapes our knowing. Throughout this project 
I have tried to be reflexive about my own background and the way that it influences 
my outlook. My first degree was in Genetics, before I subsequently moved to 
Science and Technology Studies and this has undoubtedly had a bearing on the way 
that I ‘know’. From a world where bias in research was focused on tangible 
influences like temperature or apparatus or researcher technique it came as a struggle 
to analyse my own background as influencing my work. Indeed the fact that I 
struggled with the idea of reflexivity forced me to be more reflexive throughout this 
project. I tried to get into the habit of recording my feelings about each interview as 
soon as possible and to recognise how my own views might colour my perceptions of 
data. For some years now I have straddled the boundaries between science and social 
science, but I still baulk at being referred to as a ‘social scientist’. I was conscious 
that I always mentioned my background in science first, as if to give myself 
credibility in the eyes of those that I was talking to. Indeed I think that people were 
more open with me when they knew that I understood some, if not all, of their jargon 
– that I was ‘one of them’.  
 
Participant observant took place through assisting the BloodPharma team with their 
public outreach, as shall be discussed further in Chapter Six. Throughout the 
participant observation work I attempted to be reflexive about my own position as 
one of the outreach team, acknowledging that I found it difficult to be objective at 
the same time as fulfilling my role as a ‘promoter’ of the cultured blood project. I did 
not however find this attachment to the BloodPharma project to be a hindrance. 
Indeed my interest in the ethical and social implications of stem cell research allowed 
me to question the BloodPharma project in some respects, whilst still remaining 
excited about the overall innovative potential. I am in agreement with Yin’s (1994, 
pg.88) observation that using participant observation gave me the chance to see the 
‘viewpoint of someone ‘inside’ the case study’. I also took comfort from Becker’s 
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(1967) paper that acknowledges that it is impossible to work in a neutral and value-
free way, instead I sought to use my attachment to the BloodPharma project to do the 
best outreach that I could achieve, whilst also being aware of this attachment and the 
forms that it took. Establishing a close relationship with the BloodPharma team has 
in many ways set this project apart as unique. In having the opportunity not only to 
interview and watch them, but also to socialise with them, to plan outreach activities, 
and to meet at conferences has contributed hugely to the project. As they now know 
me they sometimes send me information I might be interested in or pass on 
interesting knowledge when we meet.  
 
ETHICS, DATA PROTECTION, CONFIDENTIALITY  
Guillemin and Gillam (2004) place great emphasis on ‘ethically important moments’ 
in research and believe that projects involving human participants start from a 
position of ‘ethical tension’. This did not appear to be the case during this project, 
which potentially comes back to the issue of interviewing elites and the way in which 
these interviews differ from those with more vulnerable participants. At some points 
I found myself attempting to overcome ethical tensions that were not really there – 
for example in the decision to anonymise the data as much as possible despite 
participants being happy to be named. I was concerned that they may not understand 
the implications of things they had said, or were so relaxed that they did not realise 
people could potentially use that data against them. One interviewee took a telephone 
call during an interview and proceeded to have what sounded like an extremely 
confidential discussion, in the full knowledge that I was in the room and the tape 
recorder was running. All interview recordings and transcripts were kept in a locked 
cupboard at the Innogen Centre or were stored on a password protected computer. 
Files were saved onto the University server which protected them in the event of a 
computer failure. The main issue of concern during this project was protecting the 
confidentiality of respondents. Many of them had few issues about being identified 
and were happy to be named, however the decision was taken to annonymise all the 
participants as fully as possible. Care was also taken during interviews not to 
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mention other participants by name but just to refer to them as members of the 
research or regulatory communities.  
 
THEORETICAL AND CONCEPTUAL FRAMEWORKS   
Alongside the methods that were used to gather empirical data for this project it is 
also necessary to consider the theoretical frameworks which underpin the analysis of 
this case study. Just as this project has used a mixed methods approach to gather data 
in different ways so I have also identified different theoretical concepts which have 
been used throughout the research. Drawing on concepts of grounded theory (Strauss 
and Corbin, 1994) the data collected was used to drive the theoretical framework 
used for each chapter, taking care to avoid what Gilbert (2006) terms ‘theoretical 
arrogance’ in attempting to force theory to fit observations or vice versa. 
 
Science and Technology Studies (STS) seeks to ‘explore technology in a wide range 
of fields’ and to analyse relationships between the actors involved in creating and 
using such technologies (Brown and Webster, 2004, p.29-30). It is sometimes 
referred to as opening the ‘black box’ of technology, to look deeper at technologies 
themselves rather than their impact on the social world.  The case study element of 
this project draws on this idea of the black box, as through in-depth investigation of 
the actors and technology involved in the BloodPharma project a clearer 
understanding of the development and translation of a stem cell therapy can be 
developed. I shall identify the theoretical concepts that have been of most relevance 
to the themes within each of the substantive chapters.  
 
In Chapter Three the theories of tacit knowledge and expectation contribute to an 
understanding of early stage laboratory work. The BloodPharma project is introduced 
as an example of interdisciplinary working across multiple research spaces, drawing 
on Lyall et al. (2011) in order to demonstrate that this project fits the label of 
‘interdisciplinary’ working. The volatile nature of stem cells and the mixed grouping 
of the team mean that tacit knowledge is an important consideration in the 
development of early stage laboratory processes. Many of the findings reported by 
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Collins are evident in the day-to-day work of the BloodPharma team, showing that 
his conclusions are relevant across different decades and scientific disciplines. For 
example the BloodPharma team is an example of Collins’ (1974) observation that 
scientific communities share within themselves large amounts of tacit knowledge, 
and indeed in this case study it can be seen that this tacit knowledge is shared at an 
even deeper level, within laboratories and even by individual scientists. The 
exchange of staff members between laboratories is an example of the importance of 
‘personal contact’ identified by Collins (2001) in his work on the quality factor of 
sapphire. The importance of tacit knowledge within this early stage laboratory space 
leads to a recognition of the ultimate goal of standardisation within the stem cell 
field, and  the problematic nature of this goal, as identified by Webster and Eriksson 
(2008) and Eriksson and Webster (2008). For the BloodPharma team the use of 
images is identified as a main route towards higher standardisation between 
laboratory members, in similarity to Lösch’s (2006) case study of visionary images 
as communication in the nanotechnology sector.  
 
The in vivo RBC is identified by the BloodPharma team as an exemplar, or 
benchmark, for which their early scientific work is aiming. Here I view this through 
the idea of ‘bioequivalence’, as it is discussed for the technology surrounding 
Genetically Modified crops by writers such as Meredith (2003) and Millstone et al. 
(1999). Bioequivalence leads us to question the ‘naturalness’ of the cultured blood 
product, in comparison to both donated RBCs and chemical blood substitutes. 
Although the public response to the BloodPharma product is not yet certain I draw 
on the work by Douglas (1966) to explore some of the concepts around ‘dirt’ and 
‘matter out of place’ in anticipating potential reactions to the cultured blood product. 
In the final section of Chapter Three the importance of expectation in early stage 
laboratory work is introduced. Foresight is seen as crucial in mobilising funding 
(Anderson, 1994), and building the shared bonds and expectations necessary for 
project coordination (Bidault and Cummings, 1994; Borup, Brown et al., 2006).  
 
Chapter Four explores further the standardisation of stem cell research to consider 
the challenges of automation identified by Webster (2008) and Placzek et al. (2009). 
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The contrast is seen here between the standardisation required for automation and the 
‘whatever works’ approach (Shaw, 2010) to early stage laboratory research identified 
in Chapter Three. Such standardisation requires an acknowledgement of the 
importance of path dependency and ‘lock-in’ (Liebowitz and Margolis, 1995). Work 
by Webster and Eriksson (2008) and Eriksson and Webster (2008) shows the 
difficulty of standardising stem cell research, but the outcome of an attempt to 
standardise stem cell research is the problem of ‘lock-in’ to a particular protocol, 
resulting in a loss of biological diversity in the stem cells themselves and tacit 
knowledge for the researchers.  
 
Whilst the BloodPharma team continue to work towards a workable scale-up solution 
for the cultured blood product, uncertainty still surrounds the clinical trials route, 
which represents one of the main hurdles in the translation from laboratory to 
clinically useable product. Uncertainty particularly surrounds the appropriateness of 
animal models for the BloodPharma product, and for the stem cell field as a whole, 
questioning the idea of ‘nature implied’ (Lynch, 1988; Hansen, 2006; Davies, 2010) 
and the laboratory as a ‘sub-place’ (Asdal, 2008). The BloodPharma process 
represents a change to the established method of obtaining blood from human 
donation, yet as a product is can be considered a continuation of an established use, 
albeit obtained from a different source. The survivability of the stem cell field more 
widely depends on the cost effectiveness of therapies and on the future regulatory 
system for such products (Tait, 2007). One method of introduction is likely to be the 
identification of key target markets. The team are also imaging futures beyond these 
initial markets, visualising a series of goals such as the use of adult cells as the 
starting source material. As in Chapter Three the use of informal anticipatory 
procedures is considered necessary in the bringing together of the team and 
identifying future translation goals. In addition we see here the teamwork between 
scientists and clinicians, identified by Wainwright et al. (2006) as key to the 
translation process from bench to bedside.   
 
Chapter Five focuses on the interactions between the BloodPharma project and the 
wider regulatory system for stem cells. Croley’s (1998) theories of regulation are 
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used as a basis for understanding the creation of different types of regulation, with 
consideration of the formalising of ‘good practice’ using Messner (2009). Chataway 
et al. (2006) is used to explain further the precautionary and reactionary methods of 
regulation, with further discussion of the precautionary method of regulation drawn 
from writers including Majone (2002) and Levidow (1996). The regulation of stem 
cell products is seen as an exercise in boundary work (Williams, Wainwright et al., 
2008), with stem cells considered to be traversing boundaries (Cooper, 2004) and 
requiring the reordering of regulatory boundaries (Brown and Michael, 2004). 
Expertise is also a crucial part of the regulatory relationship, with expertise required 
by the regulators and especially by the scientists in navigating the regulatory system. 
There is also a distinction seen between the formal expertise achieved qualifications 
and the hands-on expertise of those who work on a day-to-day basis with the cells, in 
a similar fashion to Wynne’s (1992) sheep farmers and the subsequent discussion of 
expertise by Collins and Evans (2002). In the latter part of Chapter Five I discuss the 
BloodPharma product in the context of specific risks, using as a basis Sadler and 
Zeidler’s (2005) model of ‘informal reasoning’, to explain how the BloodPharma 
team discuss the specific risks related with their work.  
 
In Chapter Six the public outreach work carried out by the BloodPharma team is 
discussed, beginning with an outline of the objectives behind public outreach. 
Engaging with the public is viewed as a way to minimise future risk perceptions of 
the product, as alternative blood products were found by previous studies (Fleming, 
Ferguson et al., 2007; Ferguson et al., 2008) to be perceived as riskier than 
conventional transfusion, and prevent a resurgence of the direct action groups which 
became synonymous with the proposed introduction of Genetically Modified crops 
(Grant, 2004). Public outreach is considered to be moving away from the ‘public 
deficit model’ (Sturgis and Allum, 2004) towards an increasing focus on engaging 
the public in scientific decision making (Irwin, 2001). This causes us to question the 
role of the scientist as public communicator and the support given by institutions for 
researchers to carry out this role (Mathews, Kalfoglou et al., 2005). The outreach 
work carried out here demonstrates the challenge of upstream engagement (Tait, 
2009), especially considering the presence of the already established technology of 
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human blood donation. The team therefore have to balance the dual message of 
promoting both a novel technology, whilst seeking to keep public faith in the current 
donation system.  
 
This thesis is interested in exploring the different interests and choices of those 
involved in the stem cell field, and as such draws on (although is not driven by) a 
SCOT paradigm. Social Construction of Technology (SCOT), acknowledges that 
what we accept as scientific ‘fact’ has been created through this process of social 
shaping and that writers make knowledge claims that are accepted or rejected by the 
academic community around them through negotiation (Myers, 1985). This is in 
addition to recognising that all technologies are socially shaped through the ‘choices’ 
that are made during the design of technology and between different technologies 
(e.g. in the market). This is known as Social Shaping of Technology (SST) and is 
explained in more detail in Williams and Edge (1996). SCOT is an important concept 
to acknowledge in a study that examines an area of research that is going through a 
period of both scientific and regulatory shaping. Many of the decisions required 
throughout the regulatory process build on the perspectives of the actors involved, 
and decisions that are taken over how to regulate, over what are considered 
acceptable standards of safety, about what previous technologies could be used as 
comparisons etc. Boundary Work (Gieryn, 1983) is acknowledged in Chapter Five 
on regulation, but in thinking reflexively about how I carry out my data collection I 
have to acknowledge that I often started from an assumption that boundaries between 
organisations, and the way that they maintained these boundaries, are important. This 
is reflected in the way that I instinctively grouped my proposed interviews for this 
project in to ‘researchers’ and ‘regulators’, even though the boundaries between 
these groups may be more blurred than they initially appear.  
 
This chapter has introduced the methods that were used for gathering the empirical 
data and some of the most appropriate theoretical perspectives for analysing these 




CHAPTER 3: EARLY STAGE LABORATORY 
WORK 
INTRODUCTION 
The BloodPharma project team is seeking to develop a final product that is 
standardised, controlled, clean, and meets required regulatory standards. However, 
the reality of early scientific development is instead a story of scientists working 
together and ‘muddling through’ to overcome enormous scientific and technological 
challenges. Muddling through refers to the making of small incremental steps rather 
than having a defined plan, for example Lindblom (1959), Bendor (1995), and Fortun 
and Bernstein (1998). Walking into a working laboratory is very different from the 
image of a controlled environment; although scrupulously clean you are likely to 
encounter desks covered with equipment, teetering stacks of deliveries and every 
spare inch of space crammed with supplies of gloves and sterile plastic-ware. Walls 
are covered with notes and schedules, plans for cells feeding, technical pictures, 
cartoons and posters. It is very clear that the laboratory is a place where people work 
every day. And the scientists themselves are not standardised and controlled, they 
have hopes and fears for the project, moments of elation when things go well and 
panic when they do not. They differ in what they envisage the project outcomes to 
be, and they argue, gossip and contradict each other. This chapter will use empirical 
data from meetings, interviews and laboratory observation to tell the story of early 
stage laboratory development through the words of the scientists.  
 
The overarching research question that this chapter will address is: 
How is early stage laboratory work achieved through interdisciplinary, multi-lab 
working, where standardisation of methods is difficult and where there exists an 
accepted technology?   
Focusing predominantly on the work of the scientists, the chapter will explore how 
the team constructs and seeks to find workable solutions to the early stage biological 
challenges, in the context of looking ahead to various imagined futures and product 
development pathways for the cultured blood product. The BloodPharma project 




that distinguish it from many other types of laboratory research projects. Firstly, it 
brings together a number of teams physically separated by geography; each 
contributing different types of expertise to the project. This is a project that 
highlights the importance, as well as the associated problems, of interdisciplinary 
working. Secondly, the project is not simply a basic science research project with 
short-term milestones and deliverables. Instead it has very long-term aims and 
objectives. The project team are in some cases looking 20 years into the future of the 
product, so the temporal dimension is crucial and brings both opportunities and 
challenges. Thirdly, the emotive nature of blood donation and transfusion makes this 
a socially and politically salient project in which interaction and engagement with the 
public is given a high priority. Fourthly, the regulatory pathway for cultured blood is 
still unclear, as blood has certain characteristics (e.g. the lack of nuclear DNA) which 
set it apart from conventional stem cell treatments. Finally, this project is strongly 
grounded in the perceived idea of a final product that will be potentially marketed to 
a large proportion of the population. The expectation is that the development of 
cultured blood will require industrial level scale-up; thus creating a promissory 
vision of both jobs and value creation for the UK economy.  
 
The specific areas of regulation and public engagement will be addressed in more 
detail in Chapters Five and Six respectively, but here I will examine four key themes 
that are important in the development process of early stage scientific work for 
cultured blood – interdisciplinarity in practice, the role of tacit knowledge, the 
construction of a natural/synthetic distinction, and imagined future products. To do 
so I will draw on data collected from three years of observation of the BloodPharma 
project and the scientific team, and semi-structured interviews with eight of the 
principal team members. Each of these four areas shall now be introduced in more 
detail.  
 
The first section of this chapter will focus on the use of interdisciplinary working 
amongst the BloodPharma project team. The BloodPharma project is set apart from 
many standard research projects by its strong focus on interdisciplinarity, with a 
scientific team spread over many sites and researchers with different disciplinary 
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backgrounds. This section will identify some of the challenges and benefits that arise 
as part of working in such an interdisciplinary group.  
 
The second section will draw upon the interview and observational data to explore 
the importance of tacit knowledge in early stage laboratory research, contrasting 
these with examples of tacit knowledge from the literature, such as Collins (1974) 
and Busch (2008), and exploring how the ‘tacitness’ of stem cells affects the long 
term development of stem cell products.  
 
In section three I will explore the natural/synthetic distinction that has been 
operationalised in different ways by the scientists in this project. The BloodPharma 
project is seeking to make cultured RBCs in the laboratory which are 
indistinguishable from donated blood, raising questions of whether this cultured 
blood is natural, unnatural, or synthetic. The role of the human body as an exemplar 
will also be discussed, along with reflections on whether the natural/synthetic 
distinctions matter in practice.   
 
In the final section, I will focus on the different ways and contexts in which the 
scientists imagine the future product development pathways and regulatory 
requirements. The long-term nature of this project requires that the research team 
continually look ahead and identify future challenges/roadblocks and ways to 
mitigate them. In so doing they construct different product imaginaries, a predicted 
end goal towards which their research is directed. The broader discussion around 
foresight that will conclude this chapter will lead us into Chapter Three, where the 
(as yet) imagined world of animal testing and target populations will be discussed.  
 
THE CHALLENGES OF WORKING ACROSS MULTIPLE SITES AND 
DIFFERENT DISCIPLINARY AREAS 
The BloodPharma team operate in four scientific laboratories and multiple office 
sites, whilst the researchers themselves come from different backgrounds in blood 
cell research, stem cell research and clinical research/medicine. Covering the entire 
team is the Wellcome Trust’s imposed project milestones, which for many represent 
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a different way of working and reporting. This section will introduce some of the 
backgrounds of different team members and identify some of the challenges that 
arise as part of working in such an interdisciplinary group. It will show that there are 
contrasting views found in the literature over what constitutes ‘interdisciplinarity’ 
and I will introduce some of my own reflexive thinking about my role as an 
interdisciplinary observer. The empirical data gathered reveals incidences where 
different researchers base judgements, quite naturally, on their background and 
experience.  
 
The BloodPharma team initially came together in response to a call from DARPA 
(the research arm of the American military), which wanted to study the generation of 
blood transfusions in a battlefield setting. Although the UK team was unsuccessful in 
obtaining the DARPA funding the project continued under the auspices and funding 
of the Wellcome Trust. There has been some discussion about the use of the title 
‘BloodPharma’, as this was originally the title given to the project by the DARPA 
funding call. However the team have continued to refer to themselves as the 
BloodPharma project whilst under the funding of the Wellcome Trust, so I have 
taken the decision to continue using the BloodPharma title throughout this thesis. 
The research project pulled together teams from all over the UK, with differing 
backgrounds, in the pursuit of this shared goal of culturing RBCs. The Wellcome 
Trust also imposed milestone-led guidance on the researchers which differed to the 
way in which many members of the team were used to working. The overall 
BloodPharma team is comprised of people who specialise in (among other things) 
blood cell characterisation, stem cell growth and characterisation, GMP compliance, 
and regulation. The staff is also a mix of clinicians and laboratory scientists, and 
have backgrounds in both university and industry settings. It is evident that this 
project has been instrumental in pulling together collaborators who visualise the 
project, and its outcomes, in very different ways. Case studies such as these allow us 
to open the ‘black box’ (Baumard, 1996) of scientific research and to see the 




The mixed grouping of the BloodPharma team therefore creates a research 
environment that is very different to many basic research projects, where researchers 
often share both a common discipline and single working space. Instead we must 
look at how research is produced across a mixed team, and such knowledge creation 
has been divided by Lyall et al. (2011) into three categories: 
• Multidisciplinary: Researchers from different disciplines contribute to a larger 
project, but work on separate sections with little collaboration between the 
partners.  
• Interdisciplinary: Researchers from different disciplines in a much more 
collaborative way, learning from each other and creating knowledge which is 
‘more than the sum of its parts’.   
• Transdisciplinary: Attempts to move beyond the idea of disciplines to work 
towards finding solutions to problems without relying on particular disciplinary 
backgrounds.  
Using evidence gathered from the case study I shall consider which of these 
approaches best characterises the knowledge creation during the BloodPharma 
project.  
 
Interviews with the Principal Investigators on the BloodPharma project highlight the 
advantages that the team have gained from working with others outside their 
discipline.  
 “I mean the challenge of the project, nobody could do it on their own, 
first of all. So we couldn’t get GMP grade ES cells and we can’t do the 
differentiation of erythrocytes and all the erythrocyte characterisation. 
So, you know, everybody needs each other and I think maybe that’s why it 
has to be a bigger thing, because it does, it covers a huge area, from the 
GMP grade right to a functional erythrocyte, nobody could have the 
expertise in all these areas.” (CS/Lab) 
 
The interviewee acknowledges the expertise which must be combined to produce the 
end product, something which it would be impossible for one team to do alone. 
Bringing together a larger team from different disciplines allows access to all the 
years of knowledge and experience that each member possesses.   
“So in a way we need each other, like the basic scientists need the 
clinicians to know the regulations, to know the sort of functional clinical 
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properties of RBCs, but they need us, as basic scientists, because we’ve 
worked in the area, in the differentiation area and understand the 
differentiation and understand the complexities of what you need to 
do.“(CS/Lab) 
 
Here the interviewee categorises the team into two distinct groups, the basic 
scientists and the clinicians. Whilst the basic scientists are seen as having expertise in 
the physical growing of the cells the clinicians are considered to have the knowledge 
of application, in how these cells will function, and the regulatory hurdles. Tacit 
knowledge is discussed in more detail in the second section of this chapter but is 
alluded to here with the suggestion that expertise is vital for understanding and 
controlling the differentiation of these cells. 
“To go from an ES cell to a RBCs…it’s a huge, you know, developmental 
biology project, to do that. So, I guess they need us as much as we…you 
know it’s not a need it’s a collaboration, and I think this project’s 
particularly good because I think there is a feeling of equal footing on it, 
and we all have our expertise, it’s appreciated by others and respected, if 
you like, you know, I think there’s a lot of mutual respect between the 
different PIs because we have got such different expertise, which I think 
that’s maybe one of the strengths of the projects to be honest.” (CS/Lab) 
 
The interviewee is very insistent that this project has a collaborative feel, with 
everybody on an equal footing. There is not an awareness that this project belongs 
primarily to one group, with the others being brought in more on a consultant level, 
and this did appear to be the reality thoughout the project. It is seen that all the areas 
of expertise are equally valid and appreciated and this combining of expertise is seen 
as a major contributor to the strength of the project. The respondent here articulates 
the idea that the BloodPharma project is in some way special, unique and distinct 
from other research projects in that the research is very broad, aiming towards the 
derivation of a potential stem cell product, rather than focusing on a narrow part of 
the scientific work. This wide range of research makes the project very challenging, 
and relies on input from a variety of expertise, hence the reference to the 
BloodPharma project being a ‘bigger thing’ than other research projects. This 
suggestion that the wide scope of the project is only possible by bringing together 
people from different backgrounds highlights the importance of both expertise and 
experience. The respondent makes the distinction between a ‘need’ and a 
‘collaboration’, with his view being that collaboration is more about mutual respect. 
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Again the BloodPharma project is held up as being different from other research 
collaborations due to the mutual respect that the researchers give to each other.  
 
There is a strong focus not just on the research but on the translation, getting all the 
parts of the project to coordinate to produce the final end product. Differences 
between individuals from diverse disciplinary backgrounds were highlighted by their 
approach towards this translation of basic laboratory protocols into methods suitable 
for industrial production. There appears here to be a distinction between the 
researchers who are considered to be ‘commercial’ and those who are purely 
‘academic’.   
“It’s a strange one, because the grouping is also very mixed. So of course 
X are, they are academically derived but are really commercial, and 
there’s ourselves, and I’ve kind of hit the middle ground between 
commercial and academic with the X program and other funding that we 
have. And then pure academics. So it’s quite a strange grouping.” 
(CS/Lab) 
 
Academic research more generally is recognised as having poor translation from 
basic knowledge production to innovation and economic returns, called the European 
Paradox (Audretsch and Lehmann, 2005). The same is true of the US, where the 
monumental financial input of the National Institutes of Health into basic research 
had, as of 2009, resulted in only 84 examples of new drugs or biologics being 
discovered in the previous 60 years (Gottlieb, 2009). There is a perception of 
academics in ‘ivory towers’, engaging with basic research but not with the translation 
of this research or the wider communities around them (Bond and Paterson, 2005). 
This would seem to imply that the academic, or basic research, way of working 
translates poorly into the commercial sector. Academia, however, is also seen as less 
target driven, contributing more fully to the wider scientific community through 
papers and teaching, and giving greater autonomy to researchers (Klee, 2001). 
 
A 2012 report highlights that the types of team working common in industry are less 
well utilised in academia, and that these sorts of team science prioritise the solving of 
complex problems and the translation of research (The Academy of Medical 
Sciences, 2012). Certainly the empirical data gathered from the case study shows that 


the academic/commercial distinction is emphasised by the different ways in which 
the two groups work. Those from a commercial background were used to constant 
reporting, whilst the academics had been more used to self-directing their research. 
The reactions to the Wellcome Trust milestone-based style of project funding are an 
example of this:  
“So we have quite tight milestones and deadlines to meet within the 
project, which is a kind of unusual way of working, normally in a grant 
you get the money to do the work and at the end they say ‘what did you 
do?’. Whereas this is like, they keep tabs on what we’re doing  and ‘oh 
have you reached that mile..’ you have to say what your milestones and 
your goals are over the three years and then, you know, we’ll be checked 
up on to see whether we’ve met the milestones.” (CS/Lab) 
 
“I’ve got used to the milestone led system, more recently, so I don’t mind 
that at all, in fact I actually find it quite reassuring that we have those 
checks and balances in place because it’s very easy to get three years 
down the line and not have done what you were supposed to do. So I like 
that we have that governance system.” (CS/Lab) 
 
Both of these quotes were taken from individuals with a purely academic research 
background, who had little experience of working with a milestone-led project. In 
contrast milestone led working was considered normal practice for those that came 
from a more commercial background. Although not experienced with this sort of 
project leadership the academics came to value the role of the milestones and 
appreciated the governance process imposed upon them. In some cases, they 
considered that the milestones could actually have gone further, for example 
incorporating regulatory, rather than purely research milestones, or forcing the team 
to address at each meeting how its work contributed to each of the key goals.  
 
Another distinction manifested in the team, which also appeared to fall within the 
academic/commercial boundary, was working to Good Manufacturing Practice 
(GMP). GMP is essential in translating a process from laboratory working to an 
acceptable manufacturing protocol and it includes such things as formalising the 
protocol steps and sourcing suitable reagents. Strict requirements for safety testing of 
stem cell products require cells to be produced to the same consistent standards, 
relying on control of the process as much as the product itself (Rayment and 
Williams, 2010). Rayment et al. (2010) also suggest that the cell specifications and 
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culture conditions are set at the beginning of the process to ensure a consistent 
product. This paper, however, is concerned with the clinical translation of stem cell 
products and fails to address the inconsistencies of earlier basic research.   
 
Stem cells are heterogenic by nature and have the ability to differentiate into over 
two hundred cells types, controlling this process is more art than science (Shaw, 
2010). Laboratory bench processes are time-consuming and difficult to scale 
(Williams and Sebastine, 2005) and culture conditions are continuously varied in an 
effort to optimise the process. Shaw (2010) refers to this as a ‘whatever works’ 
process. Whilst this is perhaps true I feel it does injustice to the scientists who 
carefully plan and record all their experiments, and therefore I prefer to refer to it as 
a ‘trial and error’ approach. The message though is still the same, that there is a 
difference between the methods employed by those working in basic research and 
those involved with the translation of that research to produce a viable, and 
consistent, therapeutic product. That is not say that scientists working in basic 
research do not use GMP, indeed they may be working with GMP approved cells and 
reagents and working towards producing a standardised protocol. The difference is in 
the freedom that these basic researchers are allowed (many of whom have never 
previously needed to work under full GMP conditions), as one member of the 
BloodPharma team explains:  
 “A big culture change… it’s just how you work in a lab. Because in a 
research environment you can do, ‘oh I’ll try a little bit of that’ or ‘I’ll 
add a little bit extra medium’ for example, and it doesn’t matter. Whereas 
in a GMP environment you have the protocol which has to be followed, 
and you have to note down absolutely every single thing that you use, 
from what plastic-ware, how many mls of media, what time things go into 
the incubator, what time they go out of the incubator. Every single thing 
that happens to your culture needs to be noted down, just whole control 
of what happens and you feel, coming from a research background, you 
feel you have very little freedom, we are building in more freedom into 
the procedures and that’s been a learning process, how can we make the 
procedures flexible enough to do what we need to do but still comply with 
the GMP and traceability and records. So that’s the way it’s, for me, a 
big change from how you work.” (CS/Ind) 
 
Here we see the balance that must be struck between the different working patterns 
employed by different team members. On the one hand allowing the researchers the 
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necessary flexibility to experiment, whilst on the other moving the process forward 
to the standardised protocol required to produce a licensed product. A period of free 
research allows development of the method which will eventually form these 
protocols. At some point it is necessary for these protocols to become ‘locked-down’, 
at which point the reagents have been approved and the protocol becomes the 
Standard Operating Procedure (SOP) which is followed by all the research sites. 
Although the SOP can be changed if necessary this lock-down prevents the constant 
tweaking which could otherwise carry on indefinitely and ensures that all the 
researchers are working to the same protocol. It can be speculated that this ‘locking-
down’ of protocols may have some parallels with the discourse on innovation ‘lock-
in’. Liebowitz et al. (1995) discuss path-dependence, the idea that technology 
innovation often follows a path that is difficult to deviate from, even when this path 
is later found not to be optimal. Non-optimal technology might be seen as ‘locked-in’ 
to a path, because it would be too costly to change this technology. The QWERTY 
keyboard is often used as an example; the arrangement of keys is not optimal but the 
time and expense of changing keyboards and re-training users makes changing to 
better technology difficult. It is possible that the same problem could arise in locking 
down research protocols, that by the time it is discovered that the protocol used is not 
optimal the cost of changing the path is prohibitive. It is perhaps too early to tell if 
this is the case with stem cell therapies and problems may only come to light many 
years down the line. For now it is clear that manufacturing will require consistency 
as well as quality, and these GMP protocols allow the team to produce consistent 
outcomes across a range of research sites. 
 
Given the different disciplinary backgrounds present within the team the issues of 
expertise were invariably raised throughout the project. The ‘GMP-ing’ of protocols 
was left to those who had experience in the translation of these protocols from 
laboratory to SOPs. The topic of expertise was seen especially in the approach of the 
researchers towards regulatory concerns. The attitude of the researchers towards the 
area of regulation was something which I specifically asked about in the interviews, 
and most of the comments articulated this idea of an ‘expert’, who took care of 
regulatory affairs so that others did not have to.  
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“Yeah, that’s why this is good that, I know that, X deals with that, it’s not 
my area of expertise. [..] And that is where X comes in and knows, and 
that were we can sit back and say ‘well that’s fine, we know that will be 
dealt with appropriately’ and we don’t actually have to be too concerned 
about it ourselves. [...] Because you can only be an expert in a certain 
area and it’s a huge area, it’s a whole area of expertise, let’s face it isn’t 
it.” (CS/Lab) 
 
“You shouldn’t have to be looking at regulatory, that’s why you should 
have someone like me, that I can advise, because it’s a full time job and 
you can’t be expert at everything.” (CS/Reg) 
 
The scientists appeared to be happy to leave the regulatory concerns to others in the 
team, in a way which did not seem the case for other key areas of the project. This 
dividing up of the regulatory process will be discussed further in Chapter Five. 
Indeed in all other areas emphasis was on the need to gain a good knowledge of the 
entire research process. This differentiation could be due to a number of factors, most 
prominently that the scientific research is a coming together of different disciplines 
which are all dependent on each other. Therefore there is a greater incentive to 
understand another person’s work because it may help or hinder something which 
you also are struggling with. In contrast the regulatory areas can be seen as set apart, 
something which the researchers have no need to engage with as long as they follow 
the directions given by those who act as a bridge between the scientists and the 
regulators. It is of course also possible that this distinction between the regulatory 
and the scientific is an artefact of the data collection methods used, that 
misunderstandings between different areas of the scientific work only came to light 
in meetings which I was not allowed to attend. This struggle for each team member 
to understand the wider project shows that what is really needed in the future are 
more people trained in different disciplines, who can bridge the gap between the 
different areas of scientific research, medical and regulatory.  
“I think the one thing we’re missing all round, which is going to have an 
impact, is knowledgeable people in management positions. So, OK 
there’s a lot of good scientists but people with, for instance X’s 
awareness of the regulatory and the clinical and the science are very 
rare. And then the project managers, the regulatory managers with 
specific stem cell knowledge, you were asking whether the regulators had 
that but I think even the next step down, the people that are trying to 
prepare the paperwork are not there. I think we’re missing a tranche of 





Highly skilled and trained staff that can interact with different areas of research are 
clearly seen as the future of scientific work, especially in assisting the translation of 
therapies from laboratory to hospital bed. Stem cells are highly specialised tissues 
and the development of therapies will require people trained in lab work, but who 
also understand the manufacturing and regulatory issues. This convergence of 
expertise is something which sets the BloodPharma project apart and leads it to be a 
‘paradigm shifting’ project.  
 
This section has detailed the importance of expertise and experience that have 
combined in the BloodPharma project through the work of a mixed team. 
Considering the three categories of knowledge creation outlined at the beginning of 
this section my evidence points to interdisciplinary working as the approach which 
best characterises knowledge creation within the BloodPharma study. The quotations 
reveal the importance placed on the bringing together of researchers from different 
disciplines in the pursuit of a common goal. It is possible to discount 
multidisciplinary working, as the BloodPharma case study brings teams together in a 
collaborative way to produce knowledge which is more than just the individual 
inputs. This is articulated by the respondent who talks about the project being a 
‘bigger thing’, with all the groups requiring the knowledge and expertise that is held 
by other members of the project team. This emphasis on the disciplinary 
backgrounds and expertise of the different team members therefore means that the 
third option of knowledge creation, transdisciplinary, is not applicable in this case.  
 
Although working collaboratively the team are still focused on the backgrounds 
which their discipline can bring to the larger project and have not fulfilled the 
transdisciplinary requirement for moving beyond disciplines altogether. It can be 
seen that translating early stage laboratory protocols into the GMP protocols required 
for industrial production requires knowledge in a range of areas. In the BloodPharma 
project this is possible because of the large team that has been brought together. The 
interdisciplinary knowledge creation has relied on many people, with specific 
expertise in a small area, contributing to the larger project goals. An interdisciplinary 
team constructed of researchers with a high degree of expertise in their chosen field 


can bring potential problems in the form of tacit knowledge. The importance of this 
tacit knowledge in the culturing of stem cells will be discussed in the next section.  
 
THE ROLE OF TACIT KNOWLEDGE IN EARLY STAGE LABORATORY 
PRACTICES 
Stem cells are volatile tissues which require skill in control and manipulation, as well 
as in regulatory and manufacturing concerns, to develop a useable product. The 
previous section identified how experience and expertise are vital to the work of the 
team, attributes which are especially important when working with stem cells due to 
the large amount of tacit knowledge used in basic research. This section will explore 
the types of tacit knowledge used by the BloodPharma team, and how this impacts on 
the translation of basic science to future therapies. In the field of stem cell research 
tacit knowledge is seen as contributing to the ability of researchers to grow cells 
which, by their very nature, are unpredictable. The unpredictability of working with 
such tissues is a contrast to traditional pharmaceutical company products, which are 
in the main chemical compounds.  
 
The role of tacit knowledge is becoming more prominent as traditional 
pharmaceutical companies move into the area of biologics (Wong, 2009) and tissue 
based therapies (McKernan, McNeish et al., 2010). Tacit knowledge is considered to 
be knowledge that must be gained through personal experience, the opposite of 
codified knowledge which can be written down or distributed through some form of 
media (Busch, 2008, pg.3). Collins (1974) argued that communities of scientists are 
distinct from each other because each community shares within it large amounts of 
tacit knowledge. This knowledge was difficult to convey through journal articles or 
presentations, and so it could only be shared by people who worked in close 
association with one another. Collins saw that knowledge diffusion between 
laboratories required not just phone-calls and written information, but also visits and 
staff exchanges. In many cases information transfer alone was not enough for another 
team to be able to replicate an experiment, the missing tacit knowledge was crucial. 
This idea of crucial tacit knowledge is repeated in Collins’ later paper (Collins, 2001) 
on the measurement of the quality factor of sapphire. Experimental results achieved 
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in Russia were not replicated until twenty years later, due to the important tacit 
knowledge missing from the original journal articles.  
 
Case study methods are an ideal way of identifying knowledge transfer within a 
particular organisation, providing examples of how tacit knowledge is acquired and 
what happens if crucial tacit knowledge is not transmitted. The use of tacit 
knowledge in the BloodPharma project is related both to physical handling of the 
cells and also to observation. Examples of this observation will be used to 
demonstrate some of the laboratory challenges related to tacit knowledge. As stated 
earlier the laboratory work must be translated into standard protocols and so I will 
focus on the difficulties associated with that transition. Tacit knowledge is an 
important concept in stem cell science because of the nature of working with living 
tissue. Stem cells, by their very definition, are extremely volatile. Capable of 
differentiating into many different cell types the struggle is not simply to 
differentiate them, but to get them to differentiate into the cell type that is required. 
Standardising for uncertainty in the field of stem cell research has proven difficult to 
implement at laboratory level, with many research groups developing ‘local’ 
conditions to produce the best cell growth within a specific laboratory as 
standardised conditions produce inadequate results (Webster et al., 2008).  
 
The reason for this push towards standardisation is that currently different methods 
are used to ascertain the ‘potency’ of a stem cell line. Such examples of uncertainty 
make it difficult to exchange research findings across a field, and so calls are being 
made for increased standardisation of stem cell research (Eriksson et al., 2008). Tacit 
knowledge is also commonly acknowledged within the stem cell community, as I 
discovered when talking to scientists or from conference presentations. People talk of 
laboratory workers being ‘green fingered’, able to grow cells when others could not, 
or of incidences where shaking a bottle the wrong way resulted in failed experiments. 
These appear to be explicit accounts of tacit knowledge at work. The visualisation of 
research processes is an important tool in describing these techniques to others and 




 Images and visualisation are important tools in the early stage development of the 
cultured blood project and here I will concentrate on the use of images for 
visualisation of biological process in the laboratory, and images as they are used in 
discussions by the team, e.g. in presentations. Imaging and visualisation have always 
played an important role in laboratory work, but this is often focused on how 
scientists visualise items that are invisible to the naked eye.  How to ascertain that 
instruments were recording the ‘truth’ gave rise to the idea of the ‘experimenter’s 
regress’ proposed by Collins (1992). As visual identification techniques such as 
electron microscopy become accepted methodologies in their own right the problems 
of validity diminish as the instruments become trusted (Ruivenkamp and Rip, 2010). 
Instead focus turned to which methods were most reliable for visualising the 
imperceptible, and to how these methods become accepted within a scientific 
community.  
 
Visual inspection is a key part of certain processes during this early stage laboratory 
work. For chemical compounds it is normally possible to have set timings and 
temperatures for every step of the process; however this is more difficult for 
experimentation that involves living tissue. Cells may grow faster or slower than 
Figure 2: Cell colonies  
Visual identification of haematopoietic cell colonies during differentiation, to be 




expected and so steps in the protocol require the researchers to make a judgement, by 
eye, of how well the cells are growing and which colonies of cells they should be 
taking forward in the process. Visual identification is therefore used to separate 
mixed batches of cells, to check whether cells are growing correctly or are at the 
right growth stage for the process to continue. Visual identification requires expertise 
and practise and the ability to conduct certain visual identifications is often 
knowledge that is shared within one laboratory, or between a few of the team 
members.   
 
This expertise implies that there is a certain element of tacit knowledge associated 
with making such identifications. Whilst it is true that practice and learning in the 
laboratory accounts for a much higher speed and accuracy it is also the case that 
attempts have been made to codify this visualisation process.  Pictures are used not 
just in training but were also displayed in the lab to give researchers a method of 
visual comparison. The images in Figure 2 and 3 are taken from a PowerPoint 
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Figure 3: Identifying Cell Colonies 
Flowchart showing the different steps in the visual process to identify different types 
of cell colonies, a flowchart made to assist identification using a microscope and 
showing the expertise required to make judgements at each stage of the process. 




presentation designed by a member of the team to teach new laboratory staff how to 
visually identify different types of haematopoietic colonies during cell culture, using 
a microscope. This picture in Figure 2 is also displayed next to the microscope in the 
lab and is accompanied by the identification flowchart shown in Figure 3. The fluffy 
white object, second from left in the bottom row in Figure 2, is actually a bacterial 
colony. It is included as a ‘trick’ after an incident where a student team member 
believed that they were obtaining lots of good embryoid bodies (clumps of cells 
formed at early stages of growth), but had in fact been counting balls of mould. It 
appears that what the rest of the team would consider were obvious differences 
between cells and bacterial colonies were not apparent to the new member of staff 
who had little experience in the visual identification. A mistake such as this had 
subsequently prompted the team to highlight these distinctions in their training 
information. Here we can see that tacit knowledge is not just important in the 
physical processes of handling laboratory experiments but also plays a crucial role in 
mental decision making and identification.  
 
Tacit knowledge is considered to be shared between teams that work closely together 
(Collins, 2001), and the BloodPharma project is no exception to this. Due to the 
nature of the wider project grouping there are researchers who share close working 
environments and similar expertise, but who also interact on a regular (but not daily) 
basis with other researchers, all of whom are working towards a common goal. 
Visual representations of research therefore become an important tool for 
explanation, especially as many of these wider group meetings take place away from 
the laboratory. The visualisation of the RBC has also been prominent throughout the 
project. As will be discussed further in the next section the team have used the 
human body as a benchmark throughout the project. The RBC has therefore come to 
represent the image of the ideal goal towards which the team are striving, in 
similarity to Lösch’s (2006) case study of visionary images as communication in the 
nanotechnology sector. RBCs are highly recognisable and much of the literature used 
in public outreach by the team has featured pictures of RBCs, alongside visual props 
such blood donation bags filled with ‘blood’ (for health and safety reasons actually 
made with glycerol and food colouring ). This visualisation of a RBC demonstrates 
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how the BloodPharma project team is seeking to create something which already 
exists in nature. They are not chasing after a new, imagined, drug or compound but 
are instead attempting to reverse engineer something which the body produces with 
little trouble. The frustration is that whilst RBCs are produced with apparent ease by 
the body, the processes which produce them are extremely difficult to replicate in the 
laboratory.  On one occasion a subset of team members were presenting visual data 
of RBCs, referring to them as ‘doughnuts’ or ‘bagels’, to differentiate what was 
clearly an important difference visual between the two. I was unable to see any 
difference in the pictures shown and the person sitting next to me admitted the same. 
This differentiation was clearly only visible to those who were trained to spot it, and 
therefore a clear example of the expertise and tacit knowledge that existed within the 
different laboratory teams, but not between them. The copyright of these pictures has 
been assigned so I am unable to reproduce them here, however see Figure 2 in 
Griffiths et al. (2012) for an example of the RBC visualisation often presented by the 
team. 
 
The importance of pictures in explanations is becoming more apparent in latter 
stages of the project where different fields of expertise are being brought together. 
Rose (2012, pg.13) writes it is not simply the images used which are important, but 
who is viewing those images. The biological team has now been joined by physicists 
and biochemical engineers who will work on the next stages of the project (the 
subject of Chapter Four). The team is therefore faced with having to explain its work 
to others who may have no understanding at all of the area of expertise. I noted at 
recent meetings that the biologists often use quite complicated explanations, an 
example of which is shown in Figure 4, as if assuming that all those in the room have 
at least some understanding of the diagrams they are presenting. In contrast the 
engineers and physicists use very simple explanations (Figure 5), even using 
everyday objects to represent complex processes. Their reasoning for this was that 
they always assume nobody understands what they are attempting to explain. The 
pictures used here are attempting to visualise the thoughts that the researchers have, 
and we are reminded  
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of the difficulty of explaining cognitive thoughts as discussed by Nersessian (2004), 
who acknowledges the difficulty of explaining a thought process that is not only 
highly individual, but is also shaped by ‘social, cultural and material aspects of 
Figure 4: Scientific explanations by biologists 
This picture was used by member of the scientific team to explain the action of small 
molecules on cell surface receptors. The diagram uses standard annotation to 
represent the two membranes and the receptors which sit within them. The arrows 
represent modes of action of proteins. Although this diagram has a standard layout it 
requires a reasonable level of education in a biological science to understand.   
 




Figure 5: Scientific explanation by physicists  
In contrast to the picture above these two diagrams are typical of those used by the 
physicists in the team to explain the complex methods behind cell sorting technology. 
They clearly show the effort to simplify their explanation so that everybody in the 
group can understand. In this case using the example of balls running down 




practice’.  Coincidentally the subject of her case study was a laboratory growing 
artificial blood vessels, in which those with engineering backgrounds also sought 
biological knowledge on an ‘as needed’ basis.  
 
PowerPoint presentations have been the standard way in which data is formally 
presented and explained to members of the different laboratories in a wider group 
setting. It has also been noted that the researchers draw or doodle on a regular basis, 
especially when in a smaller group setting. These drawings occurred on the back of 
pieces of paper, on napkins during conference dinners, in the margins of slide 
handouts etc. The act of drawing was rarely in order to show the drawing to others, 
instead they seemed to be a way of the speaker collecting their thoughts or of 
sketching out biological processes to see if a certain suggestion held possibilities. 
The lack of examples available to present here to the reader was due to the 
propensity of the researchers to tear them up or throw them away immediately after 
they had finished drawing. I can only speculate as to why the researchers used 
drawing to visualise their work, but I will propose that it is a way for them to collect 
their thoughts in the absence of a laboratory. The complex processes with which they 
work had to be distilled in some way so that they could check that nothing had been 
missed in their explanation. In the laboratory, when talking to me for example, they 
could point at screens or show me images down the microscope. Outside the 
laboratory this was not possible and so they resorted to drawing cells and doing 
Figure 6: Informal drawings 
Two informal drawings by one of the project team. On the left detailing the make-up 
of the blood donation system in the UK. On the right the production of cultured 





calculations on paper instead. These explanations were never ‘for’ me (the example 
in Figure 6 is the only one that I was able to retain) but they seemed to act as a way 
for the researchers to ground their explanations.  
 
The possibility of this mis-identification occurring through the use of visual 
identification highlights some of the problems with tacit knowledge in the context of 
manufacturing these therapies on a larger scale. The important consideration of 
GMP, which requires very specific protocols, does not lend itself well to necessities 
of observation and decision required in stem cell growth. There comes a time when 
the working protocol must be locked-down to the SOP protocol which can then be 
distributed to the other laboratories to ensure that all staff are working to a consistent 
method.  
“And that translation process really starts with getting the protocols from 
the researchers and that can be either something on the back of an 
envelope or it can be something with numbered pages and a title and 
approved.” (CS/Ind) 
 
This idea of the ‘back of an envelope’ protocol reflects some of the spontaneity and 
trial-and-error that exists in laboratory work. The majority of experiments are 
carefully planned, written-up in the appropriate method in laboratory books and 
signed off accordingly. There still, however, exist ‘eureka’ moments, where plans are 
scribbled on napkins during conference dinners or quick calculations are written on 
work benches.  This trial and error represents a constant striving to make the process 
as ‘good’ as possible, be that more efficient, quicker, cheaper (or most likely all of 
these). Protocols could be tweaked almost indefinitely: 
“It’s never something that “this is something we’ve now taken as far as 
we think we can go, it works nicely, here’s the process a, b, c and well off 
you go.” (CS/Ind) 
 
Researchers can become extremely attached to the protocols that they have designed 
and trialled over a long period of time, and it must be difficult to stop improving the 
method and hand it over to be standardised. This close interaction between the staff 
and their protocols could be considered the basis for why tacit knowledge plays such 




basis in the protocols that they designed it is easy to miss the small but crucial steps 
that they perform, and have perhaps missed recording in the written protocol:  
“Or just something you, you just do it ‘like that’.” (CS/Ind) 
 
Once these protocols are taken away and eventually passed to other researchers they 
may find that the original results are not replicable. It is the challenge of those 
translating these protocols to uncover why the method used by one researcher cannot 
be repeated successfully by another, as this conversation shows:  
“A: ”Oh I always reverse pipette at that stage” something simple like 
that can have a big impact on dilutions or the way things are done, so. 
Often with cells I think there’s a lot of, we’re still at the stage where it’s 
still down the microscope observing these, the critical decisions are made 
through observation. So actually the person doing that, if you’ve got 
somebody in a research lab who’s doing that for three or four years, and 
that you hand it to somebody else and they can’t replicate it.  
B: You have to have your eye in for the right, what they’re supposed to 
look like, and that is the thing that’s hard to translate.  
A: But I think it’s engaging early and being able to identify those bits of 
in-house knowledge that people have and identifying those reagents that 
are likely to cause issues down the line and tackling that early.” (CS/Ind) 
 
As we saw earlier the visual identification of cells is extremely important, and 
requires a lot of training in order to get right. Members of the team occasionally 
spend time in each other’s laboratories in order to be able to replicate the protocols 
which are being used (an example of Collins’ (2001) ‘staff exchange’). In later stages 
of the project the team has been calling for a secure online file store that can be 
accessed by all team members across the country, primarily so that protocols can be 
accessed and discussed between team members.  
 
Tacit knowledge is so important because researchers are attempting to gain control 
over cells which, by their very nature, could potentially differentiate into many 
different types of cell. The researchers have to ‘persuade’ the cells to think that they 
are blood, and to think that they are blood inside a person who has been born and is 
breathing outside the womb (in the case of the switch from foetal to adult 
haemoglobin, which is explained below). This manipulation of cells can be seen as 
an excellent example of the experimental intervention that is discussed by Radder 
(2009), who talks of scientists producing new objects through their intervention in 
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the material world. What distinguishes this intervention as an experiment is the level 
of control and discipline over the environment and the experimental process, as well 
as an element of reproducibility (Radder, 2009). Collins (1975) uses the idea of 
reproducibility to study knowledge transfer between scientists, which again returns to 
the importance of tacit knowledge in the replicability of scientific experimentations.  
Whereas some areas of experimentation allow control to be so defined that 
proceeding experiments can be considered identical replications (Radder, 2009), this 
clearly does not apply to the manipulation of living tissues with all its attendant 
inconsistencies. This control that the scientists must gain over nature leads us on to 
the next section, which discusses some of the issues around 
naturalness/unnaturalness associated with RBCs, as well as the use of the body as an 
exemplar by the researchers.   
 
 THE ROLE OF THE NATURAL/SYNTHETIC DISTINCTION AND OF THE 
HUMAN BODY AS AN EXEMPLAR 
The previous section discussed the tacit knowledge that is required in the production 
of stem cell therapies, due to the fact that stem cells require large amounts of 
experience and expertise to control. This section will continue to discuss how the 
team has attempted to use stem cells to produce the tissues that are required, by using 
the human body as a template or exemplar. It will also discuss whether trying to 
mimic the human body is appropriate not just as a tool for research but also as a 
benchmark for regulation. Finally it will introduce the idea of 
naturalness/unnaturalness in the case of cultured RBCs, and discuss the importance 
of this distinction.  
 
Stem cells are, depending on their level of potency, capable of producing some or all 
of the tissues in the body. In the human body they will be subjected to a vast range of 
physical and chemical cues which direct the differentiation of these cells. In the 
laboratory these cues are difficult to mimic, because the cues themselves are not well 
understood, or because the growth conditions and surrounding tissue found in the 
body are not present. In order to control and differentiate these tissues in the 
laboratory the team must look towards the one thing that is capable of this control, 
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the human body. The human body is used throughout the project as an exemplar, a 
benchmark of what the team should be aiming to replicate. The early attempts to 
create alternatives to donated blood had focused on chemical substitutes such as 
artificial oxygen carriers. Despite much effort and funding these alternatives never 
produced safe and effective therapies. As one interviewee pointed out the researchers 
then decided to look towards the human body and realised that the answer probably 
lay in the cells themselves.  
“And it [using chemical substitutes] didn’t work, and then that threw a 
bolt at us, why didn’t it work? And then you think, well there’s probably 
something wrong with it because nature doesn’t have it in the raw, it’s 
taken very great care to evolve a packaging system for this. […] So we 
are going to have to make cells. Something that looks like cells, either 
membrane encapsulated haemoglobin, which might still work.” (CS/Med) 
 
Here we see a theme arising that ‘nature knows best’, recognising that the attempts to 
create free-form haemoglobin was a failure because the body had already worked out 
that this couldn’t be done.  
 
Throughout the project the team constantly look to the human body in attempting to 
improve the growth and maturation of the cells. It is challenging the pre-conceived 
idea that stem cells grown in culture require space and good gas supply in order to 
grow ‘happily’. By looking to the human body it can be seen that haematopoietic 
stem cells give rise to RBCs inside the bone marrow, where they are densely packed 
and gas exchange is minimal. It is hypothesised that the cells may actually perform 
better if these conditions are replicated in the laboratory. The difficulty of getting 
RBCs to enucleate also demonstrates the difficulty in replicating RBC growth in-
vitro. Mature RBCs contain no nucleus, but during development these cells do 
contain nuclear DNA and the nucleus is then lost through the process of enucleation. 
Enucleation literally expels the nucleus from the RBC, and the free nucleus is then 
destroyed by macrophages. Enucleation is visible down the microscope, but the 
signals that direct this process are still not well understood. Early stage RBCs taken 
from human donations and matured in the laboratory do enucleate, whilst the 
cultured RBCs appear to get very close to enucleating without completing the final 
steps. There is speculation therefore that some cues early on in the process of cell 
development are required for the RBCs to later enucleate. This is problematic as the 
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cells grown in culture are a homogenous population of developing RBCs and do not 
contain other cell types. If this unknown signal comes from the macrophages, for 
example, then the team will have to chemically mimic this signal or find another way 
to force the cells to enucleate.   
 
A key theme throughout the BloodPharma project has been the use of the human 
body as an exemplar, as discussed above, coupled with the concept that cultured 
RBCs must look like in vivo RBCs. My data show that the BloodPharma team are 
anxious to distance the cultured blood product from previous technologies, such as 
synthetic blood products, GM crops, and gene therapies, which were not well 
accepted by the wider public. As for cultured RBCs we are discussing how a 
manufactured entity can be shown to be the same as something which already exists 
in nature it may be useful to look more to the area of genetically modified crops, and 
the use of ‘substantial equivalence’. Millstone et al. (1999) write “if a GM food can 
be characterized as substantially equivalent to its ‘natural’ antecedent, it can be 
assumed to pose no new health risks and hence to be acceptable for commercial use”. 
However it is uncertain if substantial equivalence would be an appropriate tool for 
assessing cultured red blood cells.  
 
In the same paper Millstone et al. (1999) claim that substantial equivalence is 
nothing more than pseudo-science, a marketing ploy to satisfy biotechnology 
companies who want to prove that GM crops are safe, whilst setting safety barriers as 
low as possible. However published substantial equivalence studies, such as Baker et 
al. (2006) and Beale et al. (2008), show that a wide range of sophisticated laboratory 
tests are required to produce the results of this so-called ‘pseudo science’. A more 
practical criticism is that the tests used to ascertain substantial equivalence cannot 
stand alone as a methodology because, whilst they identify differences between the 
natural and GM plants, they do not predict what effects (if any) these differences 
may cause (Kuiper, Kleter et al., 2002).  Additional methods, such as toxicology and 
immunology testing, would be needed to establish the phenotypic differences 
between the two plant types. Miller (1999) expresses disbelief at the widely held 
conviction that, because the genes introduced into GM crops are known, this 
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therefore confers superior knowledge of the phenotypes of GM crops over natural 
crops. The criticisms of substantial equivalence tests have led to scientists and 
regulators calling for a move beyond the idea of substantial equivalence, to instead 
focus on safety and toxicology testing. This testing would bring GM crops in line 
with pharmaceuticals, pesticides and food additives, putting the focus on safety to the 
consumer rather than on proving that the GM crop shows substantial equivalence to 
the original variety (Schauzu, 2000).  
 
The need to show that cultured RBCs have equivalent properties to in vivo RBCs 
also has parallels with the concept of ‘bioequivalence’ in generic drug manufacture. 
Once a named-brand drug is at the end of its patent life there is the opportunity for 
rival companies to develop a generic, and normally cheaper, version of the drug. This 
is permitted providing that they can show bioequivalence, that their generic version 
acts in the same way as the original drug (Meredith, 2003). Many companies 
specialise in creating generic drugs, for example the 1972 Patent Act introduced in 
India (which allows patents for production processes only on pharmaceuticals, food 
and agro-chemicals) opened up huge possibilities for R&D in generic drugs and in 
reverse engineering of pharmaceutical processes (Kale, 2010). Proving 
bioequivalence can be difficult and there are criticisms of the different methods used. 
For example Meredith (2003) highlights the problems of extrapolating from test 
subjects to the general population, whilst Hauck and Anderson (1994) and Fluchler et 
al. (1981) chart some of the varying formulas that can be used for measuring not just 
prescribability (the affect that the drug will have on a new patient) but switchability 
(the affect that the drug will have on a patient used to the named brand who is now 
switching to the generic). Although bioequivalence shows some useful parallels with 
cultured blood production it still refers to the equivalence between two man-made 
chemical based compounds, and the way in which these are proven to have the same 
action. 
 
Whilst the team may use comparisons with previous technologies in order to 
understand the regulatory hurdles around the cultured red blood cells, neither 
substantial equivalence nor bioequivalence appear to be fully applicable to cultured 
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red blood cells. One reason is that bioequivalence and substantial equivalence are 
generally used as a way of justifying the requirement for less stringent regulation of 
the new product, whilst in the case of cultured RBCs this regulation will be 
unavoidable. Another point is that substantial equivalence focuses on equivalence in 
everything but the desired change, which is possible in areas such as genetic 
manipulation but not for cultured red blood cells, where such changes are less well 
defined. Similarly bioequivalence looks only for equivalence in function, without 
taking into account the underlying properties. However the BloodPharma team are 
interested in not just the functionality but also the genome of the cells prior to 
enucleation and the proteins present in the cells, as we shall see below,. Therefore it 
would appear that whilst functionality and underlying properties of the cells are both 
of interest, such comparisons are not fully met by drawing on the ideas of substantial 
equivalence and bioequivalence. The general comparison of the BloodPharma 
product with GM crops, although understandable, would also be well avoided lest the 
cultured red blood cells become caught up in a regulatory debate framed around the 
issues of GM crops. It is clear however that some form of ‘equivalence’ will be 
unavoidable in assessing the comparison with the current in vivo red blood cells, and 
to understand fully the issues of public acceptability, as will be discussed further 
below.  
 
Despite the unsuitability of both bioequivalence and substantial equivalence in this 
case, the need to show likeness with in vivo RBCs has been a recurrent theme 
throughout the project, as the quote below illustrates.  
“What they will have is an expectation that they perform physiologically 
the same. And in terms of the physical dimensions I assume that they will 
want them to be the same so that they can squash through the small 
capillaries, because otherwise you are going to get clots.” (CS/Reg) 
 
This quote raises a number of points which the previous substantial equivalence 
literature addressed. The first is the comment that the cells need to ‘perform 
physiologically the same’, which appears to be a reference to both bioequivalence 
and substantial equivalence – i.e. this new product will be safe and effective if its 
performance is indistinguishable from the existing product. This reasoning seems 
sensible (as the second sentence of the quote explains) because if the cells are the 


same size and the same shape then logically they can squeeze down the same 
capillaries as in vivo RBCs.  
“If they didn’t look and act the same, in terms of plasticity and stuff, then 
the regulators would ask you to justify that they won’t cause a 
thromboembolism, that’s.. I’m guessing that’s what they would ask. 
Whereas if you could say, look that pint of blood down a microscope 
looks the same as that pint of blood down a microscope, then there’s 
going to be an ease to that.” (CS/Reg) 
 
It is the second half of the quote that brings in the interesting notion of the visual 
aspect, “if they didn’t look the same” (emphasis mine). There is an assumption that 
looking the same implies that these cells will also act in the same way. We saw 
earlier that a criticism of substantial equivalence is that even detailed knowledge of 
the genetics of an organism cannot predict its phenotype or indeed its physiology. 
Surely then the physical appearance of a cell cannot be expected to accurately predict 
how it will work in the body.  
 
And who is doing the looking? In the previous section on tacit knowledge we 
encountered the expertise and judgment calls which must go into making decisions 
based on visual aspects. Is it the regulators that are looking at these cells or 
somebody who is an experienced RBC researcher? In talking about the ‘ease’ of 
regulation the interviewee is not implying that the regulation will be easy, the team 
are fully aware of the difficulties of regulating this new product, but rather that there 
will be an advantage if they can show that cultured RBCs are identical to donated 
RBCs. This assumes that the regulators will be comparing cultured blood with in 
vivo blood, rather than taking the approach of regulating as if this were a new 
product. Donated blood is currently regulated by the MHRA under its own set of 
regulations (The Blood Safety and Quality Regulations 2005, which include 
components such as traceability, inspections of blood donation facilities, collection, 
processing and storage for both blood and blood products) whilst cultured RBCs are 
expected to be regulated as an Advanced Therapy Medicinal Product (ATMP). 
Clearly then the applicability of requiring cultured RBCs to show equivalence is 
unclear for the present, given that they will be regulated in different ways. It is likely 
that the issue will be resolved only by moving further through the regulatory 
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pathway. There is clearly more scope for discussion on the regulation of cultured 
RBCs, and this will be considered in more detail in the following two chapters.  
 
In discussing the importance of cultured RBCs ‘looking’ visually the same as 
donated RBCs, the question should be raised about what exactly the team mean by 
‘looking the same as’. It is of course possible that by ‘looking’ they mean that these 
cells perform identically to donated RBCs in all of the barrages of tests that the team 
expect to put them through. The previous quote, however, uses the analogy of a 
microscope, which would show only visual data, so in this case it appears the 
interviewee is referring to ‘looking the same’ as being a visual comparison. I must 
also consider the potential that the team ‘dumb down’ information for me in an effort 
to be helpful and allow me to understand. Therefore their idea of ‘looking’ might 
extend beyond mere visual appearance and cover a multitude of other physiological 
testing, for example testing of how well different cells will deform to fit along small 
capillaries.  
 
I think it is therefore helpful to use a concrete example of an instance where the team 
talk about the idea of similarity between cultured RBCs and donated RBCs. This 
example also illustrates the importance of the human body as an exemplar. The 
instance that I have chosen to discuss in more detail is the maturation of 
haemoglobin, from foetal haemoglobin to adult haemoglobin. This quote explains the 
process of haemoglobin maturation in the human body:   
“Foetal blood, the blood you have circulating at the time of birth, it’s not 
the same as adult blood, there is a subtle difference. The haemoglobin 
form is different, and it switches over immediately after birth. All sorts of 
things go on for reasons I cannot begin to imagine. [….] So you start to 
breathe, your circulation changes, things close in your heart. The 
different passageways [that are] open in your heart [in the womb] 
because you don’t need your lungs, so the blood is all shunted right to 
left, at the moment of birth all those things start to happen. And your 
haemoglobin changes.” (CS/Med) 
 
Haemoglobin is the oxygen carrying molecule present in RBCs and comes in two 
forms, foetal and adult. Foetal haemoglobin circulates in the body of the foetus 
before birth and this form of haemoglobin binds oxygen with a greater affinity than 
the adult form, allowing the foetus to maximise oxygen transfer from its mother’s 
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bloodstream (Giardina, Scatena et al., 1993). After birth the foetal haemoglobin is 
gradually replaced by the adult form of haemoglobin, until it has reached its eventual 
level of <1% by the time the child is around two years of age (Thein and Menzel, 
2009). This change is not irreversible and adults retain some ability to produce foetal 
haemoglobin. There are certain blood disorders in which this normal switch from 
foetal to adult haemoglobin levels does not occur and these disorders are clustered 
together under the term ‘Heredity Persistence of Foetal Haemoglobin’. In normal, 
healthy, persons a persistence of foetal haemoglobin produces no major 
physiological effects (although it can be advantageous in those who also suffer from 
sickle cell anaemia2) (Conley, Weatherall et al., 1963).  
 
Getting RBCs to produce adult haemoglobin is no small task. In the human body 
they will be interacting with various other tissues and subject to a vast range of 
biological cues from the body. In the Petri dish this is an entirely different matter, as 
the cells must be persuaded that they are in an adult human and not in a laboratory. 
The biological cues that give rise to this change are not well understood in vivo, so 
mimicking these in the laboratory will be a difficult task, with seemingly little 
advantage other than to show biological equivalence to the regulators. There seem to 
be few biological problems associated with foetal haemoglobin, as evidenced by 
those who continue to produce foetal levels throughout adulthood. However, the 
effort and research funding that the team are currently spending on making sure these 
cells mature in the laboratory would appear to be evidence that it believes the 
cultured RBCs have to exhibit mature haemoglobin. This then is an explicit example 
of the team striving to show substantial equivalence, using the human body as an 
exemplar, because it believes that this substantial equivalence will be required by 
regulators. It also highlights the necessity of specific testing, as (as far as I am aware) 
the presence of foetal or adult haemoglobin could not be identified through visual 
identification alone. This discussion of bioequivalence and substantial equivalence 
and their relationship to the development of cultured RBCs only arises because of the 
                                            
2 Normal haemoglobin molecules are composed of two pairs of protein subunits, known as 
alpha and beta, whilst foetal haemoglobin has slightly different subunits, alpha and gamma. 
The gene for sickle cell disease affects the beta subunits, which are not present in foetal 
haemoglobin, and therefore RBCs containing foetal haemoglobin do not sickle.     
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distinction between the in vivo RBCs and the cultured RBCs. This could be 
constructed as a difference between the ‘natural’ RBCs of the body and the 
‘unnatural’ RBCs of the lab.  
 
If we consider blood made within the human body to be ‘natural’, in that it is formed 
by nature without human intervention, then what should we consider cultured blood 
to be? And does this distinction matter? Cultured RBCs occupy a unique niche when 
considering questions of natural/unnatural. As mentioned in the previous section on 
substantial equivalence cultured RBCs can be seen to have many parallels with 
genetically modified crops, in that they are essentially a manipulated version of the 
natural product. The abiding worry with GM crops seems to be that they are too 
natural, able to potentially hybridise with wild variants and escape the control of 
their producers (Raybould and Gray, 1994; Stewart Jr, Halfhill et al., 2003). RBCs 
do not have the potential to ‘escape’ in this way, but are there other important 
reasons to distinguish between the natural and the manufactured?  
 
Scientifically being able to distinguish between the in vivo and the cultured cells 
would have certain advantages, one of which is the prevention of doping in athletes. 
Blood transfusions (either autologous or allogeneic) can be used to give a competitor 
a boost of RBCs beyond their normal levels, leading to increased levels of 
haemoglobin, better oxygen uptake and therefore faster race times (Brien and Simon, 
1987). RBC doping cannot be detected by standard urine samples, and relies on 
blood sampling to gauge whether the number of red cells and haemoglobin levels 
appear to be exceptionally high in particular individuals. Anti-doping organisations 
have already approached the BloodPharma team to see if its expert knowledge of 
blood can assist in identifying whether athletes are using donations to boost their 
haemoglobin levels before an event. These organisations are especially interested in 
changes that may occur to the RBCs, which would indicate that cells have recently 
been returned to the bloodstream. Haemoglobin-based oxygen carriers have also 
been used in doping and, like RBC transfusions, require the athletes to undergo blood 
tests as these doping methods cannot be detected using urine sampling (Ashenden, 




production stimulants such as EPO used to boost the athletes own red cell count 
(Jelkmann, 2007).  
 
Although there are practical reasons for wanting to distinguish between in vivo and 
cultured RBCs, there is also the consideration of the natural/unnatural distinction, 
and there are two ways in which this distinction can be made. The first is the 
distinction between ‘natural’ donated blood and ‘unnatural’ cultured blood. The 
second is the distinction between ‘natural’ cultured blood and ‘unnatural’ artificial 
blood.  
 “Remember the pluripotential stem cell line itself is not something that 
you normally see in-vivo, it’s an artefact…” (CS/Med) 
 
The stem cell line is an artefact, one that does not exist in the body, or in nature. This 
would indeed imply that the products of that stem cell line, in this case RBCs, are in 
some way unnatural. Although it would appear that cultured blood could be 
considered distinct from in vivo blood I was interested to note that in a conversation 
with some Jehovah’s Witnesses3 they articulated that they would not accept cultured 
blood. Although they will accept some chemical blood products they will not accept 
anything containing the main blood components, so in this case cultured RBCs were 
too ‘natural’, even though they did not come from a living donor.  
 
However we contrast the cultured and in vivo RBCs they are still different versions 
of the same biological entity, much like the distinction between established and GM 
crops. The aim of the BloodPharma project has been to create RBCs which are as 
indistinguishable from the natural version as possible. This is then in stark contrast to 
chemical blood substitutes which are markedly different from either cultured or in 
vivo blood. In her book ‘Purity and Danger’ (1966) Mary Douglas raises questions 
that are also pertinent to the subject of naturalness in the case of cultured blood. 
Beliefs about uncleanliness and defilement demonstrate the deep-seated anxiety 
                                            
3 Jehovah’s Witnesses interpret literally the Bible verse Deuteronomy 12:16 - “Only you 
shall not eat the blood; you shall pour it upon the earth as water” (King James Version 
2000). They do not accept blood donations or any blood products made from red cells, white 
cells or platelets. 
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about bodily waste and certain body tissues. Douglas states that in modern society 
dirt can be considered as ‘matter out of place’, that something is ‘unclean’ because it 
contravenes the accepted system (Douglas, 1966 pg.44-45). Cultured blood could be 
said to contravene our accepted system. By being neither a synthetic chemical 
derivative nor a human donation it does not fit into either category with which we are 
familiar.  
 
Cultured blood could be considered ‘dirty’ because of its unnaturalness and out-of-
place-ness, but in vivo blood has historically been considered unclean. Douglas 
(1966) includes many examples of societies in which menstruating women are 
considered not just unclean but able to defile others by their touch. Blood donations 
in the USA were marked with the race of the donor to pacify white recipients who 
believed they would be defiled by receiving blood from a black donor (a practice that 
continued until the 1960’s) (Starr, 1999, pg.109,169). More recently the HIV/AIDS 
and Hepatitis scares have led to blood being viewed as potentially unclean and 
contaminated. Whilst cultured blood could be considered unclean it is apparent that 
cleanliness is something that has rarely been attributed to natural blood. Using the 
human body as an exemplar may have implications if the cultured RBCs come to be 
viewed in some way as unclean or a substandard synthetic alternative. The scientific 
team does, however, have the distinction that the product it is aiming for already 
exists in nature. We see here then that instead of reliance on substantial or bio-
equivalence we should turn instead to recognise the important of ‘bio-social 
equivalence’. This is a sign that other forms of ‘equivalence’ are important in 
understanding the acceptability of the cultured blood product, as wil be discussed 
further in Chapter Six. This has implications for the foresight of the product, as the 
end product is more concrete than some innovation visions can be seen to be. For 
example in Fleck et al. (1990) the requirements for some sort of word processing 
technology were clear, but in the early stages the form that this technology would 





THE ROLE OF EXPECTATIONS IN THE DEVELOPMENT OF CULTURED 
BLOOD  
Developing a product or technology over a long time frame necessitates some use of 
‘foresight’, an imagined end goal towards which the developers are working. 
Although drawing here on ideas of foresight it should be clarified that the 
BloodPharma team was not engaged in formal foresight procedures, rather the 
foresight here refers to more informal anticipatory activities. In the BloodPharma 
project we see that such informal foresight is not limited to the product itself but also 
to a perceived notion of what the regulators will require from the product and the 
long-term expectations of the product itself. The choice to discuss some aspects of 
foresight here, before the following chapter on scale up, clinical trials and future 
markets, is a deliberate one. Introducing the imagined ‘end product’ early on in the 
thesis reflects the early stage at which foresight occurs in the scientific research. This 
section will address how foresight and expectations contribute to early stage 
laboratory work, starting with the choice of the project itself before discussing 
expectations of both funders and the project team, anticipation of regulatory 
concerns, and potential future markets.  
 
Although the original funding call from DARPA initiated the bringing together of the 
BloodPharma team the decision to pursue cultured RBCs was directly influenced by 
the physiology of the RBCs themselves. It was considered that compared with many 
other stem cell therapies RBCs have distinctive properties that would make them 
easier to pass through the regulatory system, as this interviewee explains:  
 “And it’s such a simple tissue, this is the thing, and I think this is why as 
a stem cell product it is ideal because it’s a single cell type, it’s 
administered IV, it’s a short lived transplant so, it just seems like the 
ideal thing to reinvent. [..]And we can sterilise it, you can irradiate it at 
the end as well, you can clean it up as far as possible. And we know how 
to handle it and it’s being done at the same volume already, it’s just the 
manufacturing issues, the actual distribution and administration issues 
are all dealt with. So it seems like a no brainer, but that’s with the rose 
tinted glasses on.” (CS/Lab) 
 
Other stem cell products show increased levels of difficulty in administration of the 
stem cell therapy to the target site. Two recent stem cell trials include the ReNeuron 
stroke trial and the US Geron paralysis trial. The ReNeuron project aims to use stem 
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cells to repair damage caused to the brain tissue during a stroke, whilst the Geron 
trial sought to repair spinal cord tissue after paralysis. The Geron trial has since been 
abandoned, whilst the ReNeuron trial is still ongoing.  These therapies, although the 
trials were initially only looking for safety, required the injection of stem cells 
directly into the brain and spinal cord of patients respectively. These are both 
complex operations and in comparison, the intravenous method of introducing 
cultured RBCs into the patient is inexpensive, easy and low risk.  
 
The length of time of patient follow-up is also under discussion regarding stem cell 
therapies. For most stem cell therapies a long patient follow-up time is proposed due 
to the potential risk of tumorigenesis, which may take many years to become 
apparent. In comparison to other stem cell products RBCs are short lived, lasting 
only around 100 days. The length of patient follow-up appropriate for cultured RBCs 
is not yet clear. Fully developed RBCs are the only cell in the human body that do 
not contain a nucleus, meaning they do not pose the same risk of DNA transfer that is 
problematic for other types of stem cell derived tissue. This lack of DNA also means 
that cultured RBCs can be treated to remove pathogens, for example by using 
radiation, which is not possible with other tissue types. The irradiation step shows 
that RBCs also contradict Rayment and Williams’ (2010, pg.997) statement that 
“viable cell- and tissue-based produces cannot undergo a terminal sterilization step, 
as is the case with other pharmaceuticals”. RBCs have some unique advantages over 
other types of stem cell therapy and they are therefore perceived by researchers as a 
potentially unproblematic therapy to pass through the regulatory system. They also 
illustrate one of the major difficulties in regulating cell based therapies, that often 
blanket regulations are inappropriate in the face of therapies which are exceptions to 
the normal rules.  More about the regulation of cultured RBCs and stem cell 
therapies in general will be discussed in Chapter Five.  
 
The reason for an anticipated end product is primarily a pragmatic one, it would 
simply be impossible to direct multiple individuals and millions of pounds worth of 
funding without a definite research target.  Indeed, it is recognised that expectations 
are crucial for mobilising funding (Borup et al., 2006). The criteria for obtaining 
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research funding also forces researchers to identify at an extremely early stage things 
such as target markets, potential patient groups, specific details about the eventual 
product etc. In many cases the extreme foresight required by funding bodies must 
occur before any of the basic laboratory research has started, or has even been proven 
to work, when the outcomes are still uncertain. Rappert (1999) presents the UK 
Foresight Programme as an attempt to overcome this uncertainty in innovation, 
whilst Anderson (1994) demonstrates that foresight could be seen as working against 
the nature of early stage research by attempting to engineer in certainty, which does 
not yet exist. This is similar to Williams’ (2006) work on the compression of 
foresight, with early assessment of Ethical, Legal, and Social Implications (ELSI) 
leading to a linear vision of the technology trajectory. Whatever the impact of 
foresight on the autonomy of researchers the increasing disparity between the 
funding available and the number of proposed projects means funding agencies must 
apply some level of strategic forward planning, in order to fund projects seen as most 
beneficial to society and that demonstrate best value for money (Anderson, 1994). 
The Wellcome Trust, which has funded this stage of the cultured blood project, is 
seen to have taken a considerable risk funding such a large project, the outcomes of 
which are unclear. The sentiment expressed by the researchers is one of gratitude that 
the funding body was able to take that leap and fund the project despite the 
uncertainty. The risk taken by the Wellcome Trust in funding this project perhaps 
explains the stricter milestone-led method of funding. Using milestones allows the 
funder to keep closer control on the project outcomes and to check that the goals of 
the project are being met within a reasonable time frame. The criticisms of foresight 
in removing the autonomy of researchers are perhaps exacerbated by this milestone 
way of working, which not only sets out what the researchers must be achieving but 
gives a stricter time frame in which this must occur. On the positive side having 
milestones allows the researchers to concentrate on a subset of activities for a shorter 
time period, rather than constantly having to project their expectations to an end 
product that may be many years away.  
 
The expectations of the researchers themselves are a key consideration throughout 
the project. Those working on the BloodPharma project not only have to engage with 
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a projected vision of an end product that may be many years away; they also face 
challenges of working in a diverse team. Each team member has their own 
expectations about the outcome of the project, and managing these expectations is 
key to coordinating the team as the project moves forward. Borup et al. (2006) call 
this the ‘performative’ nature of expectations, building mutual bonds and shared 
goals. The foresight employed by researchers during the case study appeared to be 
highly individualistic. Whilst the team presented a collective front to other 
academics, the public and potential funders there were underlying differences of 
opinions between members of the research teams. I do not wish to imply that the 
united front presented by the team was in any way disingenuous, simply that some 
appeared to look further into the future than others.  
 “I mean if I really want to speculate then I don’t see it taking over blood 
transfusion ever actually. But I can see it being used to produce cells that 
could be used in specific circumstances.” (CS/Lab) 
 
Another researcher also told me that they personally did not see the end goal as being 
the supply of blood to the transfusion service. Instead for them it was a research 
project in which they would dramatically advance knowledge and understanding of 
RBCs and how they develop in the body. In contrast many of the researchers did see 
the end goal as potential replacement of the blood transfusion service: 
“Fifty year view I think it has to. I just think that the risks of donor based 
collection and transfusion services are as outdated now as giving person 
to person transfusions were in the early days. I think we have to move 
on.” (CS/Lab) 
 
Although they did see this as a very long term view, with the aim of the current 
funding stream simply to be the first step on that ladder.  
“It is to my mind that in the end of the three years we have a small 
amount of a product, that has been produced at a clinically acceptable 
grade, which would be able to go into a person if we were in the position 
to do so. […] But no, to my mind if we have a tube with 10 mls of blood 
in, 10 mls of packed red cells from ES, that were suitable to go into a 
patient, a person, that’s my defined aim, very much.” (CS/Lab) 
 
Understanding the different goals articulated by the researchers has only been 
possible through focusing on this case study and eliciting empirical data from a 
variety of actors over a long period of time. The united front which the team must 
present to funders and the public is difficult to unravel without this methodological 
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approach. Managing the expectations of a diverse team is an essential part of 
working in a mixed team (Bidault et al., 1994). Literature on interdisciplinarity often 
highlights the need for teams to produce a consensus, a shared view of the project 
which includes defining the project outcomes, a suitable methodology and 
appropriate theoretical perspectives (Frodeman, 2010). Whilst the BloodPharma 
team have undoubtedly reached a consensus as to the main project outcomes there is 
still retention of individual expectations about the project.  
 
From inception and through basic research the future requirements of the regulators 
have been considered. If the cell lines are not derived to the appropriate standards 
then there is a fear that the development of the product may have to be repeated from 
scratch using approved methods. The team, therefore, have sought to go above and 
beyond the current requirements, in order to ‘future proof’ their research against any 
requirements that are later introduced.  
“We would make small choices, so for example if there was a clinically 
used reagent available rather than a bog standard research grade one we 
would start with the clinical reagent, just to build in that extra.” 
(CS/Lab) 
 
But they were also very clear that they wouldn’t do something for the sake of the 
regulatory system that was not also academically viable:  
“So no I don’t think I would ever take a route purely because it was 
regulatorely more simple, if it wasn’t scientifically screaming out as 
being the right route. […] If X were to say to us ‘look guys, this is never 
going to be acceptable, there’s no way you can use this reagent or this 
method, start again’ then obviously we’re going to have to listen to that. 
But given that at the moment a lot of the work is informing the regulation 
still it’s not yet become an issue.” (CS/Lab) 
 
This quote illustrates the difficulty of attempting to adhere to expected future 
concerns of the regulators, when the regulators themselves are also making decisions 
based on new scientific evidence that arises during the research. Indeed it became 
apparent that there is a fine line between foresight and ‘second guessing’. When 
visiting the laboratories the researchers often told me that they were doing something 
‘because the regulators will want it’. When questioned further however it often 
became apparent that that dialogue had not yet been had with the regulators. This is 
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not to say that the researchers were wrong in their assumptions, simply that on 
occasion they were working to perceived regulatory conditions which had not yet 
been verified. As one interviewee said when the question was put to them-  
“Aye, they shouldn’t do that. That’s why they have regulatory affairs 
people!” (CS/Reg) 
 
The eventual end use is an important future vision for any new innovation (Bidault et 
al., 1994) and we have seen that the imagined final target is used to coordinate both 
researcher effort and research council funding. We discussed above some of these 
expectations, with different individuals articulating a different envisaged goal for the 
project. These envisaged goals did not appear to be connected with the background 
of the individual, or with their status within the team (as a PI or a lab researcher for 
example). What, however, did differ with background experience was the 
expectations of how this product will be used – particularly referring to the proposed 
target populations. The choice of target populations will be discussed in greater detail 
in Chapter Four, but these populations are likely to be patients suffering from 
thalassemia or sickle cell disease. Cultured blood has the benefit of better blood-
group matching and reduced side effects for patients such as these, who require 
regular blood transfusions. One member of the team with a medical background 
talked about his work with sickle cell disease in Ghana, where he had seen first hand 
the devastation that it caused.  
“So anyway, we go there and wandering around Northern Ghana, where 
sickle cell disease is endemic, sort of where it began really, malaria is 
endemic. And every hospital “do you see many sickle cell patients?” – 
“oh no, we don’t see any”. Right. And “lots of carriers but we never see 
any sickle cell disease”. Kids all die, and they don’t resuscitate them. 
[…] So one in four of the children die, children of a couple of carriers, 
and 2 in 4 are carriers and 1 in 4 gets malaria, sadly. So it’s an awful 
gene.” (CS/Med) 
 
The interviewee had gone to Ghana because he wanted to see first hand the effects 
that sickle cell disease has on a population where it is endemic. His reference to 
malaria is due to the connection between the sickle cell trait and the malaria parasite. 
Whilst having two copies of the sickle cell gene is generally fatal, having only one 
copy offers the individual protection against the malaria parasite, hence the 
prevalence of the gene in areas of high malarial infection (Aidoo et al., 2002). In 
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discussing future work the team often referred to sickle cell or thalassemia patients as 
potential target populations, the way they would benefit from the cultured blood 
product, and so on. It struck me, however, that on the one hand there are members of 
the team that are medics specialising in haematology and who have experienced first 
hand patients suffering from these diseases (both in the UK and abroad). In contrast 
there are research scientists, working towards the same goal but who have probably 
never met a sickle cell or thalassemia patient. Their closest contact may have been 
witnessing some misshapen RBCs under a microscope. Yet all the team appear to 
speak about the target populations in the same way, about how they see the benefits 
that their cultured red cells will bring to improving the lives of these patients.  
 
It would seem as if the research scientists have ‘borrowed’ this insight from the 
medics, who perhaps in turn relay to the scientists what they have witnessed first 
hand of these patients. It is an interesting consideration that people from diverse 
backgrounds have been able, together, to form a cohesive view of the benefits to 
target populations, which all seem to believe with equal fervour. Borup et al. (2006) 
write that “expectations link technical and social issues” because expectations look to 
the future where the technology is in use, and is therefore bound up with social 
considerations. The imagined use in target populations shows this technical-social 
linkage in action. The expectation focuses not just on cultured RBCs that are suitable 
for use, it is also bound up with the vision that they will be used to help vulnerable 
populations where current treatments are less than perfect. Although the end goal 
may be to supply the whole blood transfusion service this is a 20 year vision, whilst 
the target populations are a much closer possibility. This is also a reason why the use 
of target populations is likely to be foremost in the researcher’s minds. 
 
This section of the chapter has discussed the importance of foresight and 
expectations in the early development of a stem cell therapy. We have seen that 
blood cells have unique properties which may give them certain regulatory 
advantages, but that the regulatory path is still unclear and that the researchers must 
‘second-guess’ the regulators or go above and beyond what is expected in order to 
avoid future problems.  There is an important distinction that can be drawn out, 
	

however, between stem cell therapies and other potential innovations. The literature 
around foresight and expectations generally refers to a future vision of something 
that does not yet exist. With stem cell therapies (and to a certain extent with drugs 
and biologics) the end vision is very clear because these therapies are designed to 
mimic tissue which already exists in the body. As one interviewee commented - “it 
just seems like the ideal thing to reinvent”. The end product here is very clear, as was 
discussed in the previous section on the exemplar, they have to look and act like in 
vivo RBCs. Although the route to this end product may still be unclear, and the 
eventual uses of the product uncertain, the team do benefit from having a clear vision 
of the end goal which can be shared by the whole team. Although this clear vision 
may assist in the co-ordination of a team who come from mixed backgrounds it can 
also be a burden. Where the end product is just a vision it is possible to change that 
vision as challenges come to light along the developmental pathway. This is not 
possible with the cultured blood project as its end goal is to mimic biological cells, 
there is no room for manoeuvre around this and anything short of substantial 
equivalence may mean that the project is halted before the therapy reaches the 
market.   
 
CONCLUSION  
This chapter has revealed how early stage laboratory work is achieved through 
interdisciplinary, multi-lab working, where standardisation of methods is difficult 
and where there exists an accepted technology. Themes of uncertainty, non-
standardisation, and foresight feed into early stage laboratory work in the 
development of a stem cell therapy. The BloodPharma case study has shown how 
groups from different backgrounds carry out interdisciplinary knowledge creation 
under a funding model that is very different to standard laboratory working. We have 
seen how interdisciplinary working brings together groups with a diverse range of 
expertise and tacit knowledge to tackle such a large research challenge. Differences 
can be seen between basic scientists, who understand the biology of the cells, and 
clinicians who understand the clinical applications of such a therapy. There is also 
diversity between basic scientists and those with an industrial background, 




translation. Despite differing areas of research the team work collaboratively, giving 
no impression that certain types of expertise are more important than other.    
 
The importance of such expertise in the production of a stem cell therapy can be 
linked to the use of tacit knowledge in the stem cell field. We have seen that stem 
cells are volatile and unpredictable cells, requiring large amounts of control in order 
to direct to become the desired tissues. Much of the basic science requires visual 
processes, which in turn are dependent on the experience and expertise of the 
researchers. Examples of visual identification were presented here, showing the 
difficulties of identifying stages of cell growth and the charts which had been created 
to assist researchers in this process. The different presentation styles between the 
biologists and the physicists was also used as an example of visualisation within the 
project, as were the use of diagrams drawn by the researchers when discussing their 
work. The difficulty of standardising these ‘back of an envelope’ protocols into the 
standard operating procedures required for future work was discussed as one of the 
main challenges which tacit knowledge brings to basic research.  
 
Throughout the case study we witness the importance of the RBCs themselves, and 
here we have seen their importance in relation to the use of the human body as an 
exemplar. The BloodPharma team occupy the unusual position of already having a 
viable product in blood donation, and therefore seek to mimic this in vivo blood in 
the laboratory. This use of an exemplar provides a target for which the team can aim, 
for example looking at the human body and trying to mimic the cues and conditions 
for RBC production in the laboratory. The use of bioequivalence and substantial 
equivalence was introduced, as they relate to pharmaceuticals and GM crops, and 
how they can also be seen to apply to cultured RBCs in this case. The use of 
equivalence was seen mainly to relate to an expectation of the regulatory system to 
see a cultured product which compared exactly with in vivo RBCs. However I 
introduced the use of foetal haemoglobin as an example of equivalence seemingly 
being placed above discussions about whether exact similarity matters in practice. 
The use of the human body as a benchmark led to discussions of the 
natural/unnaturalness of the cultured blood product. It was seen that there are a 
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variety of comparisons, between the ‘natural’ in vivo blood and ‘unnatural’ cultured 
blood, or between the ‘natural’ cultured blood and the ‘synthetic’ chemical blood 
substitutes. Whilst this distinction may not affect the regulation of the cultured blood 
product, we saw that questions of perceived cleanliness or ‘matter out of place’ could 
affect the uptake of a potential product.  
 
Finally I have discussed the use of foresight in the BloodPharma project, which 
mimics the early stages at which the team themselves must look ahead to the 
eventual end product. Managing a consensus about the eventual end product is 
crucial to building such an interdisciplinary team, although we have seen that there 
are variations in expectations between team members about the eventual use of this 
end product. RBCs were shown to be an ideal target for research due to their easy 
administration and ability to be sterilised, in contrast to most other stem cell based 
therapies. Much of the foresight employed by the BloodPharma team referred to an 
expectation of the future regulatory requirements, using the best available reagents 
and GMP conditions for example, in order to convince the regulators of the 
provenance of the cells and avoid having to repeat any earlier work. Much of this 
regulatory foresight however had not been articulated by the regulators themselves 
but was an attempt by the researchers to anticipate future problems which they could 
tackle during the basic research stage. Scale-up and clinical trials require not just 
GMP quality research but also consistency, to take laboratory protocols and translate 
them into working protocol that will produce many litres of product. This is the next 
step towards a clinical trial of cultured blood, which is one of the many hurdles 







CHAPTER 4: IMAGINING AND SHAPING FINAL 
PRODUCT AND FUTURE MARKETS 
INTRODUCTION  
The previous chapter discussed the early stage laboratory processes required in the 
development of cultured RBCs. At that point the team was still struggling with 
uncertainty around the enucleation and maturation of these RBCs. This chapter 
explores the anticipated processes and challenges once the enucleation and 
maturation hurdles have been overcome and the team is capable of creating small 
quantities of mature enucleated RBCs in the laboratory. I will focus specifically on 
the future challenges and opportunities of translating this emerging product into a 
viable clinical therapy.  
 
The key question addressed in this chapter will be:  
What does the Team see as the key challenges associated with translating cultured 
blood into a viable clinical product and how do these shape everyday practices? 
 
Moving from laboratory scale to the vast volumes that would be required to replace 
the current donor blood transfusion service presents a number of unique challenges 
to the BloodPharma team. In the previous chapter we explored the important role that 
tacit knowledge plays in the production of stem cell therapies. Taking forward this 
‘hands-on’ laboratory approach to a larger, and increasingly automated, production 
system presents significant and complex problems for the team to overcome. The 
already interdisciplinary team of the BloodPharma project will be further augmented 
by physicists and engineers whose skills and expertise are required to meet the long-
term project goals. In this chapter we will follow the team members as they discuss 
potential routes through the primary hurdles of scale up, clinical trials and the 
identification of suitable target markets.  
 
The first section of this chapter will look more closely at the scale-up which will be 
required to produce the cultured blood product. Scaling up the laboratory product to 
a level suitable not just for clinical trials but eventually for patient use presents many 
	

challenges to the team, many of which are unique to the production of stem cell 
therapies and to cultured blood. To supply an entire transfusion service will require 
the development of specialised scale-up techniques and vessels. It is expected that it 
may require 20,000-25,000 litres of volume to produce 100 units of blood (a tiny 
proportion of the 2.2 million units required each year just in the UK), with the largest 
current bio-reactors in the world only holding 20,000L. The UK alone uses 2.2 
million units of blood a year, leaving the team with an massive scale-up challenge. 
The first hurdle will be to supply enough product to be used in first-in-human clinical 
trials, although there is likely to be an additional requirement for pre-clinical animal 
studies, which will also require production of the cultured blood product.  
 
Human clinical trials are recognised as a necessary safety measure in the 
development of any drug or therapy. For stem cells, however, the applicability of 
animal trials is not so clear cut and there is an ongoing debate about the efficacy of 
introducing human cells into animals. This second section of the chapter will present 
some of these considerations and the discussions concerning potential animal trials 
for the cultured blood product. Data from the BloodPharma team will be contrasted 
with interview data from another stem cell trial which is currently underway, and 
which is further down the regulatory pathway than the cultured blood project.  
 
Assuming that the cultured blood product is shown to be safe and efficacious in 
clinical trials the next stage in the process will be the gradual introduction of the 
product to patients, which will be discussed in the final section. This is likely to start 
with the identification of small target groups who will benefit most from the cultured 
blood product. Potential target groups will be discussed here, as will future steps for 
introducing the BloodPharma product to a wider market. Throughout the project the 
team has discussed potential improvements that could be made to the product. These 
include making the product storable at room temperature, or using iPSC techniques 
to ensure better matching for patient groups.  Some of these proposed advances will 
be presented, alongside the potential improvements that they could bring to the long-




A key theme of the chapter is the unique challenges that are presented by stem cell 
therapies during this translation phase. These challenges are especially evident in the 
next two sections on scale-up and clinical trials.  
 
THE CHALLENGE OF SCALE-UP AND AUTOMATION OF THE 
BLOODPHARMA PRODUCT 
Translating the laboratory methods used to produce small quantities of RBCs into a 
large scale production process represents a major challenge of the BloodPharma 
project. Overcoming this hurdle requires the project team to consider new 
technologies and practices which may benefit this scale-up process. It is useful at this 
stage to consider the level of scale-up which will be required if the BloodPharma 
project were to make a significant impact on replacing donated blood. Every 500ml 
unit of blood contains around 2 trillion RBCs, and the UK requires 2.2 million of 
these units just to supply the current transfusion need (Mountford and Millican, 
2011). Data obtained from the BloodPhama team show that they estimate it will 
require around 20-25,000L of manufacturing capacity for every 100 units of cultured 
blood produced. This is because in addition to the cells there is also a significant 
volume of media required, which contains food and other chemicals necessary for 
cell growth. In attempting to understand in real terms the volumes involved here I 
used these figures to make a rough estimate (around 6,000 units required per day in 
the UK, equating to 60 batches of 100 units each with each batch requiring up to 
25,000L to produce) that it would require the same volume as four Olympic 
swimming pools to produce the cultured RBCs required for one day of transfusions 
in the UK. Clearly the scale-up required will be enormous and must represent a step-
change in the technology used.  
 
Indeed it is important to note that translating a method from the laboratory to 
industry is not simply a matter of repeating the laboratory process numerous times; 
rather there are additional factors of automation and standardisation which I will 
discuss in this section. A useful analogy used by one of the team members is that 
moving from the laboratory to industrial scale is similar to cooking a meal for two 
people and then having to cook for 200 people. Although the end result may be the 
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same the process involved is very different and requires something more akin to 
factory processes. 
 
Since scaling up a stem cell product to the required volume necessitates something 
akin to a factory production process then we must consider two important 
requirements – automation and standardisation. Automation naturally leads to a high 
degree of standardisation, whilst the requirement for a standardised end product 
presupposes an automated process as the best method of production. As we saw in 
the previous chapter stem cell expansion requires a huge amount of tacit knowledge, 
experience, expertise and hands-on manipulation from the researchers. A degree of 
automation is the first step in reducing the requirement for large amounts of human 
resource which laboratory processes involve, and which makes laboratory work so 
consuming of both time and monetary resources. The constant and ongoing 
intervention currently required for most stem cell culturing has made stem cells a 
difficult prospect for processing in automated manufacturing plants which necessitate 
unvarying protocols (Placzek et al., 2009). In 2008 a workshop supported by the 
ESRC’s Stem Cell Initiative brought together members of the regenerative medicine 
field to discuss the issues of automation in stem cell research. Their report raises key 
points such as the need for technology to link production steps that are currently 
semi-automated in order to reduce human intervention, and the importance of 
automation for standardising the stem cell field (Webster, 2008).  
 
With increasing integration of research equipment and computer software the ability 
to automate certain processes is increasing. For example King et al. (2004) devised a 
robot capable of carrying out gene function experiments on yeast and generating 
further hypothesis based experiments. The robot needed minimal human intervention 
and was shown to be comparable with human researcher output.  In their work on air 
pumps Collins and Kusch (1995) also comment on the progress made in automation 
over the preceding years, but highlight how much of the process, especially the 
setting up and troubleshooting, still requires human intervention. Whilst it may not 
be possible to make the production process for any product fully automated there are 
benefits in attempting to reduce the human intervention as much as possible. The aim 
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is not necessarily to remove the expenditure of employing staff, as it has been shown 
that the introduction of automation is not necessarily a cost cutting approach (for 
example integrated laboratory automated systems can have a payback period of 5-7 
years (Mason and Hoare, 2006)). The real benefit of automation is in bringing 
increased standardisation to the manufacturing process. Automation removes the 
variation seen in culturing methods between different staff, and it could also remove 
variation between laboratories. The result would be the increased standardisation 
which is considered a goal by most of the stem cell research field.  Shaw (2010) 
writes: ‘When “the process is the product” — as would be the case with 
industrialized production of stem cells — variability is the enemy and must be 
reduced and controlled as completely as possible’. The variability of stem cells 
grown across different laboratories is making it increasingly difficult to introduce an 
industry standard, especially as many labs employ what Shaw calls a ‘whatever 
works’ approach. The definition of ‘pluripotency’ is also under review as no standard 
test exists for measuring what is essentially a prediction of future ability to form 
different body tissues (Eriksson et al., 2008). Regulatory approval for a stem cell 
product is based on a product meeting certain requirements, for example cell potency 
assays, for which the licence was granted. Given the heterogeneity of stem cell 
populations, manufacturers will need to ensure that every subsequent batch of 
product meets these same criteria (Rayment et al., 2010).  
 
Automation of the BloodPharma production processes requires significant changes to 
the biological protocol, which move beyond the design of machinery and software. A 
classic method of growing stem cells is to use ‘feeder layers’ comprised of mouse or 
human cells. Although these layers assist in the culture of stem cells they prove 
challenging for scale-up due to the large surface area which this method requires, 
relative to the amount of cells that can be produced (Xu, Inokuma et al., 2001). To 
increase the density of cell culture the most efficient method would be to use a tank 
of some kind, increasing the available space from a single horizontal layer to a three 
dimensional volume. This requires a method to be produced which allows the cells to 
be cultured without the use of feeder layers, as this interviewee explains: 
“..also because it’s [feeder layers] a contact based system the volumes 
that you need would never be suitable for conversion to full scale 
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production. So we’ve been trying to engineer out that step, which is going 
very well, but at the same time we’ve introduced considerably more 
growth factors than we had before so the potential cost has gone through 
the roof but the ease has come down a lot, and it’s going to be like that 
all the way through I think.” (CS/LAB) 
 
As is revealed here, the downside to this method is the extra growth factors, which 
are required to force the cells down the correct developmental pathway without the 
assistance of the feeder layers. In addition alternative methods had to be found for 
parts of the process which are normally done by hand, for example the cell colonies 
growing in plates are normally cut apart by hand to allow for re-plating and 
expansion. The team has had to develop an alternative method that allows chemicals 
to be used to break apart colonies growing in suspension. Once a method for 
producing cells was developed that removed the need for surface attachment this 
allowed the team to move towards production in larger containers. Within the 
laboratory setting the team has started to develop techniques using containers with 
small volumes of liquid, for example two litre or five litre flasks. This volume may 
be enough for preliminary work to be carried out, for example characterisation of the 
product or animal studies, however my data show that the team expects batches of 
1000 units to be required once Phase 2 or 3 clinical trials are reached.   
 
The incentive to develop these automated techniques is not just due to the eventual 
need to scale-up to a vast volume of product, it is also to ensure that the product is 
produced in a standardised manner. Whilst the machines themselves can contribute 
to standardisation of research there is also standardisation required within and 
between the automated technologies. Without a standard use of barcodes, software, 
connectors etc. between machines the automation of an entire laboratory can be 
extremely problematic (Mason et al., 2006). One recent example within a local 
laboratory was the many hours of discussion that it took to convince the 
manufacturers of a particular piece of equipment that although the UK is technically 
in Europe it is common for UK laboratories to have imperial, not metric, connectors. 
The act of standardisation within and between the different machines and 
technologies is a small part of the wider task, which sees the building of routines 
within the team that are necessary for establishing a consistent method. This 
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consistency is vital because a small anomaly at the two litre level will be amplified if 
that protocol is then expanded to 20,000 litres. This consistency is the reason for the 
team’s investment in a high level of protocol translation, with members of the team 
focused on identifying the correct reagents and on moving laboratory methods to a 
standardised and tested protocol. Whilst anomalies and mistakes will always take 
place within science the aim of these protocols is to engineer out potential for 
mistakes to occur. Star and Gerson (1987) talk of mistakes occurring, such as setting 
a dial incorrectly or the presence of ‘funniness’ within the experiment which cannot 
be accounted for. Such anomalies are considered normal within the laboratory 
experimental setting, but become a matter of importance when that is translated to an 
industrial process. The financial cost and the safety concerns of a mistake occurring 
in a 20,000 litre production vessel would have wide ranging implications. Star and 
Gerson (1987) used the example of cancer stem cell lines which were later found to 
be contaminated, throwing into question the results of many years of expensive 
research. Contamination is clearly a potential issue for the BloodPharma product, 
especially after scale-up when thousands of people will be transfused with the same 
product. My data shows that, although the team consider the possibility of 
contamination, the production procedure will be so controlled that they do not see 
this as a likely risk. Instead they consider that the risks already taken by transfusing 
patients with potentially contaminated donor blood to be considerably higher.   
 
So far I have considered the benefits of automation on the production and 
standardisation of stem cell therapies. These benefits would be applicable to a small 
scale laboratory production process, however what sets the BloodPharma project 
apart is the difficulty of scaling those laboratory methods to a vast volume. Turning 
the method for producing in vivo RBCs from a small scale laboratory process into 
large scale production requires a shift in the use of technology and production 
methods. Through regular meetings with the BloodPharma team it is clear that scale-
up has been a consideration from the beginning of the project, and is now (during 
2012) becoming a major subject of discussion at most of the meetings and 
conference calls. It is important to bear in mind that at the time of writing the team is 
not yet able to produce the quantity of enucleated cells that would even be suitable 
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for clinical trial (i.e. a few millilitres), yet much time, effort and resources are being 
placed on the development of large scale manufacturing. This long timescale shows 
the challenge of scale-up of this type, as the team are aware that once the laboratory 
research is successful then the scale-up will need to be in place. It also is a measure 
of the confidence that both the team and the funders have in this project, and that 
cultured RBCs will one day be required in a large volume. The team has successfully 
managed the first step of the scale-up requirements, which has been to grow the cells 
in suspension, and without the use of feeder layers. This is a crucial step in allowing 
the product to be produced in some form of bio-reactor, without relying on cells 
attaching to a membrane (which would greatly increase the surface area required).  
 
The next laboratory challenge is to find the elusive progenitor cell, which will allow 
the team to culture large quantities of RBCs without having to return to the original 
cell line each time. From the start of the project it has been expected that the only 
way to culture RBCs in the quantity needed would be to move towards the use of 
large-scale cell culture using bioreactors. There was an awareness of how difficult 
this would be to achieve, and that in all probability a new industry might arise from 
this, as these two quotes illustrate.  
  
“Oh totally [use of bioreactors], and on a scale that’s probably not 
thought of at the moment, the cell numbers are just frightening. But I do 
think it’s doable but we’re going to have to change a lot of thinking and a 
lot of systems, but why not?” (CS/Lab) 
  
“I think that to supply the country with cells there has to be a completely 
new company. With purpose built facilities I would have thought. It 
certainly won’t be happening in our clean room!” (CS/Lab) 
 
 
In late 2011 the second phase of the project brought the team together with bio-
engineers and physicists, who will be working on both scale-up and cell sorting 
techniques. Although the team had always spoken of the future requirement for 
bioreactors it was the introduction of these scale-up specialists that led to further 
discussions of the future practical challenges of large scale manufacture. The main 




gases, waste disposal and some level of protection. Bioreactors on this scale present 
physical challenges, especially in stirring the cells and ensuring that oxygen is 
allowed to reach all parts of the tank. The techniques required to build reactors on a 
large scale are not new, however many of the normal technology employed will have 
to be adapted if cells are to be grown in this way. One consideration is that tanks of 
this size require stirring in order to distribute nutrients and gases evenly throughout 
the mixture. Stirring using paddles is a well developed technique for most containers 
of this size, however living cells have very different properties from compounds such 
as cement, chemical mixes or beers, which are normally stirred in this way. Data 
presented by the engineers advising the BloodPharma team showed that they expect 
RBCs would simply be disintegrated by the force of the spinning paddle blades. 
Introducing air bubbles to disperse oxygen throughout the mix was also thought to 
potentially have an adverse effect on the cell growth.  
 
Other considerations of manufacturing at such a large scale include separating the 
cells and removing waste media. Techniques such as centrifugation, which are used 
routinely in the laboratory on a small scale, pose a challenge for larger scale 
production. Even if machines could be developed which would cope with the weight 
of rotating thousands of litres of liquid they may still take many hours, or even days, 
to reach the revolutions per minute required, and to slow down again. Some of the 
considerations of scale-up and manufacturing are exclusive to the production of 
cultured RBCs. For example other stem cell therapies can be effective with very 
small numbers of cells, for example recent human clinical trials for macular 
degeneration involve the injection of just 50,000 cells (Schwartz, Hubschman et al., 
2012). A unit of transfused blood contains two trillion cells, and due to the absence 
of a nucleus in RBCs there is also no likelihood that the cells will grow and multiply 
within the patient, so a smaller amount cannot be produced with the expectation of 
expansion in vivo. Although there is no alternative to the huge volumes which will be 
required there is some compensation. RBCs in vivo grow in the bone marrow, 
densely packed and with little oxygen. It is possible that this may be advantageous to 
the project as it may be possible that these cells do not required the same levels of 




chapter this is an example of the BloodPharma team looking to the human body as an 
exemplar.  
 
Once the most appropriate scale-up methods for cultured blood have been identified 
the next step will be to consider how the infrastructure for long term production will 
look. The company with the largest mammalian cell culture capacity in the world is 
currently Lonza, which has 4 x 20,000L bioreactors situated at its site in Singapore.  
Although bioreactors on this scale are currently available (although these are stirred 
bioreactors, which may not be suitable for RBCs), to supply a worldwide demand of 
100 million units a year, working on an estimate of 1 month per batch (100 units), 
would require 800 bioreactors of this scale. This is also based on an estimate of the 
current global usage of blood, where blood is both rationed to some extent in 
developed countries and completely unavailable in large parts of the world. It is 
likely then that the true production of cultured RBCs may be significantly higher 
than this prediction. Information from the BloodPharma team expects that:  
“This level of scale-out of current technology after scale-up of the 
process is likely to require a step change in current manufacturing 
technology.” (CS/Lab) via email  
 
It is still unclear exactly how the bioreactors will work on a large scale. Options 
include a batch process, where the reactors are emptied and cleaned between each 
batch of cells being produced, or a continuous process. If a continuous process is 
used then some form of cell sorting would be required to ensure that only cells at the 
correct stage are removed from the mix. There have already been questions raised 
around the cultured blood product about batch versus continuous manufacturing. It 
has been posed that continuously growing RBCs in large vessels and somehow 
siphoning off those cells that are ready for transplantation may cause regulatory 
concerns, as continuous processing does not allow individual batches to be identified. 
There has been some concern amongst the project team that the regulators will want 
to be able to track individual batches back to the point of manufacture in the event 
that future problems arise. Who is likely to produce this product also remains 
unclear, with my data showing that although the team hope the NHS can take the 
product production as far as possible there is an expectation assistance may be 




of large amounts of living human cellular material for therapy is at least one order 
of magnitude more difficult than that for biopharmaceutical applications’. Mason 
believes that the key to scaling up stem cell processes is for firms to collaborate with 
contract manufacturing organisations (CMOs), who already have experience growing 
mammalian cells in large volumes for the biologics industry (Mason et al., 2006; 
Mason, 2007). What is clear is that the BloodPharma project will have to continue 
building a set of laboratory routines which will result in the production of a product 
that can be expected to have consistent properties. They must struggle to overcome 
the inherent biological unknowns which are a factor of working in the regenerative 
medicine field and attempt to control biological processes to produce a product of 
both high quality and consistency. The first test of the product will be in the first 
stages of clinical trials, which will put the safety of the product at paramount 
importance.   
 
UNCERTAINTIES IN THE CURRENT CLINICAL TRIAL REGIME AND THE 
DIFFICULTY OF PLANNING BLOODPHARMA CLINICAL TRIALS 
Clinical trials for pharmaceutical products have been mandatory in both the UK and 
USA since the 1960’s and there exists an established framework for the planning and 
conduct of these trials. More recently the development of both biologics based 
therapies and tissue based therapies have raised debate about the applicability of such 
trial designs for this new generation of therapies. The BloodPharma team is therefore 
negotiating a pathway through a regulatory system which still holds many 
uncertainties. Here I shall introduce some of the wider uncertainties around clinical 
trials, and the way in which these have been responded to by the BloodPharma team, 
before focusing down onto specific challenges associated with stem cells.  
 
As the BloodPharma team is still at the early stages of developing a future clinical 
trial I will draw on data from another project, the ReNeuron stroke trial, which 
represents a stem cell product that is further down the regulatory route. ReNeuron is 
a UK based company which is seeking to develop a stem cell based therapy for the 
treatment of ischemic stroke patients. The therapy being developed involves the 




stem cells, derived from tissue of foetal origin, and are known as the ReN001 cell 
line. The clinical trial is taking place in collaboration with the Institute of 
Neurological Sciences at the University of Glasgow, which is based at the Glasgow 
Western General Hospital, and incorporates a large Acute Stroke Unit. At the point 
of writing six patients have been treated with these cells, (covering the first two dose 
cohorts of a four cohort escalating dose study), no adverse effects have been reported 
and all the patients showed improvements in their neurological function. This data 
was published by ReNeuron on their website on 14th June 2012. As part of this thesis 
I interviewed a medic who was associated with the ReNeuron trial on two occasions, 
in June 2009 and again in October 2011. At the time of the first interview the 
company had gained MHRA approval for the trial but were still awaiting approval 
from GTAC. By the time of the follow-up interview the first cohort had been injected 
and the second, higher dose, cohort was starting imminently. Some of the challenges 
identified by the interviewee raise questions about the design and implementation of 
stem cell trials, which could be applicable both to the BloodPharma project and also 
to the stem cell field in general. At this point I shall concentrate on the design and 
implementation of the clinical trial itself, but further discussion about the interactions 
between ReNeuron and the regulatory authorities will be included in Chapter Five.  
 
It has been proposed that ‘clinical trials’, in the form of comparisons of available 
techniques, have been in place since the time of the Egyptians. Evidence is scarce but 
it is considered probable that early societies who acquired sophisticated medical 
techniques must have employed some way of determining effective treatment 
regimes (Bull, 1951). Skipping forward a few millennia the study conducted by Lind 
in 1753 has become the landmark of more modern clinical trial history (Pocock, 
1983). Lind was instrumental in discovering the link between citrus fruits and scurvy 
prevention after he conducted a trial in which different sailors were fed  a variety of 
supplements, including (amongst other things) vinegar, nutmeg, and of course the all 
important oranges and lemons (Lind, 1753). The next landmark in the development 
of clinical trials considered by Pocock, which incidentally fits very well with the 
theme of this thesis, was a trial undertaken by Pierre-Charles-Alexander Louis. His 




to be no discernable difference between the treated and control groups, introducing 
the importance of untreated controls and strict observation of patient outcomes.  
 
 It was not, however, until 1927 when the first single blind study was used and 1950 
before the first double-blind study was noted (Pocock, 1983). In a single blind study 
the volunteers do not know which treatment they have received, in a double blind 
study neither the volunteers nor the medical examiners know which treatment has 
been received. The Thalidomide crisis of 1961 called into question the way in which 
pharmaceutical products were released into the public domain, and as a result of this 
the UK established the Committee on Safety of Drugs to oversee pre-market clinical 
testing conducted by manufacturers. In 1968 the Medicines Act came into force, 
requiring government approval for human clinical trials and marketing of new 
pharmaceutical products (Abraham and Lewis, 2000).  
 
Although clinical trials have been compulsory for the last 40 years this is not to 
imply that they have been without incident. Interview data from the BloodPharma 
team and the Re-Neuron medical personnel shows that adverse events in drug trials 
have made a lasting impact on the scientific community. Events recalled by the 
interviewees included the death of a volunteer in 1999 during an American clinical 
trial for retroviral therapy, the last straw for the area of gene therapy which had been 
struggling to achieve its expected results (Marshall, 1999). They also spoke of stem 
cell trials which took place during the 1990’s and involved injecting bone marrow 
into patient’s hearts and foetal tissue into patient’s brains, with the hope of curing 
heart disease and Parkinson’s disease respectively. Interviewees felt that these trials 
had been ethically dubious, for example the heart trials (which had used pre-clinical 
rat models) had been non-blinded, non-randomised and with no placebo control. The 
view was that as the product was autologous and minimally manipulated it was 
considered to be more akin to a transplant and bypassed many of the product 
regulations. One interviewee commented that the patients were treated like mice. My 
data shows that there is a real concern amongst the scientists interviewed that current 




distance itself from the potentially un-ethical or dangerous trials which have occurred 
in the past.  
    
Today clinical trials for pharmaceuticals consist of five recognised phases  (Pocock, 
1983; IDSD, 1991):  
• Toxicological Evaluation – using animal models to determine toxic exposure 
levels, sometimes including effects on reproductive capability, tumerogenicity 
etc.  
• Phase I Studies – First in human. To evaluate safety and dosage range before 
Phase II studies. Normally using healthy volunteers.  
• Phase II Studies – Small scale studies in selected patient populations. Evaluates 
efficacy and determines effective dose.  
• Phase III Studies – Evaluate safety and efficacy in a much larger patient 
population, many within a clinical setting.  
• Phase IV – Postmarketing surveillance for reported adverse drug reactions.  
 
 This list represents a very brief overview of the complexities of conducting a clinical 
trial, but a common theme of all clinical trials is an attempt to replicate in the 
laboratory the effects of clinical pharmaceutical use. It is normal for trials to contain 
a control group who receive no treatment, whilst those who receive treatment are 
randomly assigned to receive either a placebo or the real product (Jadad, Moore et 
al., 1996).  
 
Data obtained from pre-clinical studies in animals is currently considered to be a 
requirement for further human trials in pharmaceuticals and tissue based therapies, 
for example the EMA state that ‘The objectives of the preclinical safety studies are to 
define pharmacological and toxicological effects not only prior to initiation of 
human studies but throughout clinical development’ (EMA, 2011). Frey-Vasconcells 
et al. (2012) provide a thorough overview of considerations that must be taken when 
deciding appropriate animal studies. Some key considerations are the number/type of 
animals necessary and whether a certain disease mimic is required. If testing of the 




studies be required? A common theme appears to be the lack of specific requirements 
as to the numbers/type of animal studies required, leaving it to the researchers either 
to prove that their animal studies are sufficient, or that there are no possible animal 
studies applicable. Whilst it would never be said that an animal could stand as 
complete substitute for a human there is debate over whether laboratory animals can 
even be seen as representative of their own species. Davies (2010), in her work on 
the applicability of mouse models in neuroscience studies, refers to ‘nature implied’, 
the idea that a mouse in the laboratory can stand as a proxy for the mouse species as 
a whole and also in some way for human behaviour. Lynch (1988) distinguishes 
between the ‘naturalistic’ animal, the animal as we expect it to behave free of human 
intervention, and the ‘analytic’ animal, an artefact and a tool for research which is 
shaped by human interactions. Hansen (2006) also considers the use of ‘nature’ or 
‘natural’ rhetoric as drawing a distinction between what is outside the laboratory and 
what is inside.  
 
Whilst the laboratory space can be seen as attempting to replicate the world outside 
in a condensed form Asdal (2008) also calls attention to the laboratory as a ‘sub-
place’, a unique space in which certain practices (in this case vivisection) is 
acceptable in a way that it would not be in wider society. If we view clinical trials as 
attempting in some way to condense ‘nature’ into a laboratory setting then we see 
that the debates around the applicability of such trials generally focus on the 
distinctions between nature within and outside the laboratory. For example animals 
kept for research purposes often exhibit ‘cage stereotypes’ such as repetitive and 
functionless behaviours (Garner and Mason, 2002). Mice carrying certain genetic 
mutations are specifically bred in an attempt to model human diseases, with the aim 
being to simulate the progression of the ‘real’ disease under laboratory controlled 
conditions and over a reduced time period. Studies have shown that, in addition to 
cage behaviours, the behaviours and disease progression exhibited by these mice 
often varies between laboratories, meaning the results of experimental studies may 





Kaleuff et al. (2007) also provide a long list of potential problems with mouse 
models and their inability to accurately model the courses of disease in human, 
including the difficulty of modelling multi-factorial human disease and of over-
stimulation by the environment. Oyston and Robinson (2012) report that in their area 
of vaccine development Phase II trials are often disappointing, as positive results 
found in early animal studies are shown not to be replicable in later human trials. In 
these cases the mouse is often used as a test subject, despite having a significantly 
different immune system from a human.  
 
Differences in pharmaceutical trials are often reported due to the different ways in 
which drugs are metabolised in different animals. A pharmacokinetic profile study 
can be performed to test the metabolic and excretion rates of a compound in different 
animals.  One reported study (Busch, Schmid et al., 1998) for an anti-inflammatory 
drug showed that rats and dogs produced similar metabolic reactions to humans, but 
were very different to mice, mini-pigs and baboons. The mini-pigs, however, 
produced the compound excretion rate that was most similar to humans. These 
studies can be used to see which animal is most likely to be a suitable human model 
(in this case it was the rat). It is of course easy in a comparison of the laboratory with 
the ‘natural’ to pick on differences and ignore similarities. Animal models are 
required because, whilst they might not produce a wholly accurate depiction of 
human disease, they do at least go some way to allowing researchers to gain valuable 
pre-clinical data and to reduce trial volunteers’ exposure to potential harm.  
 
For the BloodPharma team the use of animal models still represents an area of 
uncertainty. Although it was hoped that animal trials may not be required it is now 
clear that they will be expected by the regulators:  
“When we went to meet with the EMA at first, I said “we are going to 
have to talk to them about the animal models we are going to use” and Y 
said “there’s no animal models, we can’t do any”. I said “they are not 
going to accept that”. So the first thing they said was “and what animal 
models are you…” Because, what regulator in the right mind would say 





The difficulty with the cultured blood product is that unlike a standard 
pharmaceutical product there are many uncertainties surrounding the applicability of 
animal models for biologics and stem cell products, mainly due to the additional 
complications of the immune response. In conversations with the BloodPharma team 
it appears to be possible that human blood can be introduced into rats and pigs once 
without harm, but subsequent infusions could cause major immune reactions. 
Outside advice was being sought on the possible animal studies which could be used, 
as this was outside the area of expertise for those working on the BloodPharma 
project. Some of the researchers had limited knowledge about animal blood, for 
example they knew that birds have RBCs that are enucleated, but detailed knowledge 
of animal haematopoietic systems appeared to be a skill that was missing from the 
team in the meetings which I attended. It was, I believe, a representative of the 
Wellcome Trust rather than a scientific team member that thought to question 
whether mouse RBCs are even the same size as human RBCs.  
 
A potential solution would be the ‘humanising’ of animal models by performing a 
haematopoietic stem cell transplantation in-utero, a technique developed in China 
using goat models. It was discussed that the regulatory restrictions will make it 
impossible for the animal studies to be carried out in China, which left the option of 
having to ship animal models from China to the UK. There is an expectation that 
smaller animal models may become available, although the literature would indicate 
these are proving more difficult to develop (Lin, Jun et al., 2008). The use of animal 
models by the BloodPharma team, although expected, was not something that 
appeared to be discussed in any great detail by the team. As an observer it appeared 
that the later human trials had been given more consideration by the team than the 
potential animal trials had. Animal trials rarely featured in any interviews or team 
meetings, although it is possible that they formed part of scientific meetings which I 
was not allowed to attend.  
 
The ReNeuron trial had undertaken studies in rat models before human trials of 
ReN001 commenced (Smith, Stroemer et al., 2012). One trial attempted to mimic the 




patients. The solution proposed was to use sticky tape applied to the paws of the rats, 
which were then monitored to see firstly how long the rats took to notice the 
presence of the tape and then how long it subsequently took the rats to remove the 
tape. A huge amount of regulatory discussion went into the development of the 
animal trials, and it was felt by the ReNeuron medical team that the authorities had 
primarily concentrated on the data obtained from these animal studies.   
“There was a lot of different opinions about what the appropriate test to 
do in a rat was, and how many rats you had to look at. How many rat 
experiments you needed to do, and that was the focus of it.” (M/O) 
 
The clinicians involved raised concerns that the focus of these early animal studies 
had led to discussions about the clinical aspects of future trials in patients being 
sidelined, as will be discussed below.  
 
After animal trials, safety studies of the drug will move into three pre-marketing 
phases in human subjects, marking a gradual move from the totally controlled 
situation of the animal studies to the very open space of the final Phase III studies in 
a clinical setting. Here we see that the focus is still on the ability of the researchers to 
distil ‘nature’ into a controlled environment, tempered with the controls introduced 
to minimise harm to human trial participants. The first phases include small doses 
and look only for safety, only later is it permitted for the dose to be increased and for 
efficacy to be studied.  
 
Perhaps the key factor of human clinical trials is ‘extrapolation’, the ability of a small 
cohort of subjects to be indicative of the results that should be seen were the product 
to be administered to the population as a whole (Rothwell, 1995). In reality early 
trials are often carried out on young, healthy, non-smoking male volunteers. Only 
later are patient groups trialled who may, in addition to having the disease being 
studied, be overweight, of different gender or ethnicity, taking a variety of 
medications, and forgetful regarding correct dosage or timing. For example the early 
Phases of the ReNeuron trial did not allow the drug to be administered to women. 
This is because the cell culture method includes the use of Tamoxifen, giving a 





increase the tumorigenesis risk if cells were kick-started to turn from neural cells 
back into pluripotent cells.  
 
For the BloodPharma team the key goal at the end of the Wellcome Trust funding is 
to have obtained a method for producing cultured RBCs at the quantity required for a 
first-in-human trial. The researchers were all very clear that for the first studies this 
quantity would amount to millilitres of product rather than anything on a larger scale. 
In keeping with earlier references to past clinical trials where adverse events have 
occurred my data shows that there is a strong emphasis on safety and on conducting 
any human trials to the highest possible regulatory standards. One interviewee 
commented that “people are not guinea pigs”.  
 
Very early trials looking for safety can only be carried out in healthy volunteers, with 
the advantage that such people are readily available in close proximity to the research 
centres taking part in the BloodPharma project. In keeping with the uncertainties of 
the potential animal models the human trials also raise questions of immune rejection 
which are not present in pharmaceutical trials. Although the team are seeking to 
make O negative, universal donor, blood it is unlikely that they will achieve this 
before the first study. Their option is simply to recruit volunteers who match the 
blood type of the cultured RBCs, for example an A negative blood type. This 
however introduces the possibility of the team having to go through Phase I, and 
possibly Phase II trials, more than once (as it is unlikely that the two different forms 
of blood will be considered the same ‘product’ by the regulators).  
 
Whilst this is physically possible it is difficult to envisage how the project will 
manage this sort of iterative process without being financially crippled. Further 
studies which move towards demonstrating efficacy will necessitate the use of 
cultured blood in patient populations. These potential target populations are 
explained in more detail in the next section, but it is likely that thalassemia patients 
will form one of the initial clinical trial groups. Thalassemia was considered to have 
a slight advantage over sickle cell anaemia in that sufficient patients might be found 
in Europe. In keeping with the wishes of the team to obtain the highest regulatory 


approval possible it is considered that approval from the European regulators is the 
only route down which to proceed, as one interviewee commented: 
“And the clinical trials on western soil. Because whether we like it or not 
the standards are much higher and the oversight is much more exact.” 
(CS/Med) 
 
The first challenge for the ReNeuron stroke trial in humans was patient recruitment. 
Whilst hundreds of willing volunteers came forward the strict criteria imposed meant 
that few were eligible to take part. Patients were required to be male, above the age 
of 60 and live reasonably close to the hospital, to have suffered a particular type of 
stroke and to be at a stable stage in their stroke recovery, where it was to be 
reasonably expected that they would not improve independently. Another critical 
area in the clinical trials design was the decision about whether or not to use 
immunosuppression. The brain is often considered to be immunologically privileged, 
therefore not requiring immunosuppressant use, and there have also been previous 
studies injecting tissue into the brain which have not shown inflammatory reactions.  
“And the animal experiment people, certainly the attitude from some of 
them involved in the review process, was ‘oh but it wouldn’t be too 
difficult just to give them [the patient volunteers] cyclosporine for 6 
months’. To which my response was ‘it certainly would. It’s a highly toxic 
drug, immunosuppression is a dangerous thing to do to patients, it’s got 
numerous drug interactions in people that are taking lots and lots of 
drugs already, and I do not want to do this to a patient’. It’s very 
dangerous.” (M/O) 
 
These examples from the ReNeuron trials demonstrate just some of the challenges 
associated with running a clinical trial in humans. Firstly there is the difficulty of 
recruiting suitable patients and ensuring that the clinical trial requirements are not 
too onerous for them to undertake. Then there is the additional decision about 
whether the use of immunosuppression is required for the particular cell line and part 
of the body that is being studied. The ReNeuron trial has entered the regulatory 
system a few years before the BloodPharma trial will, yet there are similar lessons to 
be learnt about the challenges of balancing the views of scientists, clinicians and 
regulators, especially once human volunteers enter the equation. There are also 
practical considerations to be considered when undertaking a clinical trial. For 
example at one team meeting the problem of production for a clinical trial was 
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raised. Blood does not keep for long periods, so in the case of the BloodPharma 
project how will this effect recruitment and trials? If each cohort is given a freshly 
produced batch of blood then there is an expectation that the regulators may consider 
that the product being tested is not the ‘same’ for each patient. Conversely if you 
wish to give each patient blood from the same batch then it may mean injecting all 
the patients over the period of a few days, precisely the situation that clinical trial 
designs try to avoid in case adverse reactions occur. This storage situation is one that 
could be argued is unique to the BloodPharma team. Other stem cell therapies may 
also have the potential challenge of batch production but RBCs are the only cells in 
the human body not to contain a nucleus. The BloodPharma team therefore face a 
distinctive time constraint, a deadline of 120 days before the cells die completely   
 
The clinical trial methodology outlined above has grown out of the regulations put in 
place for pharmaceutical products, but it has been seen that stem cells pose unusual 
challenges in storage and potential immune rejection. There are additional challenges 
which are exclusive to stem cells and which have been identified by interviewees and 
the wider stem cell field. The primary challenge for clinical trials of stem cell 
therapies is the issue of engraftment. Many stem cell therapies involve the injection 
of living tissue which has the ability to replicate in the body, indeed the replacement 
of damaged tissue in this way is the aim of many cell therapies. This however brings 
additional problems in that the cells will be alive and multiplying in the patient, 
potentially for many years to come, and have the possibility of forming teratomas. 
This problem should not apply to the cultured blood product which will, if produced 
correctly, have no danger of multiplying in the body. In conversations with the 
BloodPharma team they often mentioned that whilst drugs ‘went in one end and out 
the other’, other stem cell products would stay and multiply in the body. This is not 
to suggest that pharmaceutical products are not capable of causing adverse reactions, 
rather that these drugs would be metabolised over a relatively short period of time. 
This longevity of the cells has implications for stem cell trial volunteers, for example 
patients in the ReNeuron trial not only have to subject to the barrage of testing 




Ethical implications are therefore raised in the use of healthy volunteers, as it is 
considered that injecting healthy patients with stem cells into areas such as the heart, 
spinal cord or brain, would be putting them at a risk which outweighed the benefits 
obtained from the clinical trial data. Stem cell trials are also difficult to placebo, as 
this would involve injecting into vulnerable tissue without any potential benefit. 
Even if this were shown to be ethically acceptable it is very hard to blind the study as 
the bags of tissue used would have to look identical both to the patients and to the 
doctors. To this end both the ReNeuron stroke trial and the (now discontinued) 
Geron spinal cord trial used patients (rather than healthy volunteers) for first-in-
human studies and did not use placebos. The balance between using ‘unhealthy’ 
patients and wishing to identify potential teratoma risk came to the fore during the 
planning of the ReNeuron trial. In an effort to protect patients the regulators insisted 
on a higher age limit of 60 years, as opposed to the 40 year limit proposed by the 
researchers. This caused some concern to the medic that I interviewed: 
“Age limit was the specific thing that they insisted was changed, 
upwards. Which from a clinical perspective is a problem. My concern is 
that older people don’t tolerate anaesthesia and invasive procedures as 
well as younger people. And when you are dealing with people over the 
age of 60 with stroke, as supposed to over the age of 40 which was the 
original proposal, you are compromising patient safety in other respects, 
potentially.” (M/O) 
 
In combining safety with ethical considerations the trial ended up using a cohort of 
patients who were both elderly and in many cases had numerous health problems in 
addition to the effects of the stroke. The interviewee was concerned that in the 
regulatory review of the safety aspects the views of the clinicians who worked on a 
daily basis with such patients were not taken into account, and that this had resulted 
in patients being put under undue pressure: 
“And we have seen what I anticipated, which is that at least one of our 
patients so far said that he couldn’t go through another scan, won’t go 
through another scan because he can’t tolerate it. It’s very uncomfortable 
for him, he has to lie there for a long time. Can’t communicate easily so 
he can’t let people know if he is uncomfortable, if he needs to go to the 
bathroom etc.” (M/O) 
 
Although there are lessons to be taken from the balance of risk versus patient health 
it will be interesting to see how the regulators react to the BloodPharma trial, given 
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that the cells should not engraft or form teratomas as they have no nucleus. This is 
just one of the uncertainties facing the BloodPharma team as they attempt to move 
their product through the regulatory system. The contrasting ReNeuron trial has 
demonstrated that even further down the regulatory pathway there are still debates 
about the correct clinical trial procedures to ensure both the safety of the trial 
participants and future patients.  
 
THE IDENTIFICATION OF SUITABLE TARGET POPULATIONS FOR THE 
INTRODUCTION OF THE CULTURED BLOOD PRODUCT 
Given the huge scale-up challenges for the BloodPharma product, and the likely high 
cost of the initial product, there are plans to introduce cultured RBCs using a 
stepping-stone method. This would see the product being gradually introduced to key 
target populations, building towards a wider introduction to more general medical 
usage. The aim throughout the BloodPharma project has been to make the cultured 
blood indistinguishable from donor blood, and the team has ensured that the 
technology can be implemented in an incremental way. The storage and distribution 
infrastructure are already in place for the BloodPharma product, as it is currently 
expected that the cultured blood will use the same (or similar) bags, needles, staff, 
transfusion method, storage, as the current donation system. This allows the cultured 
blood product to be introduced using a gradual process, with the use of target 
populations allowing the product to be first produced and used at a much smaller 
scale, without the challenges of supplying the entire blood transfusion system.  
 
It has been difficult to obtain a definitive answer from the BloodPharma team as to 
the cost of the eventual cultured blood product. There is an agreement that long-term 
the cost of the cultured blood product must be in line with the current costs of 
donated blood (either £800 if the total cost of infrastructure is used or £140 if the 
price is based on what a hospital pays for one unit of blood). This would however be 
the cost of production at a large scale, for smaller numbers it is likely that the cost 
would be significantly above £800. The use of target populations could make this 
increased cost acceptable by changing the view of the cultured RBCs from a 
transfusion to a sophisticated pharmaceutical. Some of the proposed target 
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populations are discussed below, but a common factor in all of these populations is 
that the use of cultured blood is expected to produce benefits above those of ordinary 
donated blood.  
 
When asked whether the NHS would consider providing the cultured blood product 
one interviewee responded:  
“The NHS does provide stem cells therapies. The NHS would provide 
stem cell therapies if they were effective and low cost, with regulatory 
approval and were shown to be cost effective over the piece. In other 
words, you would work out the cost of the procedure, the Quality 
Adjusted Life Years gained and offset by the cost of other treatments 
avoided.” (CS/Med) 
 
Whether such treatments can be funded by a public health service often hinges on the 
relative cost of treatment, as the aim of any health care provider is to achieve 
maximum patient benefit for the available budget. Assessing the cost effectiveness of 
a drug or treatment regime, however, is a complex process. The Quality Adjusted 
Life Years (QALYs) referred to by the interviewee are an important consideration in 
assessing the affordability of a new medicine or therapy. QALYs are used to measure 
the cost effectiveness of different medical treatments and are a measure of both 
lifespan and health. One year of full health is assigned a value of 1.0, with death 
being 0.0. Ill-health is the range in between, for example a year of ill-health may 
score 0.6 (Bravo Vergel and Sculpher, 2008). QALYS can assist in analysing the 
benefits versus costs of different treatment regimes and QALYS are often used in 
analysis of health care economics due to their simplicity and ability to represent 
complex healthcare choices as a quantitative value. This is also the criticism of 
QALYS, that they rely on clinical decision making and do not allow for patient 
autonomy (La Puma and Lawlor, 1990), and that they focus on population care at the 
expense of individual patients (Loomes and McKenzie, 1989).  Despite the criticisms 
of the QUALY measurement it is used as one of the main determiners of the cost 
effectiveness of treatment in many countries, including the UK (Eichler, Kong et al., 
2004). As a guideline the National Institute for Health and Clinical Excellence 
(NICE) considers treatments of less than £20,000 per QUALY gained to be cost 


effective, with treatments over £30,000 per QUALY gained requiring additional 
consideration (NICE, 2007).  
 
Donated blood is currently an effective therapy for the vast majority of the 
population, however there are minority groups for which the cultured blood product 
could provide a significant improvement.  
“So there would be situations where we don’t have blood donation as a 
source, and that would obviously be the first routes for use. Maybe 
medical conditions that couldn’t take blood from somebody else, you 
would have to be more sure of the source, immunosuppressed people, you 
know that the cells that they would be given would have to be pure and 
free of anything else.” (CS/Lab) 
 
Cost effectiveness may become more apparent when taking into account the money 
currently spent on long-term care of such patients, including the treatment for side-
effects of the current treatment regimes.  
 
One target population identified is sufferers of sickle cell disease, which results in 
distortion of the RBCs4. The trait is most commonly found in people from Africa, 
Asia and the Caribbean, with some prevalence in Middle-Eastern and Mediterranean 
populations (Anie, Steptoe et al., 2002). Sickle cell is a devastating disease in Africa, 
where the constant medical attention required by sufferers is not available, as we 
previously saw from the interviewee who had worked in this area. 
“So anyway, we go there and wandering around Northern Ghana, where 
sickle cell disease is endemic.. so one in four of the children die, children 
of a couple of carriers, and 2 in 4 are cariers and 1 in 4 gets malaria, 
sadly. So it’s an awful gene.” (CS/Med) 
 
Currently sickle cell sufferers are transfused with blood to help them overcome 
various types of ‘crises’, such as sickled cells blocking capillaries. As they are often 
multiply transfused throughout their lifetime they can develop severe immune 
reactions to blood that is even slightly mis-matched. Finding donors that are an 
                                            
4
 It is a co-dominant gene, so an individual who was heterozygous (have one healthy gene and one 
sickle cell gene) for the sickle cells trait would make half normal RBCs and half sickle cells. In 
individuals who are homozygous for the gene (have two copies of the sickle cell gene) the disease is 
generally fatal without medical intervention. The sickle cell trait confers some protection against 
malaria and this gives an advantage to heterozygous individuals, who are protected from both the full-
blown sickle cells disease and malaria. 
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appropriate match is more difficult due to the lack of donors from ethnic minorities 
in the UK. Cultured RBCs could allow improved matching of blood to patients and 
for that same blood to be given every time, preventing immune reactions due to 
patients receiving blood from a variety of donors. 
 
Thalassemia is another blood disorder identified as a potential target population for 
RBCs as a therapeutic. Again it is an inherited disorder which results in the 
production of abnormal haemoglobin and is treated using multiple transfusions. 
Thalassemia patients who are regularly transfused suffer problems with iron loading, 
for which drugs must be administered (Clemente, Congia et al., 1994). These drugs 
also produce unpleasant side effects and the use of multiple transfusions ultimately 
results in a reduced lifespan. In current transfusion cells will be a mixture of ages, 
with some nearing the end of their life, meaning a proportion of the transfusion will 
be destroyed by the recipient’s body.  
“I mean, one of the unique selling points is that the cells from culture are 
all fresh, they are all day 1. When you take an armful from a donor a 
proportion of it is already coming near the end of its life. So after 20 days 
storage, which is oldish, about 20% of it is immediately mopped up in the 
spleen and destroyed. Whereas one would anticipate if they were all fresh 
then that would be a very small percentage of stuff that would be 
damaged.” (CS/Lab) 
 
Cultured blood transfusions are expected to be required less frequently (as all the 
cells produced will be ‘new’), reducing side effects for patients and extending their 
lifespan.  Currently it is expected that the first target population for cultured RBCs 
use will be thalassemia patients. This is due to the requirement for patients to be used 
in clinical trials which satisfy the UK and European regulators. As thalassemia 
patients are found in populations of Mediterranean origin this gives the potential to 
recruit enough patients to conduct a clinical study in a country which is still under 
the remit of the European regulators.  
 
As we saw in the previous section, supplying the entire blood transfusion service 
may be a challenge which takes up to 20 years to overcome. The use of target 
populations may help to realise the team’s ambition of getting cultured blood into 
clinical use within a shorter time frame. The use of cultured blood for these 
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populations may also allow the product to be produced at a higher cost, whilst still 
keeping within approved cost effectiveness ratios. This is due to cultured blood 
providing a therapy which goes above and beyond the efficacy of donated blood, as 
one interviewee explains:  
“Yes, so it [cultured blood] would have to be cheaper [than donated 
blood]. Or so much improved that it was indefensible not to spend the 
extra money. (CS/Lab) 
 
Despite the expected benefits to patients the use of target populations does provide 
some challenges in the form of clinical testing and tissue matching. The team wish to 
carry out testing with Europe in order for the clinical trials to fall under the 
jurisdiction of the European regulators, however finding a suitable number of 
patients may be challenging. As we saw with the ReNeuron trial there are very strict 
criteria for eligible patients, which could prove problematic if a target group (e.g. 
thalassemia patients) were required for Phase 2/3 trials, which normally use a large 
number of volunteers. One interviewee felt that the US may be a better route to 
regulation and licensing of the product, because of the combination of increased 
patient numbers and the very good orphan drug program, which could allow a 
quicker route through the regulatory system.  
“The FDA have a better orphan drug program than the MHRA, so where 
we are talking about these guys with sickle cell disease, they have a lot of 
people on American soil, a lot of Americans, who have sickle cell disease 
who need transfusion and who they can’t keep up with. Much bigger 
African genetic population than we do, anywhere in Europe. So their 
need is greater, but they also have this fairly good orphan drug program” 
(CS/Med) 
 
Although the US may represent a route to market Europe is still being treated by the 
BloodPharma team as the initial area of licensing.  
 
Whilst much focus is often given to target populations with specific blood disorders 
there are also other minority populations within the wider blood transfusion model. 
Although these patients are unlikely to benefit from cultured blood over donated 
blood, they do currently receive blood which is more costly than the standard, 
making them ideal candidates for being the next ‘stepping-stone’ to introduction. 
Currently the blood transfusion services in the UK have to operate around the clock 
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because unexpected trauma patients may require more blood than is held in stock by 
the hospital. Blood is processed at a central site and then taken to the hospital, 
sometimes by taxi, courier or the Nationwide Association of Blood Bikes (volunteers 
who provide motorbike courier services for the NHS). Emergency blood is therefore 
comparatively expensive due to the cost of distribution and the extra wage costs 
associated with staff working unsociable hours. If cultured blood could be used to 
obtain large quantities of O-negative blood there would be no need for matched 
blood to be distributed to trauma patients and the blood transfusion service could 
potentially operate on a 9-5 basis, greatly reducing overheads.  
 
This section has presented some of the suggested target markets for the introduction 
of the BloodPharma product. These uses are based on using the existing 
infrastructure of the current donation system, but would replace conventional blood 
donation with a product that is likely to have increased benefits for certain patients, 
and reduced infection risk for the wider transfusion field. In the next section further 
changes to the product itself will be discussed.  
 
HOW DOES THE BLOODPHARMA TEAM IMAGINE FUTURES BEYOND 
THE FIRST PRODUCT?   
Currently the focus of the BloodPharma team is primarily on the short term goal of 
providing enough cultured RBCs to be used in a clinical trial. The long term goal of 
supplying the UK transfusion service may be 20 years away and there is the potential 
for technological improvements to the product during that time. Some of these 
improvements may not yet be known but others are anticipated and discussed by the 
BloodPharma team, even though the technology to implement them has not yet been 
fully developed. Forward thinking is a practice common to all science and innovation 
and it plays a vital role in bringing together the expertise and resources required to 
see a future vision through to completion (Borup et al., 2006).  
 
The team discuss prospective changes to the product because these future visions are 
necessary for it to make decisions in the present regarding appropriate developmental 




from laboratory to clinic and are crucial for facilitating this move from bench to 
bedside. Martin et al. (2008) refer to ‘communities of promise’ in order to highlight 
the importance of translational networks sharing a common goal, or vision, of a 
future technology. Wainwright et al. (2006) also consider the bringing together of 
scientists and clinicians as playing a vital role in assisting this translation, something 
which the BloodPharma team has done from the start. In building these anticipated 
futures the team have also been insistent that it refrains from promoting the ‘hype’ 
which stem cell science has been associated with in the past. 
“They’re [the Wellcome Trust] not expecting us to be injecting people in 
three years time. It’s all the external hoo-ha that’s engendering that.” 
(CS/Lab) 
 
Stem cells have previously been associated with expectations and promises which 
have not been borne out by actual therapy developments. Some of this hype has been 
associated with areas such as embryonic cord blood banking (Brown and Kraft, 
2006), where parents have been enticed to pay fees in the hope of safeguarding their 
child’s future health.  
 
The blood type used for the clinical trial is not of great importance, provided suitable 
volunteers could be found, as this quote demonstrates:  
“That [universal donor] would be preferable, you need an O negative 
human stem cell line for that, but I think that would be the end goal of the 
work over ten years or so, that’s not necessary to get to our endpoint for 
this grant. If the cell line happens to be A pos for example we would just 
transfuse it into an A pos individual.” (CS/Med) 
 
It is clear then that the BloodPharma team has a series of long term goals which it is 
aware may take many years to achieve. It also appears to view clinical trials as an 
iterative process and is willing to go through the first stages of clinical trials a couple 
of times, perhaps first with an A positive (for example) and then later on with the 
universal donor that it is aiming for. From talking to the team it would appear that the 
primary long-term goal is the eventual use of iPS cells.  Induced Pluripotent Stem 
Cells (iPSCs) are cells of somatic origin which have been ‘reprogrammed’ to an 
embryonic-like state, and are therefore pluripotent and capable of forming many 
different tissues. The first iPSCs reported to be created from human cells were made 
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in the Japanese lab run by Shinya Yamanaka in 2007 (Takahashi, Tanabe et al., 
2007). Originally viral vectors were used to introduce small amounts of DNA into 
the somatic cells, but more recently the move has been towards using chemical 
compounds to stimulate the DNA of the cells. The potential use of iPS cells at some 
time in the future of the BloodPharma project has always been discussed by the team, 
however the reasons for choosing iPS technology has changed over the past few 
years.  During initial discussions with the BloodPharma team it was proposed that 
iPSCs cells could be used the answer to finding the elusive ‘universal donor’ cell 
line. The O negative blood type is found in about 7% of the population, so embryos 
with this blood type are rare.  
“And also just from pure practicality that making embryonic stem cells 
we don’t currently screen the embryos so we don’t know what genotype 
they’re going to have, we don’t know what blood group they are.” 
(CS/Lab) 
 
It appeared to be apparent to the team that finding a suitable blood type from 
embryonic stem cells lines would be unlikely. At the times of the earlier interviews 
there were some reservations from researchers about the use of iPSCs, which, despite 
the rapid progress of the technology, had only been around for a few years.    
“I do think there’s a role for iPS, if that’s the technology that becomes 
the best. Having said that there appears to be some drawbacks with the 
current iPS lines in these protocols, but I think an alternative pluripotent 
source will arise, and again the technology is advancing so phenomenally 
rapidly, like nothing else has advanced. That in five years time it will be 
done and dusted and the cell source will be there. And I think a lot of the 
protocols will be applicable to other pluripotent cells as well. So, we’re 
doing the groundwork that can be reapplied as and when, probably the 
Japanese, sort out the cells for us.” (CS/Lab) 
 
Although at this point it was not clear whether iPS cells would be the answer, it was 
certain that what was required was some sort of pluripotent cell line which did not 
involve the use of embryonic tissue. It did appear to be that the primary goal for 
creating this pluripotent line from a somatic cell (such as a skin cell) was the 
increased chances of obtaining an appropriate donor, both for the universal donor 
line and also for the minority populations such as the sickle cell and thalassemia 
sufferers. This would have to be achieved by obtaining tissue from a consenting 
donor who provides the best possible match for a target patient group. Although 
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biologically useful there would of course be ethical implications of doing this, and 
my data shows that the team were aware that iPSCs at the time were not as well 
defined or tested as embryonic stem cells.  
“And again I think the iPS bandwagon is being jumped on a lot in the 
states because it’s ethically more acceptable than embryonic, but it has 
its own risks as well.” (CS/Lab) 
 
IPS cells are also often heralded as an ‘ethical’ alternative to using embryonic stem 
cells as they do not involve the destruction of an embryo (Kastenberg and Odorico, 
2008). This argument fails to account for the very real ethical dilemma that these 
cells would most likely be taken from a living donor. Whilst consent processes have 
moved on from the time of the HeLa cells5 there are still questions to be asked about 
the appropriate consent that could be taken when a (potentially multi-million pound) 
therapy is made from the cells of a donor who is still alive. As many of the target 
diseases identified by the BloodPharma team predominantly affect people of 
ethnicities which are in the minority in the UK it is possible that the ‘best match’ for 
these disease populations will come from another country. There is also the option to 
create autologous therapies, by taking cells from an individual patient and growing 
blood that is an exact match to them. This would obviously be very expensive and 
could only be used in extreme cases.  
 
During the period I followed the project (2009-2012) the emphasis for iPS cells 
changed from being a potential method of obtaining a matching donor to a means of 
securing much needed intellectual property rights over the cells and methods which 
the team are developing. This change was due to a patent ruling which became 
known as the Brüstle decision. In 1997 Oliver Brüstle, a German neuroscientist, was 
granted a patent on the process of developing human neural precursor cells from 
embryos, the neural cells being required for his work on Parkinson’s disease. In 2011 
Greenpeace challenged the Patent decision, claiming that it went against EU 
Biotechnology Directive which did not allow the ‘use of human embryos for 
                                            
5 The HeLa cell line is the most widely used cell line for stem cell research. The line was 
created in 1951 from the cells of a poor black woman who had no knowledge that her tissue 
was being taken for research. The story of this process was brought to wide public attention 
in 2010 in a best-selling book, ‘The Immortal Life of Henrietta Lacks’, by Rebecca Skloot.    
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industrial or commercial purposes’ to be patented in any of the EU member states 
(Herbert-Smith, 2011). The main questions raised by the case were whether research 
activities were considered to be industrial or commercial purposes, and whether the 
non-patent rule applied only to the cells themselves or to the method. On 18th 
October 2011 the European Court of Justice decided that the EU Biotechnology 
Directive did prevent the granting of patents which involved the destruction of an 
embryo, regardless of the stage at which this destruction had occurred and even if the 
patent was for the process and did not itself refer to the embryonic stem cells 
(Plomer, 2012).  
 
The ruling caused widespread shock amongst the research community, which 
considered the ruling would have a devastating impact on investment in cell therapy 
research (Holmes, 2011), although there is some feeling that the impacts may be 
lessened by the ability to patent outside Europe or to take advantage of orphan drug 
funding (Davies, 2010).  Since this ruling there appears to have been a shift in the 
goals of the BloodPharma team, from using iPSCs solely as a source of rare blood 
types sometime in the future, to an urgent need. Techniques developed using iPSCs 
are allowed to be patented, and once the techniques are patented these patents will 
also offer protection to production using embryonic stem cells. The focus now 
appears to be on moving forward the iPS cell research so that the financial 
investment made in the project can be protected. The implication for the team is that 
they will be required to develop an entirely different technology strand whilst 
simultaneously continuing to work on the embryonic methods which they have 
already invested in developing. It still appears to be uncertain whether the embryonic 
or the iPS cell technology will be taken through to clinical trial, although it is likely 
that the already advanced stage of the embryonic work will mean it is used for the 
first trials.  
 
Although this project is taking place in the UK there is awareness amongst the 
researchers that the UK is lucky in already having an established blood donation 
system. Although infections do occur they are extremely rare and there is a low level 
of endemic disease in the general population. There is even greater potential for the 
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use of this technology in other countries, including places like India, with 
increasingly sophisticated medical technologies but high levels of endemic disease. 
The goal when talking to the BloodPharma team does seem to be Africa, which has 
the highest number of deaths per year due to post-partum haemorrhage (Drife, 1997). 
There are long-term plans to make the cultured RBCs storable at room temperature, 
which will not only allow for ease of storage in the UK but will additionally allow 
the blood to be transported more easily. There have been differences of opinion 
within the team over whether the blood will ever be storable at room temperature, or 
indeed if this is any benefit for warmer climates.   
“I thought that was the ultimate aim, so universal donor blood and room 
storage. Now for Africa room storage doesn’t really help, because 40 
degrees isn’t our room storage. So, it may need to be refrigerated. …And 
the stability study that you would set up for those countries and those 
humidities, because it’s a plastic bag which humidity could have quite an 
influence on, so that type of thing.” (CS/Reg) 
 
So we can see here that although countries such as those in Africa appear to be an 
eventual target there is a change in infrastructure required before cultured RBCs can 
be widely used. As the researcher above has pointed out, even advances in storage 
temperatures may not be enough to cope with the high heat and humidity, resulting in 
the requirement for additional refrigeration. There is also the consideration that 
without medical care an adequate supply of blood would be useless, and many 
women dying of post-partum haemorrhage in these countries are many miles away 
from the nearest hospital. Whilst cultured blood could provide a clean blood supply 
in countries with a high prevalence of potentially transmissible infection, the use of 
this blood depends largely on the storage and delivery infrastructures available.  
 
CONCLUSION  
This chapter has addressed the key challenges identified by the BloodPharma team in 
translating cultured blood into viable clinical practice, and how these challenges 
shape everyday practices. Building on Chapter Three, which focused on basic 
research in the laboratory, we have now seen the team move out of the laboratory 




The scale-up requirements of the BloodPharma product are unique, demanding 
volumes of cells which are unprecedented in the stem cell field, and we have seen 
how the technology commonly used in other fields may not be applicable to a 
product which contains delicate cells. The methods of growing and sorting these cells 
are still unclear, but it appears certain that a new industry will have to be created to 
cope with the high demand for blood in the UK and worldwide. The scale-up of the 
BloodPharma product causes questions concerning the implications for automation 
and standardisation within the stem cell field as a whole, particularly linking with the 
problems of tacit knowledge as discussed in Chapter Three. In an industry that 
requires consistency as well as quality the reliance on visual identification and hands 
on experimentation becomes a challenge requiring the development of increasingly 
sophisticated automation technologies. In the case of the BloodPharma project we 
have seen how the team must look forward many years into the future, attempting to 
introduce scaleable protocols and to develop the large bioreactors required even 
when a small quantity of product cannot yet be produced in the laboratory. This is a 
clear demonstration of the challenge ahead of the team, and that they are aware of the 
many years it will take to develop the systems required for translation.  
 
The ultimate goal in producing large quantities of blood is to eventually supply the 
UK transfusion service; however the first hurdle is to produce enough product to be 
used in clinical trials. We have seen that the model for animal and human trials 
within the stem cell arena is still contested and uncertain, and the BloodPharma 
product is no exception to this. The applicability of animal models and the ethical 
acceptability of using human trial volunteers has been questioned by the larger stem 
cell community, yet the requirement for some form of safety testing is clearly 
acknowledged. Again we see the BloodPharma product as occupying a niche within 
the stem cell field, given that the product does not have the same DNA transfer 
potential, or the same longevity, as other stem cell therapies. Here the ReNeuron trial 
has been drawn upon as an example of a more ‘standard’ stem cell therapy which is 
also further down the clinical trial pathway. The requirement to develop new animal 
models has been shown, as has the clash between the regulators and the clinicians 
over the appropriate patient cohort and clinical trial design. The clinical trial process 
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for the BloodPharma product is still unclear, but it is likely that the product will 
introduce some new considerations for the regulatory bodies.  
 
Given the huge scale-up challenge the use of a stepping stone method of introducing 
the BloodPharma product was discussed. The identification of potential target 
groups, such as sufferers of sickle cell disease or thalassemia, could allow the 
product to be used in smaller quantities for selected patients. These patients are likely 
to benefit from cultured RBCs over and above the general population, and would 
allow the BloodPharma product to be introduced with lower volume requirements 
and in a way that would justify the high initial cost. After introduction of the product 
using these target groups there is potential for the product to be rolled out by 
concentrating on other high-expense groups, such as emergency patients, as it is 
likely that money could be saved by the blood transfusion services by reducing the 
pressure on out-of-hours staff and services. Potential changes to the cultured blood 
product have also been discussed by the team, most prominently the use of iPS cell 
technology. Whilst this is a way of obtaining an accurate donor match for target 
populations, or a universal donor for wider transfusions, more recently the advantage 
for patenting has made this an increasingly attractive option. Whilst the impact of the 
Brüstle patent decision to the long-term future of the stem cell field is not clear it 
would be advantageous for the BloodPharma team to secure as many rights as 
possible over its work and the product produced. Other long term aims, such as 
making the product storable at room temperatures, may contribute to storage and 
distribution within the UK, although supplying areas such as Africa is likely to rely 
on other advances in storage and administration infrastructure.  
 
The key challenges associated with translating cultured blood into a viable clinical 
product are therefore seen to be associated with scale-up and standardisation, the 
uncertainty of the clinical trial regime and the initial introduction mechanism for the 
cultured blood product. Such challenges are shaping everyday practices as the team 
seeks to work towards these goals many years ahead of implementation. For example 
members may be attending a meeting about the development of a bioreactor when 
the cells themselves can only be grown in small quantities. Protocols for cell culture 
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are already being designed for scalability, even if this means increased work at the 
present time, because the team are aware that they must develop standardised 
protocols which are future-proof. Similarly potential animal models are being 
considered and target markets identified whilst the early stage laboratory work is 
continuing. In considering such target markets the team are researching the most 
likely blood types to be required, the potential location of trials and the funders who 
may be interested in such work. Whilst the impact of the regulatory system on the 
translation of this product from basic laboratory research to clinical therapy has been 
touched upon in the context of clinical trial design, the next chapter will deal in more 
depth with the BloodPharma team navigating this regulatory pathway.  













CHAPTER 5: REGULATION IN THE 
BLOODPHARMA PROJECT  
INTRODUCTION 
Stem cells are complex and volatile products capable of producing both benefit and 
harm to patients and therefore requiring appropriate regulatory control, in the form of 
a regulatory system which both mitigates risk and supports the development of new 
therapies. As Harmon et al. (2013, pg.26) write “We expect our governance 
frameworks to defend against risk and to promote a range of valued outcomes, 
including better health, safety, productivity and prosperity”. The UK system for 
regulating stem cell based products is complex, and seeks to reflect the unique 
properties of stem cells and the safety considerations which these bring. The ethical 
and moral implications of stem cell research have received much attention both in the 
lay press and in academic discussion, in comparison to which the applicability of the 
current stem cell regulatory system has been overlooked (von Tigerstrom, 2008). In 
this chapter I will focus on the dynamic and evolving relationship between the 
BloodPharma project team and the regulatory system, to explore how the regulatory 
system works in practice during the development of a novel stem cell therapy.   
 
The overarching research question is:  
How does the regulatory system, and perceptions of risk, shape the activities of the 
BloodPharma team and the development of the cultured blood product, and what 
can this case study tell us more generally about the regulatory system for stem cell 
products? 
 
In the first section I will present an overview of the current regulatory system and 
identify the key regulatory bodies that impact on the BloodPharma team. Drawing on 
the literature around regulatory theory I will consider how the regulations for stem 
cells in the UK have been built up over time and what each of the regulations was 
designed to protect. Moving from early tissue use through to market authorisation I 
will draw on interview and observational data to explore how the regulations for each 
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stage are working in practice, and where there are important boundary issues 
between the different regulatory bodies.  
 
The second section will consider how the BloodPharma team is navigating the 
regulatory system. Drawing on different notions of expertise I will consider the 
various levels of knowledge, information and capabilities required. The laboratory 
researchers have a specific kind of scientific expertise and knowledge but find 
themselves less able to engage with the language of formal regulation. Translation is 
therefore required between the scientists and the regulators to turn the basic scientific 
data into suitable regulatory dossiers for presentation to the regulatory committees. 
The BloodPharma team is able to draw on many members of staff with differing 
expertise, but this is not always the case for other projects and may be a barrier for 
many academic researchers.   
 
In the final section I will explore the product itself in the context of regulation and 
consider how it may be perceived by the regulators and how future hurdles are being 
anticipated by the project team. The team, I will argue, use ‘informal reasoning’ to 
make sense of the potential risks associated with their product, and I discuss this 
using Sadler and Zeidler’s (2005) work on informal reasoning considerations. As the 
BloodPharma team is developing stem cell lines which they hope to use long term, 
they face uncertainty about future regulatory requirements. To avoid falling short of 
safety levels which are subsequently introduced, the team have to look ahead to 
anticipate future regulatory hurdles and plan the scientific work accordingly. Here 
the BloodPharma team has the challenge of balancing the introduction of a novel 
product with the use of an already established technology. 
 
The BloodPharma project can be considered a test case for the regulatory system due 
to the unique combination of a starting embryonic stem cell line with the eventual 
enucleation of the end product. This enucleation should result in no DNA transfer to 
the recipient, giving the BloodPharma product a different risk profile from many 
other stem cell derived therapies. There is currently much uncertainty about both the 




The regulators are also learning and seeking to develop appropriate methods of 
regulating a fast moving field. This chapter will provide a snapshot in time of a team 
attempting to engage with the regulatory system and consider what these 
uncertainties can tell us about the regulatory system itself and the appropriate 
oversight of stem cell therapies more widely.  
 
IDENTIFYING THE EMERGENCE OF THE KEY REGULATORY BODIES 
AND OUTLINING THE CURRENT REGULATORY SYSTEM FOR STEM 
CELL RESEARCH IN THE UK 
This section analyses the emergence of stem cell regulations in the UK and the 
impact of this on the characteristics of the current regulatory system.  Firstly relevant 
regulatory bodies will be introduced, alongside relevant regulatory theory, and 
secondary data used to consider how the main stem cell regulations in the UK were 
created. I shall then use examples from my own data to illustrate boundary issues 
which have arisen as the BloodPharma team, and other scientific projects, has 
attempted to navigate this system.  The regulatory system for stem cell products in 
the UK is currently comprised of a significant number of different regulatory bodies, 
which are responsible for overseeing both safety and ethical aspects of the stem cell 
field. This complex regulatory route is outlined in the Interim Regulatory Route 
Map, Figure 12 (included in Appendix). Before discussing this regulatory system in 
more detail I will present a brief overview of some of the main regulatory bodies and 
their remits. This list is by no means exhaustive as there are many other agencies that 
regulate other parts of the stem cell field and laboratory work in general6. It serves to 
illustrate the complexity and potential for overlaps. 
 
Human Fertilisation and Embryology Authority (HFEA) - oversees the Human 
Fertilisation and Embryology Act, which sets out the requirements for the collection, 
storage and use of embryos and gametes in the UK. (www.hfea.gov.uk) 
                                            
6 These include the Department of Health, the Home Office (for animal work), the NHS 
Blood and Transplant Authority, the Advisory Committee on the Safety of Blood, Tissue and 
Organs, etc.  
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Human Tissue Authority (HTA) - Responsible for regulating the use of human 
tissue in the UK, including tissue transplants, tissue banks, laboratory samples, and 
the collection and use of adult or foetal tissue in research. (www.hta.gov.uk) 
Medicines and Healthcare Products Regulatory Agency (MHRA) - Regulates 
medicines, devices, Advanced Therapy Medicinal Products7 (ATMPs), and blood 
within the UK, including safety testing, licensing, and reporting of adverse events. 
(www.mhra.gov.uk) 
Gene Therapy Advisory Committee (GTAC) - The committee with ethical 
oversight of clinical trials involving stem cells or gene therapy. GTAC was 
disbanded in June 2011, with responsibility passing to the National Ethics 
Committee8.  
UK Stem Cell Bank (UKSCB) - May not strictly be considered a regulatory body 
but oversees the transfer of stem cells between research teams, banks research lines 
and works on maintaining stable derivations of such lines.  
(www.ukstemcellbank.org.uk) 
European Medicines Agency (EMA) - Provides a centralisation of the scientific 










                                            
7 The HTA defines ATMPs as ‘innovative, regenerative therapies which combine aspects of 
medicine, cell biology, science and engineering for the purpose of regenerating, repairing or 
replacing damaged tissues or cells’. Either a gene therapy, somatic cell or tissue engineered 
product.  







Before introducing data gathered during this case study, I shall introduce some 
relevant regulatory theories. These theories explain some of the different possible 
ways of regulating new technologies and help us to see where decisions have been 
Figure 7: Simplified route map 
Showing a simplified version of the Interim Regulatory Route map (shown in Appendix). 
This representation assumes that the stem cells are intended for human application, that the 
therapy will be classed as an Advanced Therapy Medicinal Product (ATMP), and that final 
market authorisation is approved.  
 
Stem cells intended for 
Human Application 
Permission required from 
HFEA if embryonic tissue 
HTA if foetal or adult tissue 
Derive cell line 
Cell line banked with UKSCB 
Start discussions with MHRA/EMEA 
Carry out animal testing 
 
Clinical trials in humans 
Submission of regulatory dossier to EMEA 
Market Authorisation Granted 
Clinical trial approval required from MHRA 
Data reporting to relevant regulatory bodies 
Obtain Home Office approval for animal testing 
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made in the regulation of stem cells. Croley (1998) identifies four different types of 
regulatory theory to explain how regulations are created, which he believes arise out 
of the pluralist theory in which interested groups lobby for group interests: 
Public Choice Theory – Regulation is seen as analogous to economic 
markets, where stakeholders (be they public, regulators, interest groups) exchange 
‘regulatory goods’ such as access to markets, price controls etc.  
  Neopluralist Theory – Interested groups compete in order to obtain the 
regulations which best match the group interest. Legislators may seek compromises 
in order to avoid displeasing certain groups.  
Public Interest Theory – Three groups exist: the regulators, the general 
public, and special interest groups. The general public have little influence on the 
construction of regulations, while the special interest groups may have slightly more 
influence. Regulators seek to preserve their positions and may attempt to act in what 
they see as the best interests of the ‘misguided’ general public.  
Civic Republican Theory – Regulatory decisions are made as a result of 
debate and dialogue between all interested parties, with regulations representing a 
rough consensus of all parties.   
 
Although Croley’s theories explain some of the desires to regulate they do not help 
us to discuss the different methods of regulating. Chataway et al. (2006) categorise a 
number of different approaches to regulation, of which the precautionary and 
reactive methods are most relevant here. The precautionary method of regulating is 
based on a system set up to avoid potential hazards (Chataway et al., 2006; Harmon 
et al., 2013). This precautionary principle is sometimes explained as ‘do no harm’, 
however in a scientific context it is more accurate to say that it advocates foresight to 
minimise harm to human health or the environment, and to obtain proof that harm 
will not occur (Lofstedt, 2003). The precautionary principle is often used in decision 
making regarding environmental science, and here the aims of the precautionary 
principle are extended to include ‘taking preventative action in the face of 
uncertainty’, whilst also ensuring that a burden of proof is submitted by proponents 
of change, that other alternatives are considered, and that public views are taken on 
board (Kriebel, Tickner et al., 2001). Majone (2002) sees the precautionary principle 
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as becoming a key tenet of the European regulatory framework, but urges caution, 
citing that it lacks a logical foundation and may result in the distortion of regulatory 
priorities. The danger of the precautionary principle is in forming a risk averse 
regulatory system that slows the implementation of new innovations (Foster, Vecchia 
et al., 2000).  
 
There are many parallels between this regulation based on the precautionary 
principle and the previous regulation of GM crops. Like GM crops an emphasis has 
been placed on using social and moral considerations to determine potential ‘risks’ 
(Levidow et al., 1996). Tait (2001) writes that the regulation of GM crops based on 
the precautionary principle allowed judgements based on ethical or moral values to 
be given a place in the risk analysis of new technologies, and that this can override 
the use of unbiased scientific assessment (Tait and Chataway, 2003). This certainly 
appears to have become the norm for debates around stem cell regulation, 
particularly centring on the use of human tissue. Just like the BloodPharma product 
the regulators were not debating between a GM crop and no crops, but between GM 
crops and existing food crops. Similarly to the current blood donation system the 
advantages of GM crops over existing crops were largely based on expectation - the 
requirement to introduce new crops before pesticide resistance and other problems 
caused a fall in food production.  
 
The use of the precautionary principle of regulation has led to a serious of hurdles in 
obtaining permission for commercialisation of research. In contrast reactive 
regulation sees regulations set up in response to problems which arise from earlier 
use of a technology (Chataway et al., 2006). When new products are developed the 
regulations are in place to prevent a repeat of previous problems. These reactive 
regulations are something which the BloodPharma team will be familiar with, as 
many regulations within the blood system have been the result of reactions to serious 
episodes of infections within blood and blood products. The ongoing hepatitis 
transfer through blood donation from donor to recipient led to regulations banning 
the use of pooled donations (Starr, 1999, pg.216). HIV contamination in the early 
1980’s infected 1,227 haemophiliacs in the UK through contaminated plasma 
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(Darby, Ewart et al., 1995), with the authorities slow to act. The result was the deaths 
of 85% of those infected. Starr (1999) attributes this lack of immediate action to the 
reverence given to blood and its symbolic nature as a social gift, rather than a 
pharmaceutical product. Titmuss (1997) however writes that as well as the trust 
between doctor and patient there is also an element of trust required between doctor 
and donor. He attributes infections, particularly in the US, to the way in which blood 
was no longer seen as a gift. Here blood was often taken from those who had little 
choice (such as prisoners), or became a product to sell for monetary compensation. 
Both of these routes made it less likely for donors to be truthful during the pre-
donation self-selection process. 
 
Many lessons were learnt from these infection scandals, for example when a blood 
donor was subsequently diagnosed with CJD all potentially contaminated products 
were destroyed, at a cost of around £130million (Starr, 1999, pg.342). In the UK 
blood donation and transfusion is currently regulated under the Blood Safety and 
Quality Regulations of 2005, overseen by the Medicines and Healthcare Regulatory 
Agency (MHRA). Using these theories as a basis it can be seen that the regulation of 
stem cell research has grown out of a number of different approaches to regulation, 
and that these approaches impact on the regulation of the BloodPharma project. I will 
now list the key regulatory stages for the BloodPharma project, before looking in 
more detail at the regulations for blood donation and tissue collection. The following 
chapter sections will present in more detail the implications for laboratory 
regulations and licensing of the cultured blood product.  
 
The UK system of blood donation heavily influences the BloodPharma team, many 
of whom have close links with the Blood Transfusion Services and will be familiar 
with the regulations which govern blood donation and transfusion. I have previously 
introduced the reactive nature of blood donation, but many of these regulations are 
also examples of ‘good practice’ becoming formalised. Messner’s (2009) work on 
the emergence of Fast Track regulation at the FDA highlights the importance of this 
social construction in rule making. She draws on examples such as the AIDS crisis to 
show how regulations of biotechnology do not develop as a set of hard and fast rules, 
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but are instead born out of the desire of a field to develop good practices. These 
regulations are often a formalisation of practises already followed informally by 
those who work in the area, and in many cases turn out to be more adaptive than 
often expected.  
 
This is the way in which many of the regulations on blood and blood products were 
originally introduced. A member of the BloodPharma team commented  
“we [the blood transfusion services] were there before the regulators.”  
 
Formalisation of standard practice is seen in the use of the Transfusion Trigger, the 
haemoglobin level below which it is considered a patient requires transfusion. A 
level of 100mg haemoglobin per litre of blood became the standard, being easy to 
remember and high enough to account for inaccuracies in measurement. This trigger 
value was passed by word of mouth from doctor to doctor, and repeated in almost 
every medical text book, yet there was no biological basis for this value. Indeed it 
has been shown that humans can survive blood loss which results in much lower 
levels of haemoglobin. A 1988 NIH conference sought to confirm the levels of such 
a trigger, and although they recommended that a concrete haemoglobin level was no 
substitute for good clinical observation the transfusion trigger of 100mg/l was still 
accepted  (Myhre, 2001; Martyn et al., 2002). Another example of practice becoming 
standardised is in the amount of blood taken during a transfusion. Again there is little 
biological basis for this, it was the amount that it was considered a soldier could 
afford to lose. As many of the BloodPharma team are closely connected with the 
Blood Transfusion Services they are aware of the introduction of certain regulations 
linked to practices rather than strict biological markers. In other words they 
appreciate the malleability of the regulatory system to enact regulations based on 
clinical use rather than simply imposing a strict framework around which researchers 
must fit. There does seem to be an appreciation amongst the BloodPharma team that 
the regulatory system is not hard and fast, but that it is up to the team to provide the 




A key consideration of regenerative medicine is that the starting research tissue often 
comes from human sources in the form of embryonic, foetal or adult tissue. The 
regulation of such starting tissue seeks to balance the use of such material to benefit 
medical research, whilst also respecting the donor. The two main tissue regulators in 
the UK are the Human Fertilisation and Embryology Authority (HFEA) and the 
Human Tissue Authority (HTA). The use of foetal tissue for research purposes is 
permitted in the UK and foetal tissue is regulated by the HTA, rather than the HFEA.  
The ReNeuron project uses foetal tissue, and the BloodPharma uses foetal liver tissue 
in early stages of the research. Foetal tissue is collected after terminations, with 
strong emphasis on appropriate consent of the women donating the tissue (Kent and 
Pfeffer, 2006; Pfeffer and Kent, 2007; Pfeffer, 2008). 
 
The HTA was originally set up in response to a public backlash after what became 
known as the Alder Hey Organ Scandal. In 1999 an inquiry was announced into the 
removal and storage of tissue from infants, which had taken place at the Alder Hey 
hospital in Liverpool (Howard and Robert, 2001). It was alleged that between 1988 
and 1995 organs had been systematically removed from cadavers and stored without 
parent’s knowledge or consent. Affected parents were outraged that tissue had been 
taken and stored and that the hospitals continued to be reticent about the quantity of 
tissues taken. Some parents had up to three funerals for their child as more organs 
came to light. In the aftermath these parents contributed to discussions on the 
informed consent process which underpins the work of the HTA. Although the Alder 
Hey hospital has become synonymous with this scandal (and the media storm that 
subsequently erupted) the practice of retaining tissue in this way was widespread and 
accepted by the medical community (Burton and Wells, 2002). The Human Tissue 
Act of 1961, which sought to regulate the use of human tissue taken from the 
deceased, had been adhered to in this case, however it was felt that in light of the 
public backlash that updated regulations were required. These were introduced as the 
Human Tissue Act of 2004, alongside which was created the Human Tissue 
Authority (HTA).The updating of the Human Tissue Act placed increased emphasis 
on consent. Affected parents were involved in the development of new consent 
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procedures for tissue use, and these parents could be seen as becoming an ‘interest 
group’ in Coley’s Public Interest Theory of regulation.  
 
The use of embryos in IVF is another example of regulation designed to protect 
human tissues. The main instigator of the these regulations was the report of the 
Warnock Committee (Warnock, 1984), set up in response to the birth of Louise 
Brown the first test-tube baby, which sought to implement guidelines for what was 
considered a fast paced field. The guidelines resulted in the creation of the HFEA, 
which could be considered an example of the ‘reactive regulation’ introduced above, 
as it was set up in response to the introduction of a new technology. However in this 
case no problems had arisen, the regulations were designed to protect anticipated 
introductions of new technology to the field of IVF.  The considerations of the 
Warnock Committee opened up a wider debate on the use of human embryos in 
research, which is too complex for full explanation here, although for further 
information see Mulkay (1993), Mulkay (1994), and Parry (2003). The Warnock 
committee recommended the research limit of 14 days post-fertilisation, after which 
the embryos must be destroyed. This could be seen as an example of Coley’s 
Neopluralistic theory, with interest groups lobbying for different regulations and 
legislators seeking a compromise with the introduction of the 14 day limit. 
 
THE EXPERTISE REQUIRED TO NAVIGATE THE REGULATORY 
SYSTEM AND HOW THIS IMPACTS ON PRACTICE AND KNOWLEDGE  
The current regulatory system has been built up in a piecemeal fashion, resulting in a 
regulatory framework that is comprised of many different bodies and organisations. 
In this section I shall draw on my interview and observational data to discuss the role 
of regulatory expertise within the BloodPharma team, and how the regulatory system 
can be seen to impact on the development of novel stem cell therapies. Stem cell 
products can vary widely in considerations such as administration procedure, source 
of cells, and cell purity (Mittra, 2007; von Tigerstrom, 2008). Such diversity is one 
of the biggest challenges within the regulation of stem cell products as a whole, and 
the BloodPharma project more specifically. In navigating the regulatory system the 
BloodPharma team must draw on their own expertise to negotiate the spaces into 
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which the cultured blood product falls, identifying potential risks and benefits of 
their particular research. The regulators must also gather together the expertise to 
fairly regulate novel products which may be outside their normal areas of knowledge.  
 
There are a number of regulatory challenges which arise from the biological 
properties of stem cells. The bestselling book, ‘The Immortal Life of Henrietta 
Lacks’9 by Rebecca Skloot (2010) focuses on the use of a particular cell line, known 
as HeLa. The main premise of Skloot’s book is the sheer number of HeLa cells 
currently in existence, many times the number of cells which made up the body of 
the original donor. This splitting and dividing of cells is a key ability of stem cells as, 
unlike whole organs, a stem cell line can theoretically grow and divide indefinitely. 
The regulatory hurdle of tracking a donated heart, for example, from donor to 
recipient in a one-to-one model is very different from the traceability required for 
stem cells. It is already known that cells grown under different conditions can start to 
exhibit different physiological features, so distribution of cells not only leads to 
problems of accountancy but also to changes in these cells over time. Webster and 
Eriksson (2008) show how the ‘biological qualities’ of the stem cells differ, with 
markers, characterisation and protocols varying widely between different  research 
groups.  
                                            
9 The Immortal Life is a non-fiction book detailing Skloot’s interactions with the family of 
Henrietta Lacks, a poor black woman whose cells were taken without consent and now form 
the HeLa cell line. The resulting cell line is now one of the most widely used and is present 
in laboratories across the world.  
Figure 8: Key Regulatory Stages in the BloodPharma Project  
Tissue Collection 
Collection of the surplus IVF embryos used by the BloodPharma project is 
overseen by the HFEA. This regulation is taken over by the HTA at the point that 
the embryo is destroyed and a stem cell line is created. 
 
Laboratory Work 




Scientific data supplied to the EMEA who scientifically evaluate the safety data 
for proposed therapies. Once a market authorisation has been granted the 






Much of the work of the UK Stem Cell Bank (UKSCB) is concentrated on achieving 
culture conditions which ensure the stable properties of cells lines from one 
generation to the next, seeking to generate a ‘reproducible product’ (Healy, Hunt et 
al., 2005) and avoiding contamination (Cobo, Stacy et al., 2005). The UKSCB is 
therefore a regulatory body which seeks, as well as producing stem cells under GMP 
conditions, to regulate the biological properties of stem cells. Currently copies of all 
stem cell lines produced in the UK using human embryos must be deposited with the 
Bank (Courtney, de Sousa et al., 2011). The UKSCB then acts as a long term 
repository, allowing other approved research projects access to these stored cells. 
Only on rare occasions are human embryonic stem cell (hESC) lines permitted to be 
transferred directly from one laboratory to another. This is quite distinct from the 
normal pattern of information exchange between laboratories, which often appears to 
be the result of networking at conferences, emails exchanges and the formation of 
friendships between researchers; practices which are very distinct from the formal 
tissue exchanges expected by the regulatory system.  
 
Another similar example of regulations imposing on ‘standard’ practice was given by 
the MRC Regulatory Support Centre, which highlighted the problem of researchers 
collaborating across international boundaries, often unaware that the Data Protection 
Act prevents the transfer of much relevant data (for example patient information) out 
of the UK.  Incidences such as these are not just about the divisions of tissue but also 
tell us about laboratory practices and the interactions between researchers and the 
regulations. Despite the rivalry which does exist between research groups it is also 
clear that researchers form a variety of networks and collaborations and are generous 
at helping each other. This includes not only the sharing of knowledge but also 
tissues, reagents, equipment etc10. In this case the regulatory system could be viewed 
as an impediment to the free exchanges of information and samples that the 
researchers consider to be ‘normal’ practice. Stem cells can be shared between 
                                            
10 Although I have not been able to gather extensive examples of these practices I have been 
aware of a desire, especially among academic laboratories, to ‘get one up’ on the large 
companies who supply reagents and DNA, often at high cost. Certainly a reasonable amount 
of the sharing that goes on between laboratories represents an effort to obtain something 
from a fellow research laboratory which they would otherwise have to pay for.  
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laboratories because of their ability to multiply and to be stored for long periods of 
time; however this potential for division is also a key regulatory concern. Whilst 
pluripotency is an asset for therapeutic development it is also a risk, because if 
control is relinquished then cells can multiply and differentiate without barriers. The 
risk of teratomas (tumours that contain a variety of different tissues) is the nightmare 
scenario of stem cell research and one which the regulatory system is anxious to 
prevent patients being exposed to. Von Tigerstrom (2008), and Mittra and Tait 
(2009), cite tumour formation as one of the main safety risks associated with stem 
cell based products, alongside potential infection (including the possibility of transfer 
of infectious agents from animals tissue), genetic changes and immune reactions.  
 
Stem cells therefore have the ability to replicate in large numbers and have a double 
value as both a body tissue and a research tool. In an effort to encompass these 
different facets, the regulatory system has employed what one of my interviewees 
termed a ‘two pronged approach’. This is that the system attempts to regulate from 
both a safety and a moral standpoint, with different regulatory bodies having a 
different emphasis. For example the HFEA and the GTAC are almost primarily 
concerned with ethics, whilst bodies such as the MHRA and EMA are more driven 
by safety and efficacy. Brown and Michael (2004) see this as assembling ‘regulatory 
ingredients’ in an attempt to envelop novel technologies with some form of 
oversight. This has resulted in a convoluted regulatory pathway which has been 
summarised into the Interim UK Regulatory Route Map for Stem Cell Research and 
Manufacture (Figure 12 included in Appendix). The route map highlights the 
complexity of the pathway which researchers must navigate and the boundaries at 
which regulatory organisations meet. For example embryonic and foetal tissue is 
initially regulated by the HFEA but oversight is passed to the HTA when this tissue 
is transformed into a cell line. The sheer number of bodies, each attempting to fulfil 
its own individual remit, leads us to question the boundaries which are placed 
between different regulatory bodies and between researchers and regulators. 
“It is a conjunction of processes which were principally designed for 
other related purposes and they’re all coming together, so when you do 
that you would normally find that there is some degree of overlap and 
some differences between what different regulators want, partly because 
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they have slightly different remits and perspectives and partly because 
people just do things in slightly different ways.” (CS/Med, my emphasis) 
 
This coming together of regulators who oversee stem cell research in slightly 
different ways, but who both occupy the same regulatory space, is the subject of 
some confusion amongst researchers in the stem cell field. An overview of the 
regulatory process in the BloodPharma project is shown in Figure 8. A common 
theme within the BloodPharma team, which has also been raised by many other 
members of the stem cell community, is the difficulty of dealing with a regulatory 
system which does not itself appear to be entirely sure of its own responsibilities. My 
data shows that the two-pronged approach for regulating stem cell research from 
both a scientific and an ethical viewpoint is causing an overlap between the remits of 
certain regulatory bodies. The BloodPharma project currently uses stem cell lines 
created from surplus IVF embryos, and as such is overseen by the HFEA (whose 
remit is to regulate the use of sperm, eggs and embryos in fertility treatment and 
research). At the point at which the embryo has been destroyed and the stem cell line 
is created the research then falls under the jurisdiction of the HTA. As responsibility 
for this tissue passes between the different regulatory bodies areas of confusion are 
exposed, as this researcher from the BloodPharma project describes: 
 “There has been a lot of grey areas in terms of our raw material, which 
is embryonic material and then at the point that that embryo no longer 
exists and we have a stem cell line, at that point we have the HFEA 
regulating embryonic work but the HFEA regulations stipulating things 
that you must do with the resulting stem cell line, which they don’t 
officially regulate. So there are grey areas like that where one regulator 
is telling you to do something with some tissue which they don’t 
actually regulate. I think they are aware of that and are starting to clear 
things up.”  (CS/Lab, my emphasis)  
 
The interviewee is referring to the HFEA wishing to know details such as the 
eventual application of the resulting stem cell line, even when they are considered by 
the researchers to be regulating only up until the point at which the embryo ceases to 
exist. This overlap of regulatory remits between the HFEA and the HTA has resulted 
in the research teams having to submit the same data to two different regulatory 
bodies. As part of my data collection I interviewed a member of the HFEA who 
stated that, in their belief, the HFEA had responsibility for ensuring that the embryos 
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were treated with adequate respect. The interviewee felt that the HFEA could not do 
this without a thorough understanding of what the stem cell line would be eventually 
used for. There seems to be a difference of opinion between the researchers, who 
believe that organisations such as the HFEA are overstepping their remit, and the 
regulators themselves who feel that asking for additional data is necessary to 
properly oversee the use of such starting material. In this case, whilst the submission 
of data to two different regulatory bodies is both time consuming and costly, 
permission was granted for the BloodPharma team to create such stem cell lines. The 
acquisition of other starting material has not been so straight forward, as another 
researcher explains:  
“Getting diseased tissue from patients is very, very straightforward in the 
majority. Normal samples are always difficult. When donors are giving 
stem cells for bone marrow transplants it used to be that you, with patient 
consent, could take a little bit extra for research, whereas more recently 
that was changed and the criteria for collecting was tightened up so that 
there was a very small window of excess. Which basically meant that we 
lost all access then to normal research material. We’ve actually bought 
in from America normal control samples because we can’t get the tissue 
here.” (CS/Lab) 
 
Here we can see restrictions placed on the collection of adult tissue becoming a 
major obstacle to those who require samples for research use. The comment that 
researchers were forced to buy in control samples from outside the UK raises 
questions of how such tissue collection regulations will impact on the long-term 
future of the UK stem cell field. Without adequate sources of research material, the 
UK may become a less attractive option for companies and academic researchers 
who are looking to develop new cell based therapies.  
 
Regulatory bodies attempting to work outside their individual area of responsibility 
has been presented in both conference presentations and informal discussions as one 
of the biggest problems for navigating the regulatory pathway. Similar instances 
were raised by those I interviewed in the ReNeuron team, particularly with regards to 
the Gene Therapy Advisory Committee (GTAC):  
“I think I’m puzzled by their [GTAC] role, and I suspect it’s because it’s 
not really very well worked out yet. Normally if you were going through a 
clinical drug trial development you would get approval for your protocol 
from MHRA and take that to an ethics committee. Now the ethics 
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committee has a role to advise on aspects of ethical concern within a 
study. But they don’t go back to re-review the basic science. Whereas 
the experience with GTAC has been that they have concentrated, almost 
exclusively, on those components which are to do with the basic science. 
If GTAC require changes in the protocols, well you have to go back to 
MHRA to seek their approval of the changed protocol. So if MHRA 
approved the first protocol and then the ethics committee request changes 
you’ve got to go back and make sure the changes are also agreed with, so 
you end up in a loop.” (O/Med, my emphasis) 
 
Here we have an example that the regulatory authorities do not appear to be 
sufficiently bounded, and there is often an understanding that the stem cells 
themselves are ‘not right’; they don’t fit neatly into any conventional area that we 
understand. Stem cells have grown out of work conducted in both IVF treatment and 
in tissue transplantation and engineering, with human embryos considered as 
‘boundary objects’ by Williams et al. (2008) who discuss the different meanings of 
embryos used in either stem cell research or pre-implantation genetic diagnosis. The 
distinction here is between destroying embryos in the pursuit of a healthy baby, and 
using ‘waste’ embryos for some therapeutic good. Williams et al. show that the same 
tissue can be considered to have different meaning in different contexts. Stem cells 
also traverse the acceptable boundaries of species, cutting across animals and human 
lines with new technologies of human/animal hybrids. Cooper (2004) likens this to 
19th century views of ‘monstrosities’, creations which cut across boundaries and 
make us question what constitutes ‘life’ as we know it.  The result of this 
overlapping into different spaces is not just that stem cells move beyond the 
boundaries of individual regulators, but that they account for only a small proportion 
of each organisation’s regulatory oversight.  
“The problem with advanced medical therapies is that it intrudes into the 
space, or it occupies part of the space, of multiple agencies. So all of 
them, or many of them, have a legitimate interest.” (CS/Med)  
 
The diversity of stem cell products means they are spreading over a wide area of 
research, which is divided between different regulatory bodies. The interviewee 
above echoes the words of Brown et al. (2006), who write that stem cells ‘traverse 
the borders between regulated reproduction and transplantation’ and also Brown and 





As part of this project I also interviewed a number of people involved with the 
regulatory bodies, including one member from each of GTAC and the HFEA. My 
data shows that both these interviewees did not feel that the concerns of the research 
community were justified. We have seen that the interviewee from the HFEA raised 
the problem that the HFEA cannot guarantee to protect the interests of the embryo 
without knowing the proposed use of the cell line. A similar argument was made by 
the representative from GTAC, who felt that an understanding of the development 
and eventual use of the cell line was vital to GTAC’s decision making and any 
confusion stemmed from the researchers not fully understanding the role of the 
GTAC committee. We saw in the quotation above the boundary clashes which took 
place between GTAC and ReNeuron, and this is one hurdle that the BloodPharma 
team will not have to face as GTAC has now been disbanded. It is however 
interesting to note that much of this misunderstanding relates once again to the use of 
contentious tissues in stem cell research. The view of the HFEA that it must protect 
the interests of the embryo does not sit very well with the HTA, which regulates the 
line once it has been created and focuses more heavily on regulation from a health 
and safety viewpoint.  
 
It appears that stem cells are ‘messy’ because they are both a commercial, scientific 
product and are imbibed with some form of ‘specialness’ due to the presence of 
human tissue. Navigating the regulatory system therefore becomes a story of 
boundaries, boundaries between existing and novel technologies, between 
regulations and regulatory bodies and between researchers and regulators.  It is at 
these boundaries where meaning is negotiated (Jones and Graham, 2009) about the 
validity of different scientific work and about expertise and hierarchy. Much of the 
boundary work that exists is between regulatory bodies, each of which believes it is 
following its own legitimate remit, as we saw in the examples of the GTAC and the 
HFEA. This would appear to be an example in practice of what Shakley and Wynne  
(1996) refer to as ‘boundary-ordering devices’, as each regulator attempts to 
overcome uncertainty by situating themselves on either side of the boundary but 
attempting a dialogue that takes into account both sides. Such diversity in regulatory 
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objects must also be accompanied by a diverse body of expertise and such expertise 
is crucial for navigating the regulatory system. The next section will discuss how the 
BloodPharma project makes use of differing types of expertise within the project.  
 
Collins and Evans (2002) discuss different forms of expertise in their paper on the 
Third Wave of Science Studies, drawing on the distinction between the scientists and 
farmers in Wynne’s (1992) study of Cumbrian sheep farmers. What is highlighted 
here is the difference between the ‘formal’ expertise of the scientists and the 
expertise of the sheep farmers gathered from many years of observation and 
experience on the hills. In this case the scientists often disregarded the ‘expertise’ of 
the farmers, while interestingly the opposite appears to be the case within the 
BloodPharma project. Those with many formal qualifications often defer to the 
expertise of those with fewer qualifications, but who work day-to-day with the cells 
and have a working knowledge of the scientific project. Therefore when discussing 
expertise in this section I refer equally to both formal expertise and expertise gained 
through experience. The distinctions that I make are instead between the scientific 
expertise to understand the BloodPharma project, and the expertise required to 
understand the language and requirements of the regulatory system.  
 
I have discussed previously how stem cells cross multiple regulatory spaces and it is 
important to emphasise the wide-ranging roles of the stem cell regulatory bodies. The 
regulation of fertility clinics represents the main bulk of the HFEA’s work, whilst the 
MHRA oversees all medicines and medical devices. In addition to stem cell lines the 
HTA also regulates the use of human tissue for organ transplants, display purposes, 
and tissue and laboratory collections. Stem cells therefore represent a minority of 
each regulator’s overall role.  On this point it is interesting to note the parallels with 
Castle and Culver’s (2013) work on the regulation of aquaculture in Canada, and the 
resulting policy and social implications which have arisen from a new technology 
which does not appear to fit into the existing regulatory framework. In this case 
aquaculture was overseen by the fisheries regulator, which puts it in direct 
comparison to established fishing methods but alienates it from the rest of the food 
industry, which is overseen by a different regulator. As in the stem cell field attempts 
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have been made to fit this new technology into existing legislation, with the 
consequence in both cases that the regulatory requirements of this new innovation 
have become marginalised.  
 
My data show that questions are being raised within the research community as to 
the appropriateness of these regulators to oversee stem cell research, which can be 
very different from the other areas which these authorities regulate. For example, as 
one researcher commented: 
 “the HTA are used to dealing with whole organs and parts of people that 
are being moved around and are now dealing with stem cell lines which 
kind of behave differently, and can be split up differently. Rather than 
having one organ or bits of tissue there can be multiple passages of 
different cell lines.” (CS/lab) 
 
The researcher is articulating the view that the expertise held by regulatory bodies 
such as the HTA does not necessarily transfer to stem cells, in this case due to the 
stem cells themselves, with biological properties so different from those of whole 
organs. Whilst the HTA has expertise at moving and tracking a whole organ from 
donor to recipient (normally in a one-to-one model) this expertise does not 
necessarily transfer to cell lines which can be divided multiple times. Researchers 
have also commented that the stem cell oversight undertaken by the HFEA appears 
to be relegated in favour of their ‘main’ work on regulating IVF clinics, as most of 
the HFEA’s work is centred around its original focus on regulating embryo and 
gamete use for fertility purposes.  
 
There is an awareness that the stem cell side occupies a small part of the HFEA’s 
remit and has been somewhat ‘tacked on’ to its overall responsibilities. This did not 
appear to result in any concrete suggestions of time delays, more a sense amongst the 
researchers that the HFEA did not really want to be regulating stem cells. Others 
stated that the HFEA placed too high an emphasis on the moral status of the embryo 
because its main focus was on fertility treatment. Franklin (2006) refers to the 
‘double value’ of embryonic cells as both a reproductive and a research tool, two 
values which the HFEA perhaps struggles to separate. Whilst researchers both 
recognised that the HFEA did an excellent job regulating fertility clinics (and saw the 
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necessity for laws around the embryo) many questioned the appropriateness of the 
HFEA to oversee embryo use in research. One researcher commented that more 
embryos were likely to be created on Lothian Road11 on a Saturday night than 
annually in UK laboratories, reflecting the argument that nature is very cavalier with 
embryos and that there is room for discussion regarding their ‘special-ness’ in 
relation to other body tissues. One possible option is that embryos be regulated as 
any other human tissue, overseen by the HTA.  
 
It is interesting to note that foetal tissue donated after abortions is permitted to be 
used as a research material in the UK, under strict regulations concerning consent 
and collection procedures. The use of foetal material attracts much less attention than 
embryonic material in the public/media sphere. This may be because the use of foetal 
material is reasonably rare, although the ReNeuron stroke trial uses cells derived 
from foetal tissue. I wish to draw the reader’s attention to the use of foetal tissue 
because this use is currently regulated by the HTA, not the HFEA. Foetal tissue is 
also an emotive tissue source that requires strict laws around procurement, yet here it 
is treated solely as a research material in the same way as any other adult tissue 
source, disconnected from its double value as a reproductive material. This would 
indicate that it could be possible for embryos also to be treated in this way, removed 
from the responsibility of the HFEA and passed to the HTA to be considered a 
research tissue distinct from any reproductive value.  
 
The question of expertise to regulate extends to the licensing of such products by the 
European Medicines Agency (EMA). Advanced Therapy Medicinal Products 
(ATMPs) are regulated through the EMA in order for a wider area of expertise to be 
called upon. Peer reviews can be called from any of the member states to ensure that 
an adequate knowledge base is present at any meetings where a particular product is 
being considered. This peer review is considered to be a crucial process in assessing 
the scientific robustness of a new technology (Abraham et al., 2000), and shows that 
the regulatory system is taking note of the wide variety of stem cell products and 
acknowledges that specialist expertise is necessary to adequately review the 
                                            
11 A road in Edinburgh well known for containing a large number of bars and strip clubs.  
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scientific information submitted. This will perhaps allay the fears of some in the 
research community who express concern regarding the expertise of those who sit on 
regulatory committees: 
“I’d hope that they’re open minded enough if not knowledgeable enough, 
and that the review boards and the discussion boards that they bring 
together are wide enough to cover all the bases, and that they don’t give 
undue weigh to any single voice.” (CS/Lab) 
 
Whilst the BloodPharma project team understand that the regulators cannot always 
be experts in every particular field, there is a hope that the bringing together of 
advisory committees will result in balanced consideration. Of course in order for the 
regulators to consider the application of a particular research project they must be 
presented with the relevant scientific data. This data is crucial to explaining the key 
points of the project to the members of any regulatory committee, alongside the 
relevant risks analysis, scientific testing, and so on. One criticism of the regulatory 
system is that there are few guidelines regarding the data that must be submitted; 
simply that this data must be sufficient for the regulators to make an accurate 
decision. This results in projects submitting incomplete data or submitting more data 
than is necessary.  
 
A lot of specific expertise is therefore required to navigate a project through the 
regulatory system, and the BloodPharma project now employs a specific member of 
staff to oversee its regulatory submissions (something that looks set to become 
increasingly common for large scientific projects). This member of staff is the 
regulatory affairs manager for the SNBTS. A scientist by background, she now 
works exclusively on navigating projects through the regulatory pathway. The 
BloodPharma project is a small part of her work, she estimates around 2%, and so 
she is not always present at scientific meetings or conference calls. Despite this, the 
team defer to her in most matters of regulation and she is responsible for preparing 
the majority of regulatory submissions to the regulatory bodies. In interview she 
mentioned the conflicts that she has between the day-to-day job of the SNBTS and 





“BloodPharma’s a nice project but it’s not our business, do you know 
what I mean? So if I’ve got an inspection for our blood business 
compared with the BloodPharma, and they’ve both got the same deadline 
it causes a lot of conflict. So that’s a conflict for all of us, the conflict 
between the day job and the interesting job.” (CS/R) 
 
The members of the laboratory research team sought to delegate regulatory issues to 
this member of staff or to others on the team who had some understanding of the 
regulatory issues. Much of this delegation appeared to be due to unwillingness 
amongst the laboratory researchers to become involved with the minutiae of the 
regulatory system, mostly due to the length of time that that would be required to 
read and understand the regulatory documents. The language of regulatory reports 
was a key area of expertise which the dedicated regulatory person held, and was 
identified by respondents as one of the main barriers preventing them from becoming 
more engaged with the regulatory system.  
“To be honest I think some of the language and the way the documents 
are written are…do you know what it’s like if you read something that 
you don’t even get some of the language, or it’s written in a way that 
you’re not familiar with? So it’s much harder work to plough your way 
through it. Whereas I can pick up a protocol for molecular biology and 
go ‘I understand that, that’s good’ so, we’re all really busy and it would 
take me a long time to plough my way through it and I’ve got enough to 
do. I’m sure the regulators would be the same if they tried to read my 
scientific papers. Because you can only be an expert in a certain area 
and it’s a huge area, it’s a whole area of expertise. I’ve got an interest in 
it and I look at what’s relevant to our project and get a basic 
understanding of it but that’s as far as I go.” (CS/Lab. Emphasis mine) 
 
Many of the regulatory documents are required to be written in very precise language 
as they represent the legal Acts which the regulators must enforce. Although places 
like the MRC Regulatory Support Centre attempt to assist the researchers in 
understanding these regulations it can be difficult to summarise the documents 
without losing important parts of the legal responsibilities: 
“When the human tissue act came out we did some summaries for 
researchers, just two A4 sides. There are merits to doing that sort of 
thing, but there is a danger in paraphrasing that you don’t include stuff 
that you need to know. Or they just read that and they go off and do 
something and they didn’t know that there were other bits that they 




The scientific researchers are experts at their own work and in writing and 
understanding scientific articles. The regulatory system to them represents an entirely 
new language and area of expertise, which requires additional training in order to 
engage with. Regulatory affairs in the stem cell arena therefore seems to be an 
excellent example of Collins and Evans’ (2002) work on different types of expertise. 
The scientists have formal expertise in their area of research, but struggle with the 
regulatory affairs which often falls outside this narrow area. Yet their expertise is 
vital in contributing to the decisions made at a regulatory level, they have 
‘contributory expertise’ in this sense. What they would appear to lack, therefore, is 
the expertise necessary to understand the documentation rather than the regulatory 
system itself.  
 
As a consequence of scientists not possessing regulatory expertise they attempt to 
delegate regulatory matters to those who have experience, and in this case the 
BloodPharma team have a dedicated staff member to delegate to. For other 
researchers outside a large research project this can be more problematic. The MRC 
Regulatory Support Centre (and members of other regulatory authorities who I have 
spoken to or have heard present at conferences) all comment on the problem of 
researchers looking to delegate regulatory work to others.  
“We get a lot of people wanting somebody to write their ethics form for 
them, but really they are the only person who can write that, because they 
are the ones that know the project. We can advise them on things they 
might want to tighten up on, but they know the projects more than 
anybody else.” (O/R)  
 
Here the problem seems to be that researchers shy away from any interaction with 
the regulatory system and hope that somebody will take on the job of writing 
submissions to the regulators. Although the researchers may not be well acquainted 
with the language of the regulatory system, they are experts in their own projects, as 
the interviewee above comments. This expertise on the scientific work is required for 
the regulators to fully understand the data, and so what appears to be lacking here is 
the translation of this expertise into regulatory reports. This translation is why the 
BloodPharma project is building up a good relationship with the regulators through 
their dedicated staff member, and there are also other members of staff on the 
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BloodPharma team who have an understanding of both the regulatory requirements 
and the scientific work. The regulatory advisor here has to hold a large amount of 
‘referred expertise’ (Collins et al., 2002), able to understand and coordinate 
regulatory affairs for big projects, even though they may not possess the same level 
of contributory expertise as the laboratory scientists. Indeed many of the researchers 
have commented that students should be given a good grounding in regulatory affairs 
during University courses, in the hope that there will not be a barrier between 
scientists and regulators for future generations of researchers.  
 
This early training of scientists to understand the language used by the regulators and 
an appreciation of what is required in regulatory submission could be key to pushing 
academic work towards the creation of new therapies. We have seen how navigating 
the regulatory system requires expertise which, in the case of the BloodPharma 
project, is undertaken by staff that have a specific role in managing regulatory 
affairs, and who could be seen to hold ‘referred expertise’ (Collins et al., 2002). It 
has been proposed that many academic researchers without this support do not 
engage well with the regulatory system and that this can have a detrimental impact 
on the innovation of new therapies. University research across the board is often 
acknowledged as having poor translation into eventual innovations and economic 
returns, and this problem is not just applicable to stem cell research (Audretsch et al., 
2005).  
 
Particular problems of stem cell research cited by interviewees include the length of 
time it takes to prepare data for the regulators, with one of the BloodPharma 
regulatory experts explaining that it can take up to three months to prepare a dossier 
required for a meeting with one of the main regulatory bodies (it was unclear from 
the data if this referred to three months of full-time work). What is clear is that this 
length of time is likely to include the variety of projects on which she has to work 
simultaneously, the gathering of data from many different scientists, and the reading, 
understanding and distillation of such data into an acceptable format to present to the 
regulators. With dedicated staff working on only one project it could be possible to 
write submissions in less time; however one of the main arguments of the 
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interviewee is that academic researchers are not ‘rewarded’ for writing such dossiers. 
They do not count towards forwarding their career in the same way a journal article 
would, although dossiers would probably take as long as a peer reviewed article to 
write. In an academic world which prizes journal publications above other outputs, 
and interactions with other academics over engagement with industry, this is likely to 
be a substantial barrier for university based researchers (Bond et al., 2005). Whilst it 
might be expected that researchers in companies would be more attuned to the 
implications of navigating the regulatory system, it appears that problems still arise. 
A common observation from those involved in the regulatory bodies was that 
developers consistently underestimated the time and money required to bring a 
product through the regulatory route.  
“People forget, people always underestimate how long it is going to take, 
people always underestimate the regulatory requirements and people 
always forget about involving the regulatory departments soon enough, 
so that they know all of these additional things. That’s a common 
problem. But not here, everywhere.” (CS/Reg) 
 
Another interviewee also commented on the financial implications of often 
overlooked aspects of the regulations, such as the keeping of records and 
documentation which requires space and management. This is consistent with 
Croley’s (1998) account of the costs of undertaking regulatory work, in which he 
speaks of the often overlooked costs of printing and preparing documentation for 
agencies, and the expense of obtaining validation data. The reluctance to involve the 
regulators at an early stage could be attributed to the ongoing boundary work 
between the regulators and the researchers, the ‘them and us’ perception which 
appears in many conversations with the stem cell community. This results in a 
reluctance to approach the regulators with simple queries or to engage early enough 
with the regulatory system. Improvements appear to be being made, with more 
openness from the regulators and additional assistance from places such as the MRC 
Regulatory Support Centre.  
 
Uncertainties still exist around the late stage EMA regulation and Market 
Authorisation of the cultured blood project. As we saw in Chapter Four the clinical 
trials route for the BloodPharma product, and for the stem cell field in general, is yet 
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to be established. The EMA considers its central responsibility to be the protection of 
human and animal health, and we may see that the presence of an already established 
blood donation system makes regulators more cautious to introduce a novel therapy. 
Throughout the project the BloodPharma team have been working at GMP grade 
wherever possible, aiming to lessen future hurdles which could arise from doubt 
about the provenance of the cells. It is clear that large uncertainty still surrounds the 
step from the laboratory to the clinic, and Rutter and Plomin (2008) argue that 
strengthening basic science will never be of benefit unless the translation of that 
basic science from bench to beside is also addressed. Indeed this translation should 
be of key importance to the stem cell field, where large amounts of potential products 
have failed to translate into many useable therapies (Brown et al., 2006; Brown et al., 
2006). This lack of translation is also having a detrimental impact on investment in 
stem cell companies, with the uncertainty of the regulatory pathway and the 
ambiguity of IP potential being cited as being as important as ethical or safety 
concerns to investors (Giebel, 2005). It is easy to see how the regulatory system can 
impact on a company, for example with ReNeuron:  
“We’ve also found that GTAC have found ways of parking things so that 
carefully worded responses have had the effect of stopping the regulatory 
clock ticking. Which has been a frustration, particularly to ReNeuron, 
who I dare say probably see their money evaporating with every passing 
day that things don’t get going. And that’s been frustrating, and I think 
somewhat counter to the intention of the overall framework for approving 
clinical studies. These timelines were set up in order to ensure that things 
went through in a fairly clearly defined timeline.” (O/Med, emphasis 
mine) 
 
There is a requirement for staff with new skills dedicated to translational research 
(Littman, Di Mario et al., 2007), and this is articulated by the BloodPharma team in 
their call for more researchers who understand both the scientific work and the 
regulatory implications.  
 
The slow speed of translation can be seen as having a detrimental impact on patients 
and researchers in the UK setting. During interviews some respondents commented 
that the UK was fast losing its advantage as a primary driver of stem cell research, 
with researchers who had been initially attracted by the regulatory regime in the UK 
now seeming disillusioned with the process. The rising powers of India and China 
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were mentioned regarding the potential production of the BloodPharma product, 
echoing Salter et al. (2007) who see India employing new models of innovation to 
attract stem cell investment. We have seen that expertise plays a significant role both 
in the ability of stem cell regulators to understand the science and in the ability of 
researchers to navigate the complex regulatory system. Although the laboratory 
scientists involved in the BloodPharma project often delegate interactions with the 
regulators to other team members it is these scientists who are the experts on the 
unique properties of their own research product. The next section will examine in 
more detail the regulatory questions which arise when considering the cultured blood 
product.  
 
BLOODPHARMA AS A PRODUCT IN THE CONTEXT OF THE 
REGULATORS AND SPECIFIC RISKS 
In this section I will concentrate further on the cultured blood product itself to 
explore how the project team considers the specific risk issues associated with this 
project. After completing the early stage scientific work, the BloodPharma project 
will need to negotiate market authorisation through submission of data to the MHRA. 
The uniqueness of the cultured blood product makes it a test case for the regulatory 
system, as this BloodPharma researcher explains:   
 “We’ve always argued that red cells are an ideal test case for all of this 
because they’re enucleated. And therefore we should be able to use 
genetic manipulation and we should be able to use embryonic stem cells 
because we’re mitigating the risks in the end product. However, what 
we’re never going to be able to get around is that the level of purity is 
going to have to be ludicrous.” (CS/Lab, emphasis mine)  
 
As the eventual BloodPharma product will contain no nuclei, techniques such as 
irradiation can be used to destroy any residual DNA in the cells (as the researcher is 
referring to in ‘mitigating the risks’). RBCs are the only cells in the body not to 
contain a nucleus and so the researcher is commenting on the unusualness of this 
product amongst other cell therapies, as the presence of DNA is normally a major 
risk of stem cell therapies. Cells with nuclei will contain DNA which could be 
transferred from donor to recipient and can also allow the cells to multiply, 
potentially causing teratomas. This risk mitigation however depends on the 
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enucleation techniques working for every single cell, and the BloodPharma team will 
have to transfuse thousands of cells into a potential recipient. The BloodPharma team 
is therefore interested to see how the regulatory system will react to this product, 
which does not fit previous risk models of stem cell therapies.  
 
The area of stem cell based products covers a vast number of potential therapeutics 
with varying biological properties and accompanying risk factors (POST, 2004). The 
BloodPharma team must ascertain which particular parts of the project would be of 
interest or concern to the regulators.  
“The reflection paper on Stem Cells from the EMEA, that basically tells 
you, here’s your risky bits, and what we need to do is go ‘ok, that’s risky’ 
and from that reflection paper we built what we thought we needed to 
test.” (CS/Reg) 
 
The Scottish National Blood Transfusion Service already has a good record of 
interaction with the regulators, due to its development of other cell based products 
such as corneal bandages, and is therefore able to draw on this experience to identify 
key sticking points in the regulatory pathway. As the interviewee above explains, 
knowledge of potential risks allows them to tailor data collection to give regulators a 
more accurate risk profile for their individual product.   
 
In the absence of long-term use of stem cell treatments (other than bone marrow 
transfusions) the comparison of one potential therapy with another is a useful tool for 
assessing risk. Much of the discussion with the BloodPharma team did not involve 
risk data for the BloodPharma product specifically. Instead they mentioned that it 
was more risky than the corneal bandages (which use partially differentiated cells) 
but less risky than the ReNeuron project which injects stem cells into the brain, less 
risky than treatments which involve cells growing for long periods, but more risky 
than treatments which require lower number of cells.  
“To a large extent I’m really happy that Geron
12
 are running that gamut 
ahead of us, because their cells are nucleated and ES derived, so they are 
going to have to deal with a lot of what we do.” (CS/Lab) 
 
                                            
12 Geron are a US based company that were developing a stem cell product to regrow the 
spinal cords of paralysed patients.  
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Here the researcher identifies one of the ways in which uncertain risks are debated, 
by comparing the risks of their project with another that has navigated the regulatory 
pathways before them. In this case the team were hopeful that Geron, which is seen 
as having a ‘riskier’ product due to the nucleated cells, would be ahead of them in the 
pathway. In this way the BloodPharma team can gain some idea of what risks and 
benefits were picked up by the regulators, and what data Geron had to submit. 
Unfortunately the Geron trial was stopped in 2011, so the BloodPharma team must 
look elsewhere for test cases of the regulatory pathways.  
 
The researchers here seem to be employing what Sadler and Zeidler (2005) refer to 
as ‘informal reasoning’, a way of attempting to work out problems without apparent 
solutions by debating pros and cons, causes and consequences, and so forth. Kahlor 
et al. (2002) also draw upon informal reasoning when studying risk estimates 
amongst residents after a water contamination incident. Sadler and Zeidler identify a 
number of considerations which are taken into account during such informal 
reasoning: Personal experience, emotive considerations, social considerations, 
morality, and perceptions of complexity, which I found mirrored in data gathered 
from the project team.  
 
In understanding the regulatory concerns around the BloodPharma product, members 
of the team drew on their own personal experiences of working in other sectors or in 
other countries. For example one interviewee had been working in the area of gene 
therapy when trial side-effects had stopped the scientific field in its tracks. Another 
had worked in the US and articulated how glad they were about the balanced 
regulatory system employed by the UK, especially in comparison to the religiously 
funded academic institution where they had previously worked. The researchers used 
past experiences to make judgements about the risks associated with stem cell 
products and the need for regulation, for example by remembering instances of past 
problems such as major blood contamination. They used these as examples of why it 
was so important that stem cells were well regulated. This appears to be similar to 
results found by studies such as Siegrist (2000), who found that trust played an 
important role in the perception of the risks and benefits of a novel technology. 
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Fischhoff et al. (2012) also found that perceptions of risk amongst a group of 
Americans were based on past personal experiences, although the study concentrated 
on terrorist risks rather than novel technology.  
 
The scientific team occasionally talked about the emotive considerations of their 
work, drawing upon the desperate need of patients or those who have been affected 
by previous drug safety or regulatory failures.  
 “The patients have a desperate need, but the clinician has to safeguard 
themselves too, unfortunately.” (CS/Reg) 
 
“So I think we have a very willing public and a very trusting public, but 
then things like Alder Hey have damaged it.” (CS/Lab) 
 
Throughout the project it has been evident that the BloodPharma team do engage on 
a very personal level with the expected outcomes of the research. Although some 
have commented that they do not see this project as perhaps ever reaching the clinic, 
and view it more as an academic exercise, for the most part the researchers seem to 
envision the long term goals as helping those patients who will most benefit from the 
cultured blood product. Some who had experience of working with patients with 
blood disorders drew on the terrible suffering which these patients and their families 
experience. Others talked of patients going abroad for therapies and their desire to be 
able to offer safe and appropriately tested therapies here in the UK. The researchers 
draw upon social considerations to explain why the innovation of a cultured blood 
product is necessary. 
“There might be situations where you really want to be absolutely sure 
that you really have got a very clean source, so maybe in transfusions, for 
you know, children or something. Third world as well, I mean there’s no 
blood transfusion in the third world at all, where, you know, there isn’t 
the source.” (CS/Lab) 
 
The use of cultured RBCs in developing countries or for minority populations within 
the UK is one of the first targets of the cultured RBCs. Members of BloodPharma 
team saw themselves as having a social responsibility to help those who currently do 
not have access to a safe blood supply.  
“So yeah, Italy, Spain, most of bible belt America, there’s enormous 
tranches of the world that wouldn’t consider it still now, let alone if it’s 
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the only option, so no we’re going to have to find a different source for it 
eventually.” (CS/Lab) 
 
Here we can see that the interviewees also had an understanding of the social 
problems that may occur should the cultured blood product be available to the wider 
population, for example those who would have religious objections to products made 
using embryonic stem cells. It was interesting that when questioned why stem cells 
should be regulated that the researchers drew on moral reasoning, rather than purely 
safety.  
“I start to get a bit wobbly with ES cells when you get to producing 
gametes, I’m not quite sure how well regulated that end of things is 
because it’s not something I do. That starts to make me uncomfortable.” 
(Cs/Lab) 
 
“And the early bone marrow for heart failure and the heart attack trials 
were frankly scary, to my mind that was just, experimentation, as you 
would do on mice but in humans. I was not comfortable with all of that 
stuff I have to say.” (CS/Lab) 
 
They spoke of earlier trials gone wrong or of the potential for people to be exploited 
by unscrupulous clinicians in other countries. Whilst most of this does of course 
come back to the safety of the cells it was evident that the researchers also drew on 
their own moral codes about safety and protection, and appropriate use of cells in 
clinical trials. This use of morals amongst scientists brings to mind the wider 
literature on responsible innovation, and the argument for increased self-regulation 
amongst the scientific field rather than a reliance on top-down frameworks 
(Hellström, 2003; Owen and Goldberg, 2010).  
 
Finally we can see that the researchers are very aware of the complex nature of 
regulating cell based therapies and the challenges that occur in navigating the 
regulatory pathway.  
“I think its complex, and I think the reason it’s complex is because it 
hasn’t been designed by one hand, it’s evolved, so there’s a legacy of 
existing law and regulation and regulatory bodies, all of which come to 
bear on these new, very advanced cellular therapeutics.” (CS/Med) 
 
Those with previous experience in either blood or pharmaceutical industries talked 




an awareness that the regulations have been built up over time and were perhaps no 
longer fully appropriate for this fast- evolving field of stem cell research. Although 
Sadler and Zeidler based much of their work on informal reasoning on the study of 
science students it can be seen that such reasoning processes are also used by those 
who are much more advanced in their careers, and helps them to make some form of 
sense of the risks associated with stem cell research. Although this use of informal 
reasoning is unlikely to impact the regulatory system in the way Jones and Graham 
(2009) call for, it is interesting to see the impact of such informal reasoning on the 
views of researchers in the BloodPharma product towards the risk/benefit balance of 
their own product.  
 
The difficulty of guiding the BloodPharma product down the correct innovation 
pathway lies in balancing both the requirements of the regulatory system with the 
constraints of the biological processes. The team can effectively be seen to have two 
pathways to navigate, both of which require forward planning of months or even 
years. This forward planning makes the job of the BloodPharma team in navigating 
the regulatory system that much harder, as the biological processes are so intertwined 
that tweaking a small amount of the techniques may require large amount of 
background work. In order to prevent unnecessary cost (both financial and in 
time/manpower) the team must look ahead to anticipate future hurdles.  
“What you do now is absolutely critical because it is part of the 
provenance of the cells, so you might do something now and have a 
judgement on it in five years where the regulator says ‘well actually we 
don’t like that, you need to go back and start again’ and we have seen 
that in other fields. So that’s I think our purpose, we already have a very 
close relationship with MHRA and HTA and to a lesser extent HFEA and 
that’s our purpose of engaging with those regulatory colleagues at a very 
early stage, because they need to understand what we’re doing so that in 
five years it doesn’t come as a surprise to them, they don’t say ‘well 
actually if you have just asked us we would have told you to do it this 
way’. Because they’re learning as well, it’s important to understand, you 
know it’s an evolving field and they are not starting from a well 
established base in that respect.” (CS/Lab. Emphasis mine)    
 
The interviewee here is articulating one of the main concerns for any stem cell 
product seeking future regulatory approval. Producing a stem cell product is not the 
same as the batch processing commonly used in other industries. It is not possible to 
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start again easily from scratch, as the process may be based on cells which are 
derived many years before the product itself has been approved. A lay example 
would be sourdough bread, where bakers often keep the yeast culture in use for many 
months or even years, compared to one-off batches of normal bread rolls. The 
provenance of the cells is therefore a key concern and researchers must anticipate 
regulatory requirements many years before the regulators themselves have articulated 
these. Throughout the project the researchers employed what could be termed a ‘belt 
and braces’ method (being extra cautious and taking multiple steps to ensure that the 
cells would be appropriate for future use), for example deriving cells at GMP which 
did not need to be (and thereby incurring greater research costs) so that they had 
covered all bases and reduced the possibility of being asked to redo work many years 
down the line.  
 
There is also the argument that it is potentially easier to run the entire system at GMP 
than to have a separate GMP and non-GMP research stream. Running one system 
allows all the researchers in the team to work to the same protocols.  
“We would make small choices, so for example if there was a clinically 
used reagent available rather than a bog standard research grade one we 
would start with the clinical reagent, just to build in that bit extra.” 
(CS/Lab) 
 
The respondents were very clear, however, that they would not attempt to do 
something for the sake of regulatory ease unless it also made good scientific sense. 
For example the removal of cell feeder layers, although a regulatory concern, would 
also have affected the scale-up potential of the project. This shows that the 
BloodPharma team is seeking to do ‘good science’, which in some cases may be 
going above and beyond what the regulators ask for. In other cases this may result in 
the BloodPharma project having to fight for its right to carry out the best science it 
can, even if this goes against the advice of the regulatory system. This occurred in 
the ReNeuron project where the doctors had to fight against the regulators who 
wished all patients to have immunosuppression. Believing it was not necessary for 
their study and could harm the patients the medical team refused to accept the 
regulatory advice and instead spent time gathering extra data to convince the 
regulators that immunosuppression was not required. Their submission was accepted 
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and the trial is continuing without using immunosuppression. This is another 
example of scientists seeking to carry out the responsible innovation discussed 
earlier, above and beyond the stipulations of the regulatory system.  
 
I previously introduced the precautionary method of regulating, where ‘doing no 
harm’ is considered to be the primary requirement. This is an important consideration 
to the BloodPharma team, as what sets this case study apart from other stem cell 
therapies is that it is seeking not to implement a new therapy but to find an 
alternative source of producing an existing therapy. This situation of simultaneously 
promoting the novel cultured blood product whilst still recruiting blood donors for 
the current system makes this case study unusual amongst the wider stem cell field 
(as will be discussed in more detail in Chapter Six).   
“I think the issue is would you take proper blood or BloodPharma blood, 
that’s the risk the regulators see, forget what the patients see. We are in 
the advantage and disadvantage, and we did say that to the EMA, that we 
have a really well known product to compare it against. And we will have 
to prove that our product is as safe, or safer, or more efficacious, than 
this.” (CS/Reg)  
 
This quote shows that the difficulty of regulating the BloodPharma project using a 
regulatory system based on the precautionary principle is that this risk of harm must 
be measured not against the risk of no treatment, but against the risks of the existing 
treatment.  
 
Donated blood is still considered to be both a tried and tested and comparatively safe 
treatment for the majority of patients who require blood transfusions. Stainsby et al. 
(2006) put the total adverse events associated with blood transfusion from 1996-2004 
at around 10 per 100,000 components issued, with Transfusion-Transmissible 
Infection accounting for 0.4 per 100,000. Given the attention placed on such adverse 
events the reality is that modern transfusion is statistically very safe. The argument 
given by members of the BloodPharma team and other proponents of new blood 
technologies is that although the current relative risk is very low this is based only on 
known risks. The blood services can only test for diseases for which there are tests 
available and that are known to be transmitted through blood transfusion. It is 
considered that underlying problems such as vCJD may prove to be future crises 
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through symptom-less ‘silent carriers’, who infect others through transfusion because 
neither the patient nor the medical community are aware of their disease until many 
years later (Llewelyn, Hewitt et al., 2004; Wallis, 2009). The burden of proof falls on 
the scientists and regulators to ensure that the new product is not just safe, but that it 
is as safe as the existing product. The team will have to show that the regulators are 
justified in allowing an established product to be replaced with a new, potentially 
riskier, innovation. A key factor in the precautionary method of regulating is that 
other competing innovations must also be considered.  
 
There are a number of global competitors to the cultured blood team with the main 
competitor considered to the laboratory of Luc Douay (Paris) (Douay and Giarratana, 
2005). This competition is likely to be of less interest to the regulators as such 
similar innovations will all carry broadly similar risks to the BloodPharma cultured 
blood project. What, however, may be of interest is competing technologies that offer 
a replacement for the current blood donation system but which offer different, or 
reduced, risk profiles (for example chemical based RBC substitutes). There is also a 
growing movement around ‘bloodless’ techniques, which could significantly reduce 
the requirement for donated blood. These techniques were pioneered in hospitals in 
the US as a method of treating Jehovah’s Witnesses, who refuse to accept any blood 
or blood products. Such hospitals have been extremely successful at minimising the 
amount of blood used by patients and have shown positive patient outcomes. 
Techniques to minimise blood used during surgery require a co-ordinated approach 
across different clinical teams, including pre-operative, surgical and post-operative 
care (Rees et al., 1996). 
 
This may have advantages, for example by allowing the regulators to concentrate 
solely on the risk vs. benefits for those patients who will still need regular blood 
transfusions or whose blood loss through trauma is beyond the help of bloodless 
techniques. Concentrating on specific target groups may also be beneficial for the 
design of clinical trials, where specific disease profiles can be studied ahead of 
assessing safety and efficacy for the wider population. For eventual ATMP 
regulation the benefit of the product being targeted at those with specific disease is 
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the possibility to open up alternative routes to clinic, such as Hospital Exemptions, 
which allow a product to be produced and used in small quantities on a named 
patient basis. It is evident that the BloodPharma cultured blood product itself has 
unique properties which make the relative future risks difficult to determine. The 
method of regulating using the precautionary principle may have a detrimental affect 
on the licensing of such a product, given the presence of an already established blood 
transfusion model. The difficulty for the researchers is in anticipating the questions 
and concerns of the regulators which may be raised further down the line, and 
ensuring that scientific robustness is built in to cope with future problems. Only as 
the cultured blood project moves further down the regulatory system will it become 
apparent whether the expectations of the researchers have been accurate.   
 
CONCLUSION  
In this chapter I have used empirical data to analyse how the regulatory system 
shapes the activities of the BloodPharma team and the development of the cultured 
blood product, and what this can tell us more generally about the regulatory system 
for stem cell products. We have seen how stem cells are complex products capable of 
causing harm to patients, and that their use as a clinical product is therefore tightly 
controlled by a number of different regulatory bodies. These regulatory bodies have 
grown out of previous incidences in the scientific field, for example the Alder Hey 
Scandal. Theories of regulation were also introduced, as was the use of the 
precautionary principle. Drawing on the work of Messner (2009) we saw that many 
of these regulations were a formalisation of already existing norms and practices, and 
in the case of the BloodPharma project this is closely linked with the wider 
regulation of blood transfusion. The use of embryos and foetal material was also 
discussed in the context of the regulation of this starting tissue, which often draws 
upon ethical or moral judgements.  
 
The complexity of the regulatory system for stem cell research in the UK requires 
specialist knowledge and expertise in order to navigate. Stem cell research crosses 
numerous boundaries and the overlap between regulatory bodies has been seen to 
lead to confusion regarding the specific remits of different regulators. Using 
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interview data from the BloodPharma team and others in the field, for example the 
ReNeuron trial, we have seen how this confusion impacts on the development of new 
stem cell products and therapies, for example in leading to the resubmission or 
duplication of data, and increasing financial pressure on companies. Expertise within 
stem cell regulation is required not just by the researchers but also by the regulators, 
who are seeking to oversee a fast paced research area where much of the specific 
knowledge is held by the researchers themselves, in what can be seen as formal 
expertise. The transfer of this knowledge to the regulatory bodies requires specific 
knowledge, which in the case of the BloodPharma team is undertaken by a dedicated 
staff member, who possesses referred expertise in their ability to manage the 
regulatory affairs of the project. The requirement for such a staff member emphasises 
the knowledge gap which exists for most scientists, who are unable to engage fully 
with the regulatory requirements, and who see this as developing from a lack of time 
and also a lack of expertise to engage with the specific technical language used in 
many regulatory documents. This development of regulatory understanding 
highlights an area of specific skills which should be developed further by universities 
seeking to train future researchers.  
 
The BloodPharma team has argued that its product is an ideal test case of the 
regulatory system, due to its unique biological properties. The data gathered here has 
shown that there is still a large amount of uncertainty related to these risks and the 
future regulatory trajectory of the product. The use of the precautionary principle in 
regulation is of importance to the BloodPharma team, which must ascertain that the 
product is safe and efficacious compared to the existing product of blood transfusion 
from human donations. Here we have seen that the team use informal reasoning to 
make sense of the complex risk profile of the product, by comparing it to other stem 
cell products, and also by drawing upon moral and social considerations. The 
foresight necessary to ensure the provenance of the cells is evident in the decisions 
which the team make, such as which laboratory reagents to use, although it is clear 





CHAPTER 6: PUBLIC ENGAGEMENT IN THE 
BLOODPHARMA PROJECT  
INTRODUCTION  
During the three years of the Wellcome Trust funding the BloodPharma team has 
been heavily engaged in public communication and outreach. In this chapter I will 
explore how this outreach has been undertaken, and focus on the responsibilities and 
experiences of the scientists themselves within this work. As part of my data 
collection I took on the role of participant observer at many of the project’s outreach 
events, and experienced first-hand the challenges and rewards of talking to attendees 
regarding the cultured blood project. Whilst the literature around public engagement 
has moved from a focus on the lay public, to attempting to understand more about 
the motivations and frustrations of the scientists that perform outreach work, such 
studies usually take the form of interviews or questionnaires. Therefore the 
opportunity to take part in engagement alongside the scientists has provided insights 
into their personal and professional feelings about public outreach.  
 
This chapter will address the following research question: 
What are the main drivers and motivators behind the BloodPharma team engaging 
with public outreach, and how do the scientists respond to their own role as public 
communicators?  
  
The first section of this chapter will use data drawn from the BloodPharma case 
study to uncover and assess the drivers of outreach. I will analyse this in the context 
of past controversies, for which I will draw on relevant literature. This will include 
the backlash against the introduction of GM crops, as well as Tait’s work on the 
repercussions which this and other incidences had on the introduction of the 
precautionary principle. This highlights one of the key motivations for doing public 
outreach; that is to mitigate future public and/or interest group challenges to novel 
technologies. Perhaps the primary motivation for the BloodPharma team specifically 
in public outreach has been pressure from the contributing universities, and I will 
therefore examine literature around the wider pressure for scientists to move out of 
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the laboratory and into the public space. This includes the call for academics to 
justify their ‘Broader Impact Criteria’, and the critiques of measuring what 
constitutes broader impact. The final motivation considered is the more pragmatic 
one of patient and doctor acceptance. This acceptance is of vital importance to the 
use of a new product in clinical use, especially considering the purchasing power of 
the NHS. To look further at the acceptance of new therapies I will draw on past 
surveys related to blood and blood substitutes, as well as work around direct-to-
consumer advertising of prescription drugs.  
 
For the second section of the chapter I will explain the types of outreach which the 
BloodPharma team have undertaken, and assess the three key messages that formed 
the backbone of the public outreach. These are the need for blood, the similarity 
between cultured and in vivo blood, and situating the BloodPharma project within the 
wider stem cell field.  In response to a conference discussion around the 
BloodPharma project I shall also consider what public engagement means in the 
context of multi-million pound scientific projects. I question what the new 
introduction of ‘engagement’ over ‘outreach’ or ‘communication’ hopes to achieve, 
and how far it is practical to hope that public opinions will change scientific 
pathways.  
 
In the third and final section I will focus on the role of the BloodPharma scientists 
within the outreach work. For many this represented a step out of the laboratory and 
into a communications role that they had not previously been familiar with. 
Challenges included communicating complex scientific work to a lay audience, as 
well as the hard physical work which is an often unseen side of such communication 
events. Coupled with this is the individuality of the BloodPharma project in already 
having an accepted product in blood donation. This represents a double-edged sword 
for the team, on one hand giving them something which is already familiar to the 
public, whilst on the other preventing them from justifying some of the reasoning 
behind the BloodPharma project. This is due to the requirement that any outreach 
must not adversely affect the willingness of people to donate, or to receive a blood 
transfusion. Therefore factors such as the requirement for cultured blood to 
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overcome infection rates have to be down-played. The team has also struggled with 
the media portrayal of the project, which often tout the cultured blood product as 
‘synthetic’, despite the best efforts of the scientific team.  
 
KEY DRIVERS OF PUBLIC OUTREACH AND THE EXPECTATIONS OF 
THE BLOODPHARMA TEAM 
Public understanding of science is now recognised as increasingly important in 
promoting the acceptability of new innovations. The BloodPharma project uses 
human tissues that are considered to have emotive value (embryos and blood), and 
brings together branches of research which have previously been of concern to the 
public. In this section I will use the literature to discuss past incidences of public 
reactions to technology, highlighting why the BloodPharma team has prioritised 
early engagement with the public. I shall then discuss the requirement of funding 
bodies to carry out public outreach, and the need to engage early with patients and 
health care providers. Before addressing some of the past controversies it is 
necessary to explain the different uses of words such as ‘outreach’, ‘communication’, 
and ‘engagement’, which I shall use throughout this chapter.  
 
At the start of the growing trend towards making the lay public more aware of 
science the terms ‘outreach’ or ‘communication’ were commonly used. However in 
light of an increasing understanding of the two-way process of feedback between 
scientists and the public the terms ‘dialogue’ or ‘engagement became more widely 
implemented. This change is attributed to an understanding of the public deficit 
model – the idea that the public became treated as uncomprehending vessels to be 
filled with knowledge, and that any resistance to a new technology therefore 
stemmed from a lack of knowledge on the part of the publics (Sturgis et al., 2004). I 
have throughout this chapter referred to ‘communication’ or ‘outreach’ more than to 
‘engagement’, because I believe that the set-up of the BloodPharma model does not 
encourage two-way engagement but is instead focused primarily on education. I shall 




The public reaction to Genetically Modified (GM) food crops has been one of the 
most publicised incidences of resistance to the introduction of a new technology, 
with protesters often gathering wide media attention with their attempts to destroy 
fields of GM crops during scientific trials. This mobilisation of protest groups or 
‘direct action’ groups became synonymous with this reaction against GM technology 
(Grant, 2004) and highlights the power of public reactions to be taken into account in 
regulatory decision making. Writers differ in their reaction to this public input, with 
Burke (2004) writing that the turn against GM technology has been based primarily 
on public fears and concerns, rather than on scientific data, whilst others such as 
Majone (2002) argue that a lack of scientific evidence that something is unsafe is not 
the same as evidence of safety. The British Medical Association reported no 
evidence that GM crops are unsafe, although urged caution given that the long-term 
impact of GM foods on human and environmental health had not yet been 
established (BMA, 2004). The requisite for evidence of safety (rather than a lack of 
evidence of un-safety) is a key tenant of the precautionary principle method of 
regulation, which was initially introduced after public reactions to pesticide 
regulation, but has also become commonly used as a method for regulating GM 
crops.  
 
Tait (2001) sees this as highlighting a major weakness in the precautionary method 
of regulating, that it takes into consideration elements other than scientific data, for 
example ethics. For GM crops it appears that public reaction has been one of the 
primary drivers for the slow introduction of GM crops in the UK (Tait and 
Chataway, 2007), and the rest of Europe, compared with the US and China. An 
incidence such as this highlights disparities between the scientific community and the 
lay public regarding risk based decisions. Wynne (1992) explains this as the ‘real’ 
risk seen by the scientists, versus the ‘perceived’ risk seen by the public. As 
‘perceived’ risks were thought to be based on misunderstandings (the public deficit 
model) or inaccurate information, scientific outreach or public engagement was 
therefore considered to allow the public to form a more accurate view of the actual 






Stem cell research has previously garnered a share of this scientific mistrust, with the 
use of embryonic stem cells in research becoming the subject of much public debate, 
especially involving some of the major religious and moral groups. As a consequence 
of such debates the eventual restrictions placed on research (for example the 14-day 
limit on embryo use), at the recommendation of the Warnock Committee (Warnock, 
1984), were seen as representing a compromise between the pro- and anti-reseach 
sides. Stem cell technology also crosses boundaries into areas such as 
xenotransplantation, a technology which Fox (2005) describes as incurring a ‘deeper 
cultural unease about bodily mixing and rejection’, and which Cooper (2004) sees as 
returning to the nineteenth century ideas of ‘monstrosities’. Bates et al. (2010) 
identified public unease around stem cell research to be due in part to a feeling of 
distance from the scientists and a belief that the public would be kept oblivious of 
advancements in this technology. Much of this unease was related to a lack of 
awareness about the tight regulatory system, leading to concern amongst the 
interviewees about ‘rogue’ scientists having free reign to experiment as they saw fit. 
This was especially related to the use of human tissue in research, as stem cells bring 
with them the emotive issues associated with the use of embryos and other tissue, 
which has made them a popular topic both for social science researchers and the 
media. There is a broad selection of literature on the public debate around embryonic 
stem cell use, for example Warnock (1984), Mulkay (1993), Mulkay (1994), Parry 
(2003), Devolder (2005), De Sousa et al. (2006), and Lovell-Badge (2008).   
 
In an earlier chapter we saw how the Alder Hey Scandal (in which the organs and 
tissue of deceased children were retained without parental consent) was a major 
incident which created a breach of trust between the scientific/medical community 
and the public. The public backlash has been reported as ‘demonising’ the profession 
of pathology (Burton et al., 2002) and was instrumental in changing the guidelines 
for post-mortem retention of tissues. That the guidelines were changed in response to 
this public outcry, and the associated media attention, is a testament to the power of 
public opposition (Bauchner and Vinci, 2001). Indeed it is an incident which the 
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BloodPharma team have referred to, for example in this previously used interview 
quote:  
 
“So I think we have a very willing public and a very trusting public, but 
then things like Alder Hey have damaged it.” (CS/Lab) 
 
The Alder Hey affair has become synonymous with the idea of misuse of human 
tissue, despite the fact that the retention of such organs, or parts of organs, was 
considered standard practice, and as such was happening in other hospitals across the 
country (Burton et al., 2002).  
 
The BloodPharma team has been especially conscious about engaging early with the 
public as the project uses both embryonic stem cells and blood, both of which can 
garner very emotive reactions. Whilst the public unease around the use of embryonic 
stem cells has been much discussed it should not be forgotten that, for the 
BloodPharma project, the issue of emotive attachment to blood and blood donation 
represents an equally challenging subject for public engagement. Blood transfusion 
technology itself was essentially halted for almost 100 years by the public outcry 
over Denis’ work in the 17th Century (Brown, 1948, pg.7), and there appears to be an 
attachment to blood, especially to ‘real’ blood, which creates unease about 
alternatives.  
 
A study carried out by Fleming et al. (2007) into the risks and ethics associated with 
different blood types and substitutes found that those studied had a preference for 
donor blood, being regarded as the most effective, most ethically acceptable and least 
‘risky’. This was followed by chemical-based substitutes, bacteria grown substitutes 
and finally bovine derived substitutes, which were seen as being the most risky, least 
ethically acceptable and least effective. Interestingly perceptions of risk correlated 
with both ethicality and effectiveness for all of the options. The study shows that 
despite the infection scandals which have been associated with human donor blood, 
this is still seen as the preferred option by those who were interviewed. This also 
correlates with Ferguson et al. (2008), whose study found that chemical substitutes 
were seen as being somehow substandard to ‘real’ blood. To ensure public 
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acceptability of the cultured blood product the BloodPharma team is embarking on 
an outreach campaign which could be seen as an attempt to ‘market’ the product. 
This was also considered by Ferguson et al. (2008) who suggested that alternative 
blood products would require more effective marketing than had been seen with 
synthetic blood products, such as HBOCs.  It is hoped that by making people more 
aware of the potential of alternative blood sources that these associations of risk or 
ethical dubiousness can be reduced. Not considered by Fleming et al. is the 
attachment that the public have to blood donation due to the principle of altruism and 
gift giving, which forms the primary subject of Titmuss’ (1997) book. This is a 
driving force behind the blood transfusion services in the UK and many blood donors 
are very attached to giving blood, as will be discussed in more detail later in this 
chapter.  
 
Recent years have seen a turn away from a culture of individual scientists working in 
isolation to a focus on the broader impact of scientific work. In the United States an 
educational reform in 2001 led to the creation of the ‘No Child Left Behind Act’, 
which prioritised reading, maths and science subjects (Moskal, Skokan et al., 2007). 
An integral part of this new reform was the involvement of higher education 
establishments in engaging with pupils of pre-college age. Academic establishments 
were urged to go beyond research and publishing, and to incorporate also ‘discovery, 
integration, application, and teaching’ Boyer (1990) in Moskal et al.(2007). Other 
funding bodies have also begun to push for further outreach to be done by higher 
education establishments. Since 1997 grant proposals to the US National Science 
Foundation (NSF) have been required to include an assessment of the broader impact 
of the proposed research (Holbrook and Frodeman, 2007)13, and universities more 
generally are coming under increasing pressure to justify their public funding (Bond 
et al., 2005).  
 
Attention is therefore increasingly focused on the ‘broader impact criteria’ (BIC) of 
academic research. Critiques of BIC as a funding criterion are that it relies on a linear 
                                            
13 More specifically proposers and reviewers were asked to judge (1) What is the intellectual 
merit of the proposed activity? and (2) What are the broader impacts of the proposed 
activity? Holbrook and Frodenman (2007).  
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model of innovation, an assumption that a research project will necessarily lead to 
proposed goals which will then in turn have a beneficial impact on society 
(Frodeman and Parker, 2011), and that it also requires peer reviewers to determine 
what is considered a broader impact (Bozeman and Boardman, 2009). The aim of 
much of this work on BIC is to move away from the idea of the academic in an 
‘ivory tower’ (Bond et al., 2005) and towards the image of scientists engaging more 
with the lay public. This has called for more investigation to be done, not on the 
views of the public, but on the views of scientists and academics as they go about 
public engagement. A report by the Wellcome Trust (2001) found that scientists 
believed public outreach to be beneficial. Those interviewed, however, saw a lack of 
public understanding or interest, and a reliance on media output, as being some of the 
major hurdles to the communication of scientific work. Whilst over a half of those 
interviewed had been involved in some form of communication, few had any specific 
media or communication training and many felt ill-equipped to talk about the ethical 
or social aspects of their work (Trench and Miller, 2012).  
 
Other studies have shown similar results, for example Mathews et al. (2005) who 
interviewed geneticists about their role in public outreach. For the BloodPharma 
project involvement in public outreach was initially proposed by the University of 
Edinburgh, which wanted a research project to submit for a chance to exhibit at the 
prestigious Royal Society 350th Birthday Exhibition, and thereby promote the 
broader impact of research being undertaken by the University of Edinburgh. The 
BloodPharma project was chosen, with additional funding being awarded by the 
Wellcome Trust to put together an exhibition stand. Given the financial outlay it was 
decided that this exhibit could be taken to other science festivals and exhibitions.  
Therefore, like many other projects affected by the new reliance on BIC and 
outreach, we see a new generation of scientists who are made to engage with the 
public in ways which they previously did not. Researchers who perhaps before had 
little inclination to engage with the public are finding it increasingly hard to avoid. 
Despite the push by funding bodies to do outreach, a study by Andres et al. (2005) 
found that a desire to contribute was considered the top motivator, followed by 
enjoyment and thirdly by the opportunity to develop new skills. What is evident, both 
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from the literature and observation of the BloodPharma team, is that scientists are 
being increasingly pressed by funding bodies to step outside their comfort zone and 
to engage with the lay public. In doing so the scientists are learning new skills about 
communicating their work, and its moral, ethical and social implications, to a wider 
audience of non-experts.  
 
The introduction of new drugs and therapies involves not just the granting of a 
marketing authorisation but also an element of public willingness to accept the new 
therapy. In places such as the UK a decision must be made about whether a drug or 
therapy is acceptable to be used in NHS clinics and hospitals, based largely (but not 
solely) on a measure of economic factors. Indeed Jonsson et al. (2008) found that 
differing uptake rates of new therapies in different countries cannot be explained by 
health spending alone. Rather the disparities were found to reflect varying health 
spending priorities within different health care systems, with other factors including 
the incidence of specialist doctors within the population, and the reimbursement 
structure for prescribed medicines. Jones et al. (2001) write that the majority of 
decisions on implementing new therapies fell to clinicians, either at individual or at 
health board level. We should therefore acknowledge the autonomy that doctors have 
in getting new drugs (the literature is predominantly about pharmaceuticals) and 
therapies into clinical use, and the importance of early awareness and familiarity with 
a new product.  
 
Whether this autonomy extends as far as the patient is more debatable. Whilst 
advertising prescription drugs has been legal in the US since 1997 (Reast, 
Palihawadana et al., 2004) such adverts are currently not used in the UK, and such 
direct-to-consumer (DTC) advertising of prescription drugs is now considered to 
have a significant impact on the population in countries where such advertising 
methods are legal (Aikin, Swasy et al., 2004). Reast et al. (2004) found that doctors 
in the EU were against DTC advertising as they were concerned about a rise in 
patient visits to doctors (which is inconsistent with the findings of Aikin et al. above) 
and also about undermining the doctor’s role as the health care ‘specialist’. The 
authors however did note that the internet allows patients access to a wide variety of 
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information and advertising from pharmaceutical companies, regardless of the 
restrictions imposed on print media. Such studies however have predominantly 
interviewed publics about such therapies out of the context of a medical scenario, 
and therefore I would argue are unlikely to reflect the impact that public choice has 
on the uptake of new therapies in the clinic (and particularly in the emergency 
situations in which a patient may encounter the BloodPharma product). Nevertheless 
such literature shows the power of consumers to push for a new drug or therapy (and 
the opposite in the case of GM crops).  
 
A key driver of the BloodPharma outreach is to engage members of the public early 
on in the innovation of the cultured blood product. Figures often state that one in 
three individuals in the UK will receive a blood transfusion during their lifetime14. If 
this is correct, the origin of blood transfusion products should be of interest to most 
of the public. The BloodPharma team often articulated the desire that it wanted the 
public to be fully aware of the new product, and not to encounter the idea for the first 
time when they were in hospital requiring a transfusion. A focus on this early patient 
awareness may lead to long term benefits for the BloodPharma team, given the 
evidence which suggests that patient views can impact on the uptake of new 
therapies. 
 
The team were also aware of the publicity which was likely to surround the project 
and their use of embryonic stem cells:  
“I do think that there could be a lot of bad publicity about the embryonic 
source initially, which is why I think that although we need to set the 
paradigm using embryonic stem cells that eventually the real source 
might be different.” (CS/Lab) 
 
Although views differed on the impact that this media attention may have: 
                                            
14 This 1 in 3 figure is widely repeated on internet sites, however I can find no indication of 
how this is calculated. Some sources say this includes both blood and platelets, others just 
red cell transfusions. Of more importance though is the lack of clarification over whether this 
is calculated per individual patient, or if it represents the total blood transfusions carried out 
divided by the population of that country. Personally a figure of 1 in 3 appears rather high, 
given that in my circle of family and friends I know of only one person who has ever 
received a transfusion.  
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“You know, you wonder, I mean, people read the press but it goes in one 
ear and out the other doesn’t it? So I mean, some people go ‘oh I think I 
heard something about that, did I read something about that?’. Yeah, that 
was us.” (CS/Lab) 
 
There was however a desire to let people know about the BloodPharma project and 
for the scientists to be open and engaged with people outside the laboratory, 
presumably in an effort to overcome the mistrust in science which has often arisen 
from the public feeling they have been left in the dark concerning new scientific 
technologies. The input of the Universities and the Wellcome Trust was also in order 
to use this project as a demonstration of novel innovation and to publicise the 
excellent work being done amongst the scientific communities in the UK and Ireland.  
 
THE NATURE OF PUBLIC OUTREACH AND THE IMPACT OF ‘PUBLIC 
OPINION’ ON THE DEVELOPMENT OF THE SCIENCE AND 
TECHNOLOGY 
Public outreach has been an important part of the BloodPharma project and to this 
end the BloodPharma team has developed an interactive exhibit, consisting of a stand 
with interactive elements (detailed below). This exhibit has been taken to various 
science and career festivals, as shown in Figure 9. I am not generally comfortable 
with the term ‘general public’ and usually refer to specific ‘publics’. However for 
ease of use I use the term here to refer to open sessions, which generally attracted lay 
audiences of families, children, interested parties, general passers-by etc. I have tried 
to make clear where specific audiences, for example schools, were targeted.  
 
Accompanying the team to public events allowed me to take on the part of both 
observer and participant in the public outreach conducted by the team. Outside the 
scientific team I also used the BloodPharma case study when giving talks within 
schools as part of my role as a STEMNET15 Ambassador. This normally takes the 
form of using the BloodPharma project as a case study of stem cell use, at the end of 
                                            
15 STEMNET is an organisation which allows teachers to call on help from people employed 
in STEM subjects (science, technology, engineering and medicine). Stem ambassadors 




a presentation on stem cell techniques and ethical considerations more widely. A list 






 birthday festival (2010): A prestigious festival held at 
London’s South Bank, for which the BloodPharma project was selected to be one of 
the exhibitors.  
 
Figure 9: Public outreach undertaken by the BloodPharma team 
DATE EVENT NUMBERS 
ATTENDING 
TARGET AUDIENCE 
12/12/12 RCUK event in 
Westminster Parliament  
Not Available Parliamentatians and 
policy makers 
27/10/12 Exhibit at Genova 
Science Festival, Italy 
Not available Researchers, schools, 
families, general public 
23/07/12 SCRM Open Doors 
Event (part of wider 
Edinburgh Open Doors) 
366 General public 
30/06/12 Exhibit at Volvo Open 
Race (Ireland) 
800,000 people passed 
through area where stand 
situated 
General public  
01/04/12 – 04/04/12 Exhibit at Edinburgh 
Science Festival  
689 General public  
10/03/12- 11/03/12 Exhibit at Newcastle 
Science Festival  
1900 General public 
03/03/12 Family Science Day, 
Scotland  
250 General public  
13/06/11 Big Bang Fair, Scotland 300 Secondary School 
Students 
05/06/11 Glasgow University 
Science Festival Family 
Day 
100 General Public 
07/05/2011 Lymphoma Research 
Open Day, Edinburgh 
91 Patients and relatives 
09/04/11-22/04/11 Edinburgh Science 
Festival 
2,504 General public 
16/03/2011 ‘Let’s Talk’ Lecture 
Series, Edinburgh 
101 Academics, general 
public, schools 
10/03/11 – 12/03/11 Big Bang Fair, London 2,575 General public and 
schools 





13,000 to stand, 49,946 




Big Bang Fair (2011): A science fair at the London ExCel centre, which included 
exhibitors from Science, Technology, Engineering, and Medicine and had a strong 
focus on inspiring school pupils to future careers.  
 
Glasgow and Edinburgh Science Festivals (2011 and 2012): I did not attend the 
Glasgow Science Festivals, but did help at the Edinburgh Science Festivals, which 
were held at the National Museum of Scotland (2011) and Dynamic Earth (2012). Of 
note is that the Edinburgh Science Festival takes place during the school Easter 
holiday, impacting on the public who attend, as is discussed below.  
 
When accompanying the team to festivals I generally possessed enough knowledge 
about the project to talk to members of the public about the research and the general 
aims and objectives of the scientific project. I was also given the role of taking 
photographs and asking members of the public to fill in consent forms. This allowed 
me to take a step back from the project and to engage in conversations about the use 
of stem cells, or what the attendees thought more generally about the project and the 
display stand. On certain occasions an attendee with more scientific knowledge 
required information which I did not know, and in this case I handed them over to 
other members of the team. Being embedded in the project as ‘one of the team’ (to 
the views of the attendees at least) gave me a unique insight into both the views of 
the public and also those of the BloodPharma team as they took part in such 
outreach.  
 
.The exhibit which the team took to various festivals included: 
• Various backboards explaining the project and giving information about stem 
cells more generally 
• An interactive touch-screen kiosk which displayed various quizzes 
• A television screen displaying rotating slides about the cultured blood project 
• ‘Stem Cell Stella’ – a game which helped children to understand tissue 
differentiation using ball bearings, which they could direct down different human 
tissue lineages. Once they had created the ‘tissue’ of their choice they could then 
fit this into a model body.  
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• A table of laboratory equipment showing the flasks and containers used in stem 
cell culture 
• Bags of ‘blood’ (single unit donation bags filled with food colouring and glycerol 
etc.) and lengths of beads which represented the number of RBCs in the width of 
a hair.  
• Video microscope which allowed people to see the RBCs moving around the 
vessels under their tongue. Images were projected onto a large television screen.  
• Various display stands of leaflets, free gifts of squishy RBCs, pencils, and wrist 
bands, all with the website address on.  
 
This interactive exhibit allowed the BloodPharma team to promote their key 
messages (taken from the information sent to all demonstrators): 
Figure 10: Key messages of outreach  
1. We need more blood 
2. We can make blood from stem cells   
3. Stem cells have the potential to cure many diseases 
4. (This is exciting! Not really a message, but should come across in the way we 
present ourselves) 
 
These three key messages in Figure 10 have been cleverly designed by the project 
team to allow them to convey a lot of information in a clear format: 
• We need more blood – emphasising the importance of blood donation and of 
donors, whilst explaining one of the main needs for the cultured blood product. 
This point shall be discussed in more detail in the later section on the difficulties 
of foresight.  
• We can make blood from stem cells - introducing the BloodPharma project, its 
aims and project setup.  
• Stem cells have the potential to cure diseases – situating the BloodPharma project 
within the wider stem cell field. For example explaining about research into using 
stem cells for stroke treatments or to overcome paralysis. Many of the attendees 
may have heard of projects like these and could link the use of stem cells in these 





The microscope allowing attendees to see their own blood cells, along with the other 
props and literature, was focused on letting people know more about their own blood. 
The cultured blood product was then introduced as being indistinguishable from this 
donated blood, simply RBCs which are being made in the laboratory. This is a clear 
strategy for public engagement employed by the BloodPharma team, which sought to 
use in vivo donated blood as a way of capturing the attention of attendees. Most 
people were familiar with the shape of a RBC, or were aware of the work of the 
blood transfusion services, so this familiarity was used as a hook to interest people 
further in stem cell work. The project was very much placed as a continuum – the 
idea that we currently obtain RBCs from donors, but that in the future we may be 
able to obtain the same cells without these donors. In this way the focus was kept on 
the similarities between the donated blood and the cultured blood, reassuring 
attendees that the cultured blood would be just the same as the product that is 
currently used and that only the source is changing.  
 
Throughout the outreach events with the BloodPharma team there was an 
overwhelmingly positive response from the attendees who came to the exhibit. 
During the Royal Society Event approximately 13,000 people engaged with the 
BloodPharma exhibit, and the team reported only one objection to the use of 
embryonic stem cell research (this was the only objection that I was told about in the 
whole of the public outreach activities). This objection was from a woman who was a 
Catholic and had some reservations about the destruction of embryos for research 
purposes. She did however admit that in an emergency medical situation she would 
probably accept the cultured blood product.  
 
This perhaps reflects the types of people who came to such events, who were likely 
to be interested in science more broadly (given the wide range of the other exhibits 
on offer) and so this would have attracted fewer people with strong views than may 
have attended, for example, a debate specifically about embryo use in science. This 
is also interesting as it returns to my earlier point that many of the studies conducted 
with groups who object to a new technology are referring to hypothetical 
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circumstances, and the reality may be very different in a potentially life altering 
situation. The embryos used in the BloodPharma project are surplus from IVF, and 
many attendees were happy with this and felt that it was a positive thing that such 
embryos are put to good use rather than destroyed.  
 
It must be noted that despite the large amount of outreach done by the BloodPharma 
team it is likely that only a certain demographic of the population was reached during 
such events. The events did vary in attendees, for example the Big Bang science 
festival had a strong careers focus and so attracted a large number of schools. The 
Royal Society Exhibition was held at the South Bank and so perhaps had a larger 
amount of ‘passing trade’ than the other shows, although this tended to be a mix of 
tourists and those already attending a show at the Royal Festival Hall. I cannot 
comment on the Glasgow science festivals as I did not attend these. The Edinburgh 
festivals were held during the Easter holidays and so did not attract school groups, 
instead relying on parents or carers to bring children to these events. The majority of 
those who came were accompanying children, and also tended to be white, middle 
class and well educated..  
 
For many years public outreach was based on what has been termed the ‘public 
deficit model’, which assumed that if a public understood science then they would be 
more favourable towards it (Sturgis et al., 2004). This therefore led to a model of 
public outreach which assumed that, if a public was against a scientific innovation, 
that this was a failure of the scientific community to fully educate the public. Whilst 
writers such as Sturgis and Allum (2004) still see the value of knowledge in public 
attitudes towards science, it is now accepted that beliefs, and social interactions etc. 
also play a large part. The focus has therefore moved from giving facts to the public 
to a more interactive involvement between publics and scientists. This is often seen 
as the move from outreach to engagement, with ‘outreach’ implying the transfer of 
information from scientists to publics, and ‘engagement’ reflecting this more 




The distinction between outreach and engagement in the BloodPharma project 
became a subject of consideration for me when I presented the case study at the 2012 
Science in Public Conference. During the question session one of the audience 
members pointed out that I had used the term ‘outreach’ or ‘communication’ during 
my presentation, rather than ‘engagement’. The audience member seemed to be 
implying that as scientific communicators we no longer did ‘outreach’ or 
‘communication’, and that I should have been discussing how the BloodPharma team 
carried out ‘engagement’ with the public. For me this was an opportunity to reflect 
on the use of these various terms to describe the transmission of scientific knowledge 
in large scientific projects such as the BloodPharma project.  
 
Although the BloodPharma team have put a lot of time and effort into attending 
science festivals and interacting with the public it can still be argued that this has 
been restricted to presenting information to the public. Whilst the scientific team 
have entered into discussions with members of the public, this was mainly to explain 
the project and to answer queries from the attendees. The BloodPharma project has 
not yet engaged in focus groups or attempted to gather public opinion (other than on 
a superficial level during general conversation at exhibits). The intention thus far has 
therefore been to inform the public about the scientific project and its aims, and to 
direct the public to the additional sources of information (such as the project 
website). Considering the time, effort and expense which have gone into this 
endeavour I do not wish to imply that the BloodPharma team have been somehow 
lacking, indeed it has gone far beyond the public interaction of many scientific 
projects. I do however feel that this prompts a wider discussion about public 
interaction in larger scientific projects such as this.  
 
The BloodPharma project has now secured funding of £5.4 million and, as we have 
seen in previous chapters, has a scientific work plan which must be considered years 
in advance of the actual work. This raises the question that at what point should 
public views be taken into account? And which voices should be listened to? It feels 
somewhat naïve to expect a project of this size and momentum to change their work 
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practices because a member of the public has objected to the use of embryos, for 
example. Should such projects then seek public opinion before starting?  
 
This would return us to the earlier problem that garnering public opinion about a 
project that does not yet exist, and in a situation where their decision is not potential 
life altering, seems unlikely to yield accurate results. This point is echoed by Harmon 
et al. (2013) who write that attempting to engage publics during the formative 
scientific stage, when the social and ethical implications are not yet certain, is 
extremely difficult. Is the alternative option simply to not gather public opinion at 
all? If this project reaches clinical use then the individual can decide whether to 
accept the product or not. Does this option change if, in the case of something like 
the cultured blood product, not accepting the product could result in death? Does 
public opinion not matter so greatly when the technology is tucked away in a 
laboratory and not impacting on public lives, in stark contrast to technology such as 
wind turbines which gather public opinions simply due to their visibility? Perhaps 
the key is to move away from the engagement/communication distinction towards an 
appreciation of the capacity of engagement, as discussed by Parry et al. (2012). Their 
work using focus groups on issues related to stem cell research showed that 
‘engagement’ had many different meanings. Whilst engagement was considered to 
provide an opportunity for dialogue and contribution towards decision making, the 
provision of education and information was also found to be important. So instead of 
defending the use of ‘communication’, perhaps I should instead acknowledge that the 
BloodPharma team do carry out ‘engagement’, albeit focused primarily on the 
dissemination of information.  
 
The scientists on the BloodPharma project are aware that certain members of the 
community are unlikely to accept the cultured blood product, as we previously saw 
in Chapter Five: 
“So yeah, Italy, Spain, most of bible belt America, there’s enormous 
tranches of the world that wouldn’t consider it still now, let alone if it’s 
the only option, so no we’re going to have to find a different source for it 
eventually. And also just from pure practicality that making embryonic 
stem cells we don’t currently screen the embryos so we don’t know what 
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genotype they’re going to have, we don’t know what blood group they 
are.” (CS/Lab) 
 
The quote shows that the team would be willing to consider alternative methods of 
producing the product which would be more acceptable to the general public. 
However it is likely that the team will switch from embryonic stem cells to induced 
pluripotent stem cells due to reasons of patenting and increased screening ability, 
rather than primarily public opinion. Indeed throughout my data collection I saw no 
examples of incidences in which public opinion may shape the science and 
technology itself, the impact of public outreach appeared to be limited to an 
increased awareness amongst the scientists of potential concerns which the public 
may have. These concerns, however, appear to be limited to certain groups, as the 
quote above illustrates, and for example Jehovah’s Witnesses, a small minority of the 
overall target market.  
 
It would appear therefore that whilst the team have been heavily involved in public 
outreach there has been no discernable impact on the shaping of the technology 
itself. This shows that, although the nature of scientific work is changing to include a 
greater emphasis on engaging with the public, the outcome of this public engagement 
is less clear. In this case whilst public interactions may not change the technology in 
any way they could potentially alter the public perceptions and uptake of the cultured 
blood product many years down the line, but as yet it is too early to analyse the 
potential impact of this.  
 
 
THE SCIENTIST AS PUBLIC COMMUNICATOR: THE CHALLENGE OF 
PERFORMING UPSTREAM ENGAGEMENT FOR A NOVEL 
TECHNOLOGY  
The BloodPharma case study provides not only an example of a project creating 
public outreach opportunities but also allows observation of individual scientists as 
they carry out public communication. In this section I will draw on my work as a 
participant observer to discuss the role of the project team within these 
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communication events. The BloodPharma team provides an interesting case study as 
public events involved a large number of employees, from the Principal Investigators 
down to PhD students. Talking to the public was just one part of the festivals, as the 
scientists were involved in all aspects of the exhibitions. This included putting up 
and taking down stands, driving vans, crawling under tables to fix electronic 
equipment, administering first aid, restocking the display stands, and so forth. It was 
often hot, dirty and tiring, involving standing for long periods of time whilst 
maintaining enthusiasm for the project.  
 
One observation that I made during the course of these outreach events is that the 
scientific work on the project did not, or in many cases could not, stop. At the end of 
a long and tiring day talking to members of the public many of the researchers went 
back to work. At festivals where we were close enough to go home it was not 
unusual for a researcher to leave Edinburgh, travel back to Glasgow to arrive at the 
laboratory around 9pm ready to do a few hours work feeding and maintaining their 
cells. They would sometimes then pop into the laboratory again before returning to 
Edinburgh for 10am the next morning. The cells with which these scientists work 
require continual feeding and maintaining, often on a daily basis, and this often 
requires staff members to be in the laboratory at weekends and on Christmas Day. 
This aspect of scientists engaging with public outreach whilst also carrying out their 
scientific work seems to be under discussed in the literature, perhaps due to the 
nature of cell culture research which requires such regular intervention. The 
laboratories often operate rotas of staff to undertake necessary work on the cell 
cultures and even when the team were away in London and unable to return to their 
laboratories there was a continued sense of the laboratory work still going on, of staff 
who had been left behind to cope with the workload of others, or people anxious to 
know how their experiments were working. As much as the scientific team appeared 
to enjoy and become enthused by the public interactions, there was still a sense that 
they were being taken away from the work that they should be doing.  
 
It appears to be a common theme amongst scientists that they want to engage further 
with public outreach but feel unable, or unsupported in doing so. Mathews et al. 
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(2005) introduce a number of studies of scientists doing outreach, in which lack of 
time and lack of support from their employers or colleagues were cited as factors 
imposing on their ability to engage further with the public. Another consideration 
was the lack of professional recognition for public outreach, which echoes the 
feelings of researchers towards engaging with the regulatory system, as we saw in 
Chapter Five. The researchers involved in the public outreach often had little 
previous experience in working at science festivals or talking about their research 
with the lay public. Andrews et al. (2005) argue that the acquisition of new skills is 
one of the key motivators to becoming involved, and maintaining involvement in 
such activities. It is not clear if gaining new skills was a primary motivator for many 
of the BloodPharma team but it was apparent that they did develop considerable 
amounts of new knowledge during the time that they spent engaging with the public. 
Often one of the most difficult jobs is to distil complex research into a format which 
those with no scientific experience can understand. This can help researchers to focus 
on the important aims of their research, rather like writing an abstract forces one to 
pull out the primary messages from a complex study. Often at events it can be ‘basic’ 
questions asked by attendees which the scientists have no answers for. One example 
was that it was usual for researchers to explain that RBCs in the body are made in the 
bone marrow and then move out into the peripheral blood system. One attendee 
asked how the blood cells actually got out of the bone marrow, i.e. how they passed 
through the walls of the bone. Many of the researchers were stumped, and the answer 
had to be sought from a textbook.  
 
In cases such as this there was a notebook located on the display stand where team 
members could write down questions which they had been unable to answer, along 
with the contact details of the attendee. This allowed the team to look up answers 
later and email the member of the public who had raised the question. Although this 
was not used very often it did help to re-enforce an important message, which is that 
scientists do not know everything, but that an important aspect of science is that you 
can go away and find out the answer. The public seemed to appreciate this honesty 
and the desire of the team to answer questions on a more long term basis, not just 
forget about them once the festival was over. It would also become apparent over the 
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course of a day, and especially at longer festivals, that researchers would develop a 
sort of ‘script’, a spiel which they repeated when they spoke to members of the 
public. This often involved a process of trial and error, for example when it became 
apparent that the explanation they would have liked to give was too long or 
complicated to engage the interest of many of the visitors. It was also interesting to 
observe how the demonstrators picked up bits of script from somebody else, 
sometimes deliberately but often unconsciously after hearing somebody repeat it 
time and time again.  
 
Despite the need to explain the basic scientific work to the public it was also clear 
that the BloodPharma team could think on a more critical level about the ethical and 
social implications of their work. Many appeared to have an interest in the ethical 
arguments around stem cell use, and were keen to get into discussion with me about 
this. Many of the team had read the book about the HeLa cells (Skloot, 2010) (which 
had been on the best-seller lists at that time) and expressed astonishment that they 
had worked on this cell line themselves without knowing its provenance. Others had 
first hand experience of their own tissue being used without consent, and also talked 
of the ethical implications of using adult tissue which are often overlooked by the 
media and academic writers. Marks (2011) calls for more reflexivity on the part of 
stem cell researchers about the moral implications of their own work, and it would 
appear that the BloodPharma team is already engaged with such reflexive thinking.  
 
Tait (2009) writes that, whilst the impact of public-interest groups should not be 
underestimated, ‘upstream engagement’ must necessarily result in the restriction of 
some scientific innovations because debate must occur before all the evidence is 
available. Wilsdon et al. (2004) reiterate the movement over the last 20 years from 
education, to participation, and now to upstream engagement as methods of 
increasing the publics’ trust in science. The BloodPharma team is certainly carrying 
out upstream engagement well before the cultured blood product is expected to reach 
the clinic (which could be 20 years from now). Upstream engagement does, however, 
present a significant challenge to the BloodPharma team, due to its unique position in 




As previously mentioned one of the core messages of the BloodPharma public 
outreach at events was that we simply do not have enough blood from donations. 
This is true in the UK, and even more pressing in other countries which do not have 
an established donation system. It is interesting that the team do not specifically 
mention the benefits of the cultured blood to certain target groups (thalassemia/sickle 
cell patients for example) during their outreach work. It is possible that individual 
demonstrators told attendees about the potential benefits to these groups, but there 
was no reference to target groups in either the demonstrator notes or on the project 
website (other than a reference to ‘ensuring immune compatibility’ between patient 
and recipient, which would also apply to the wider blood transfusion population).  
 
In later discussions with members of the team they believed that much of the public 
outreach material had been written before the scientific meetings at which target 
groups were first identified. This is a shame as it would appear that the benefits to 
target groups are one of the main selling points of the cultured blood project, and 
would have been an ideal subject for public communication.  
 
Unfortunately one of the other considerations of the cultured blood project is 
contamination of current blood donations due to Transfusion-Transmissible 
Infections (TTIs). Statistically the chance of infection during a blood transfusion in 
the UK is extremely low, but there have been highly publicised infection outbreaks 
in the past, and added to this is the worry that the blood transfusion services can only 
test for certain infections which they know are present, and for which there are tests 
available. For example it is possible that disease such as vCJD could be more 
widespread than thought, or that there may be other diseases which we do not yet 
know about. The ability to produce ‘clean’ blood is therefore a major goal of the 
BloodPharma project. Unfortunately this provides the team with something of a 
dilemma regarding public outreach. It has always been important during public 
engagement not to put the public off donating or accepting donated blood, as the 
donation system will have to supply the blood services for many years before the 
cultured blood product can be used. The team therefore do not want to heavily focus 
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on the potential for infection risk, meaning that they cannot publicise one of the main 
benefits of the cultured blood product.  
 
Here we see another strategy of public outreach employed by the BloodPharma team. 
It prioritises certain aspects of the project when promoting to a wider audience. In 
this case the requirement to keep people donating and maintain trust in the current 
transfusion service is of primary significance, and this must be reflected in the 
messages used during public outreach. This balancing of a conventional therapy with 
the development of novel technology is perhaps a unique challenge of the 
BloodPharma project and may reflect more widely on the lack of public awareness 
about how long it takes a new therapy to be developed. It certainly represents a major 
challenge of carrying out upstream engagement and seeking to simultaneously 
promote a current technology and one which may be twenty years from clinical use.  
 
During the promotion of the cultured blood project the team had to ensure that it did 
not impact in any adverse way on the attitude of the public towards both donating, 
and receiving donated blood. Titmuss (1997) writes that “What seemingly lags far 
behind the imperative demand from medical science […] is the rate of ‘social 
growth’ in the form of adequate numbers of voluntary donors”. This is certainly the 
case in the UK, where only 4% of the population eligible to give blood do so 
(according to the website for the Blood Donation Service for England and North 
Wales, www.blood.co.uk).  
 
Recruitment of blood donors and maintaining adequate stocks of blood is a 
demanding task for the UK donation services. Much has been written, especially by 
Titmuss, of the social ‘gift’ which blood donation becomes, giving to a stranger in 
exchange for no discernable reward. The effect of this gift was certainly evident 
during outreach events with the team, as many of the attendees held a strong 
attachment to blood donation. Many attendees were blood donors and were very 
proud that they were able to donate blood. Some individuals even showed us 
keyrings or blood donation cards, which they had received for reaching a certain 




allowed to give blood, for example because they travelled regularly, were on certain 
medication or had received a transfusion themselves. Although in reality the research 
and transfusion arms of the blood services are very separate, attendees appeared to 
view us as able to speak for the donation teams and give them answers to why they 
had been turned away.  
 
Age was also a common factor brought up by life-long donors who had now been 
asked to stop giving, and were upset and disappointed that they could no longer 
continue donating. A couple of these previous donors said that they did not wish to 
stop giving as it made them feel healthier to give blood. There does not seem to be 
any medical justification for this, as RBCs renew constantly without blood loss, and 
giving blood can (among other things) adversely lower iron levels (Finch, Cook et 
al., 1977).  It would appear that this connection between blood donation and good 
health goes back to the idea of blood letting which was discussed in Chapter One, 
continuing the thought that removing blood somehow takes away old cells and forces 
the body to replenish this loss with new, healthier cells. This view was voiced by a 
small minority however, whilst most seemed to be attached to blood donation 
because it gave them a chance to help others, or because they considered it 
something that they ‘should do’ for the good of society. Others had relatives who had 
received transfusions and felt that they should donate, given that somebody had been 
kind enough to do it for their family member. Quite a few people had received 
transfusions themselves, and were incredibly grateful for those who had given blood 
for them. Due to the risk of transmission of CJD a person is banned from giving 
blood if they have received a blood donation, anywhere in the world, since 1st Jan 
1980 (UK Blood Transfusion Service, 2007). Although such people could no longer 
donate they had encouraged other friends and family members to become donors. 
Amongst the public it was clear that blood donation was an extremely emotive issue, 
raising considerations for the eventual public uptake of cultured blood in a society 
where people are incredibly attached to blood transfusion using donors.  
 
The media can be a powerful tool in upstream engagement and the BloodPharma 
project has already received media attention. Whilst the team is attempting to harness 
	

this valuable resource it can also have the problem of being difficult to control what 
reporters publish, opening up the possibility of inaccuracy. The BloodPharma team 
has focused on comparing the cultured blood product with real, in vivo, blood and do 
not wish the product to be associated with the synthetic alternatives which have 
previously received unsatisfactory public opinion. During outreach the team has been 
insistent that this product is cultured, not synthetic. Yet a quick look at the headlines 
of many of the articles written about the project shows that the word ‘synthetic’ is 
often used by the media. This would seem to be characteristic of the interactions 
between many scientists and the media, as seen in the overview by Lewenstein 
(1995). He writes that scientists are often very willing to engage with the media, but 
experience problems when the public dissemination of the research happens ahead of 
systematic peer review within the academic community. It will be crucial therefore in 
the coming years that the BloodPharma project maintains its scientific integrity, 




This chapter has revealed the main drivers and motivators behind the BloodPharma 
team engaging with public outreach, and has discussed how the scientists respond to 
their own role as public communicators. The BloodPharma team has the difficult 
challenge of promoting the novel technology of cultured RBC production, whilst 
simultaneously endorsing the current blood donation model. Their scientific method 
also uses embryonic stem cells, which have a history of public contention and 
unease. The team has therefore set out to do public outreach with many challenges, 
but also many benefits to harness. It has the backing of the Wellcome Trust and a 
large number of staff members to call upon. They also have a visually striking image, 
the RBC, which many people will recognise. The public are attached to blood 
donation and this helps to draw them in to learn more about the process of creating 
new blood substitutes.  
 
We have seen that the BloodPharma project team is driven and motivated by the 
desire to prevent public opposition to the new cultured blood technology, as had 
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occurred with other advancements such as GM crops. This was considered to be 
especially important given the use of embryonic stem cells and the attachment that 
the public have to donating blood, and to receiving blood products from donors. The 
team also has the support of the Wellcome Trust funding to take part in outreach 
activities. Increased pressure from funding councils is becoming more common and 
outreach from larger scientific projects looks likely to become the norm, with the 
dual outcome of this pressure to engage with broader impact criteria often serving to 
force scientists into becoming more involved with public outreach. This is evident in 
the BloodPharma team where many of the researchers had to take part in outreach 
events which may not have been their natural inclination. In common with the 
literature, however, many of the scientists found an unknown affinity with public 
communication and developed new skills and insights.  
 
Unlike many teams, who feel unsupported by their institutions to do outreach, the 
BloodPharma team was encouraged to take part in prestigious festivals as a way of 
boosting the reputation of the universities involved. There was also an understanding 
that they did not want the public to be faced with receiving a cultured blood product 
in an emergency situation, and instead wanted people to be aware of such technology 
well in advance of its introduction. This represented another driver to outreach, the 
hope that better understanding of the product by patients and doctors would lead to 
improved future uptake of the product.  
 
The second section introduced the outreach work that had been done by the 
BloodPharma team. Specifically their focus had been on promoting the cultured 
blood product as similar to in vivo blood, whilst still retaining the links with the 
promise of therapies from the wider stem cell field. Another primary aim was to 
show how blood is used within the medical community and the need for donors to 
supply this demand. In doing such outreach the BloodPharma team engaged with a 
wide number of publics, although it is evident that many of these events attracted 
families who are well educated and already interested enough to bring their children 




I also questioned the main aim of such outreach in light of the literature which 
emphasises the move towards ‘engagement’ rather than ‘outreach’. Whilst 
prioritising such two-way interaction is a heroic goal, I questioned how this is 
achievable with a structured scientific pathway and huge amounts of funding 
invested in this technology development. It seems uncertain in what context 
suggestions from the public could translate into a change in the product development.  
 
As part of my data collection using participant observation I was able to talk to many 
of those who attended such events, and there was overwhelmingly positive support 
for the BloodPharma project. I was also able to see first-hand the reactions of the 
BloodPharma team to carrying out such outreach, with many of them enjoying the 
activities and benefiting from the new skills learnt. It was also apparent that what is 
often missing from the literature is the struggle that these researchers have between 
the outreach and the ongoing laboratory project. This may especially be the case for 
stem cell research, where the cells must be constantly looked after, resulting in either 
delegating to other team members or to the researchers working long hours to fit in 
both the outreach and their day-to-day jobs. I have addressed how the team balance 
the difficult task of promoting the cultured blood product without hampering donor 
recruitment efforts. During outreach this has been achieved by focusing on the global 
need for blood, whilst downplaying the infection risk which is one of the key drivers 
for the whole BloodPharma project. The team have focused on the ‘cultured-ness’ of 
the blood product, attempting to remove it from any links to synthetic blood 
products. This effort has been hampered by the media , which has often referred to 
the product as synthetic. This highlights the challenge that scientific projects often 
face between promoting scientific truths to a media that seeks to attract readers using 
shock or scare tactics.  
 
In conclusion the use of participant observation has brought to my research an in-
depth knowledge of the outreach and public communication done by the 
BloodPharma team. In many ways the feelings of the researchers about doing such 
outreach tally with the views of those in the literature, although the use of such 
observation (rather than questionnaires) has allowed me to see the reactions of the 
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team members, even when they are at their most tired and frustrated. It is clear that 
the team members have enjoyed doing such outreach, even though they may not have 
sought out such opportunities in the past. Whether they have been successful in 
promoting their product and overcoming public unease will not be clear until many 
















CHAPTER 7: CONCLUSION  
This thesis has used an in-depth case study of the BloodPharma cultured blood 
project to investigate the early stage development of a novel stem cell therapy, an  
analysis which has enabled a prising open of the ‘black box’ normally surrounding 
the development of such therapies. This work has been about the important period of 
transition from an existing, well used, and publicly accepted technology to a new 
technology that may have huge consequences for patients and the current blood 
transfusion services. It is also the story of a team seeking to develop a clinical stem 
cell therapy in the face of uncertainty about future scale-up and regulation. In doing 
so this thesis has shown the changing nature of scientific work as it moves out of the 
laboratory space.  
 
The goal in this case study is ambitious; to eventually replace the entire blood 
donation system for the UK, and perhaps the rest of the world, with the extent of 
scale-up and manufacturing required making this a truly paradigm-breaking scientific 
research project. Blood is currently donated altruistically and tested, processed, 
fractionated and supplied to those who need it. In the future blood may be a stem cell 
product that reduces reliance on blood donors and supplies a continuous source of 
safe, standardised blood that is cultured in the laboratory. Cultured RBCs could 
potentially lead to a revolutionary change in the way that blood is produced, stored 
and distributed, as well as bringing additional benefits to patients.  
 
My work has investigated what an in-depth case study such as this can tell us about 
the development of stem cell therapies, and the hurdles and constraints which may 
shape and determine the innovation of new regenerative medicine based treatments. 
The work concentrated specifically on how scientists carried out early stage research 
and planned ahead for the future, and in doing so how they discussed and imagined a 
product that does not yet exist. The regulatory system has been analysed as an area of 
large uncertainty to teams developing such new innovations, and the role of public 
engagement introduced, with a focus on the scientific team stepping outside their 
area of expertise to engage with this lay audience. Whilst past research has 
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concentrated primarily on scientists within a laboratory situation my research has 
developed a more complete picture of the work and decision making involved in 
moving a therapy from early stage research to the clinic. This was achieved by 
focusing not just on laboratory observation, but by also incorporating interviews, 
data gathered from team meetings and teleconferences, and participant observation of 
public outreach events.  The findings from each of the main research questions will 
now be discussed, before the main conclusions for this thesis are presented.  
 
CONCLUDING THE MAIN RESEARCH QUESTIONS  
How is early stage laboratory work achieved through interdisciplinary, multi-
lab working, where standardisation of methods is difficult and where there 
exists an accepted technology?   
In Chapter Three we saw that the BloodPharma team carry out interdisciplinary 
research under a funding model which is very different from conventional research 
grants and which imposes regular milestones towards which the team must aim. This 
brings together not just biological scientists but also clinicians, regulatory advisors 
and public communicators, with the recent addition of physicists and engineers. This 
case study has therefore followed a team doing interdisciplinary work in practice, 
bringing together groups with a diverse range of expertise to tackle this large 
research challenge.    
 
The difficulty of standardising work across multiple laboratory sites was identified as 
one of the key challenges for the research teams. This difficulty of standardisation 
was seen to represent a key challenge of the stem cell world more broadly, where 
tacit knowledge plays an important role in the growth, research and maintenance of 
stem cell cultures. In the BloodPharma project standardisation will be crucial to 
achieve the future scale-up and potential automation required in order to supply the 
large volume requirements. Stem cell research requires a large amount of visual 
examination, which is dependent on the expertise and experience of the researchers. 
Here I have used diagrams prepared by the team as they attempt to explain such 
identification processes to other team members. Presentation slides are also used as 
an example of team members explaining their work to others in the wider team, who 
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work in a different disciplinary area. Tacit knowledge is seen here to be a big 
contributing factor towards the difficulty of standardising such research, especially of 
translating informal laboratory protocols into the ‘locked-down’ standardised 
protocols to be followed by the wider team.  
 
The biological properties of the RBCs have played a central role in the early stage 
laboratory work, as has the team’s use of the human body as an exemplar. A 
distinctiveness of the BloodPharma project is the presence of the already viable 
alternative of human blood donation, giving the team a visible target for early stage 
research. Using the human body as a benchmark the team have been able to mimic 
cues and conditions for RBC production in the laboratory. Such an examplar does 
raise further questions, however, about the importance of equivalence, especially the 
standard against which the regulatory system will measure the cultured red blood 
cells. As was seen in the example of foetal haemoglobin there may be an expectation 
to see an exact comparison between donated and cultured RBCs, even if this is not 
necessary for clinical function. The use of the human body as an exemplar was also 
considered in its relation to the natural / unnatural / synthetic distinction between 
cultured and donated blood. It is unclear if the language used will affect the 
regulation of such product, but ideas of ‘matter out of place’ show that the public 
uptake of such a product may be affected.  
 
Informal anticipatory activities in the BloodPharma product were found to occur as 
the team looked ahead to the eventual end product, a process necessary to manage a 
consensus and carry out interdisciplinary team work. Much of this anticipation 
referred to an expectation of the future regulatory requirements, which included 
using reagents and conditions which were hoped to give the cells the best 
provenance. Many expectations about future regulatory requirements were not 
conditions articulated by the regulators themselves but an attempt by the researchers 





What does the Team see as the key challenges associated with translating 
cultured blood into a viable clinical product and how do these shape everyday 
practices? 
Chapter Four saw the continuation of the work of the BloodPharma team as they 
considered the translation of their early stage laboratory research into a useable 
clinical product. We saw how the BloodPharma project can be seen as a continuation 
of historical work on blood donation, with the blood now moving away from human 
donation and into the realms of large-scale laboratory production, bringing with it the 
potential not only to negate the need for donors but also to produce blood in 
unlimited supplies.  
 
Supplying the entire UK Blood Transfusion Service (and potentially the world’s 
requirements) is the long term goal of the BloodPharma project, and the volumes 
demanded are currently unprecedented in the stem cell field. A large amount of 
translational work is required to move from the early stage laboratory research to a 
clinically acceptable product, with tacit knowledge and expertise representing one of 
the key challenges of future scale-up. Culture of laboratory produced RBCs still falls 
vastly short of the scale attained by the human body and scale-up to the numbers 
required to supply the UK Blood Transfusion service will demand a new industry 
and the development of sophisticated automation and cell sorting technologies. The 
BloodPharma team must anticipate future requirements and attempt to introduce 
scaleable protocols and develop the large bioreactors required, even when a small 
quantity of product cannot yet be produced in the laboratory. The team are aware of 
the huge translational challenge ahead and of the complex systems that will be 
required.  
 
Producing enough product to be used in clinical trials represents the first scale-up 
target. There is still uncertainty about the nature of the clinical trials that will be 
required for the BloodPharma product, and this is representative of uncertainty in the 
wider stem cell field about the appropriateness of current clinical trial regimes 
(particularly concerning the use of animal models) for the testing of stem cell 
therapies. The BloodPharma product is considered to have an unusual risk profile 
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compared to other stem cell products, given that the product does not have the same 
DNA transfer potential, or the same longevity, as other stem cell therapies. The 
ReNeuron trial is therefore used as an example of a stem cell therapy which is further 
down the clinical trials route, and which demonstrates a more ‘standard’ risk profile. 
Data from this ReNeuron trial show the complex interactions required between trial 
designers, clinicians, scientists and regulators in order to develop appropriate clinical 
trials. Although the trial pathway for the BloodPharma product is currently unclear 
its unusual biological properties are likely to introduce new considerations for the 
regulatory bodies.     
 
Introducing the cultured blood product in a stepping stone method allows the 
introduction of such blood to clinical usage, without the scale-up challenges required 
to supply the entire transfusion service. Target groups such as sufferers of sickle 
disease and thalassemia have been identified, as these patients are likely to benefit 
from cultured RBCs over and above the general population. Using such target groups 
would justify a higher initial cost for the BloodPharma product, as it could represent 
a significant improvement to the health and longevity of such patients. Further target 
markets identified include emergency patients, representing a cost saving compared 
to the around-the-clock infrastructure of the current blood transfusion services. 
Future potential changes have also been discussed by the team, such as the use of iPS 
cell technology, which would have advantages for biological reasons and for the 
patenting of the BloodPharma work.  
 
How does the regulatory system, and perceptions of risk, shape the activities of 
the BloodPharma team and the development of the cultured blood product, and 
what can this case study tell us more generally about the regulatory system for 
stem cell products? 
The regulatory system for stem cell research in the UK comprises a number of 
different regulatory bodies and has been built on a raft of existing legislation not 
primarily designed for stem cell derived products. The specific regulatory pathway 
for stem cells is still uncertain, and this uncertainty impacts on the work of the 




regulatory hurdles many years before these have been articulated by the regulators. 
The cultured blood product will be a ‘test case’ for the regulatory system as it will 
have the properties of not containing any nuclear DNA, but will also be produced 
and transfused in much higher quantities than most cell-based therapies. The risk 
profile of the product is therefore very different to other stem cell therapies.  
 
Comparisons with the ReNeuron stroke trial have shown that navigating the 
regulatory system can be a costly and time-consuming process for companies, 
although so far the BloodPharma team appears to have encountered few major 
problems with the system and is maintaining a good relationship with the regulators.  
There are clear indications that the regulation of stem cells is a two-way process, 
with awareness that the scientists hold the expertise to understand the risks and 
benefits of their own particular research. The regulatory bodies in such a fast moving 
field are dependent on interactions with researchers to consider future therapies 
which may call for a re-evaluation of particular regulatory requirements.  
 
Informal anticipatory activities are again a key method employed by the 
BloodPharma team in an attempt to plan their early stage work to anticipate future 
regulatory requirements, particularly concerning the long-term provenance of the 
cells. The scientists also use informal reasoning to draw on personal experiences or 
examples from the wider field in an attempt to understand the risks and complexity 
of stem cell regulation. The importance of expertise was a key theme in the 
interactions between the BloodPharma project and the stem cell regulatory system, 
with the BloodPharma team having an employee who deals with much of the 
regulatory paperwork and acts as the bridge between the regulators and the 
laboratory based scientists. The scientific researchers struggle to engage fully with 
the regulatory system which is outside their area of expertise, and this dedicated 
employee represents a means by which they can delegate regulatory responsibility.  
 
The lack of expertise in regulatory affairs was suggested as a barrier for innovation 
by academic researchers, who may lack the advice and financial foundations 




BloodPharma team who are in the position of having an understanding of both the 
laboratory, clinical and regulatory aspects of this project. It was suggested by 
members of the team that knowledge of regulatory requirements is a key skill 
missing from the scientific community more widely, and that increased efforts 
should be made to equip graduates with this wider range of expertise.  
 
What are the main drivers and motivators behind the BloodPharma team 
engaging with public outreach, and how do the scientists respond to their own 
role as public communicators?  
Public outreach has constituted an important part of the BloodPharma project and the 
team have carried out a variety of outreach activities. The BloodPharma team has the 
difficult dual challenge of promoting the novel cultured RBC technology, whilst still 
endorsing the current donation model. The history of public unease around the use of 
embryonic stem cells and the attachment to human donation has motivated the 
BloodPharma to engage with the public at an early stage of the research.   
 
Incidences such as GM crops have shown the importance of public acceptance of a 
new technology, and so the public outreach done by the BloodPharma team could be 
seen as a form of promotion of the new project. Such interactions between the public 
and scientists is becoming increasingly common as funders seek to prioritise Broader 
Impact Criteria. In common with many scientists most members of the BloodPharma 
team had not taken part in outreach activities before and found themselves 
developing new insights and skills through the outreach events. Although the 
literature reports scientists feeling unsupported in outreach, in this case the 
universities involved in the BloodPharma project actively encouraged public events 
as a way of promoting the research work. My own work as a participant observer 
became key to understanding the BloodPharma team’s outreach work, allowing 
interactions both with the team itself and with the public who attended outreach 
events. Even in a team supported in doing outreach there was still a struggle between 
the public outreach work and the day-to-day laboratory work, which is perhaps 
specifically associated with the daily demands of stem cell cultures, and which often 




the scientists and clinicians that they wanted patients to be aware of this new 
technology long before clinical use, in the hope of improving future uptake.  
 
A particular challenge of the cultured blood product is that the BloodPharma team 
must carry out upstream engagement whilst there is still an acceptable product in use. 
It is important that no promotion of the BloodPharma product should impact on the 
current donation system. This has led to the team focusing on the global 
requirements for blood whilst downplaying the reduced infection risk, which is seen 
as one of the key drivers for the introduction of cultured blood. Such public outreach 
was also an example of the scientists stepping outside their normal laboratory work 
and engaging with the public in an unfamiliar setting. Although for many of the 
scientists this represented a new area of work outside the laboratory it was apparent 
that many of them were very good at engaging with the public. The outreach work 
done by the team speaks more widely about the changing nature of scientific work, 
with more and more requirements for researchers to ‘work’ in areas outside the 
normal laboratory or office space.  
 
REVIEWING THE OVERARCHING RESEARCH QUESTION 
What can an in-depth case study of the BloodPharma project reveal about 
everyday scientific practice and the project management of a large research 
programme?  
The BloodPharma project represents a unique case study of innovation in the field of 
stem cell therapies and this in-depth case study has provided an insight into the 
practices of an interdisciplinary team, as it seeks to carry out the early stage 
laboratory work and translation required to bring a new therapy from initial idea to 
eventual target markets.  
 
Whilst building on previous work using laboratory studies this thesis is one of the 
first case studies to demonstrate the importance of ‘laboratory work’ moving outside 
the confines of the laboratory space. Here we see scientists engaging with the areas 
of regulation, innovation and public acceptance, and doing so in an interlinked way – 




impacting on future regulation, target markets and public outreach. A common theme 
is the increasing requirements for scientists to move outside their primary area of 
expertise and engage with the translation of therapies into clinical usage. Rather than 
the traditional view of the researcher shut away in the laboratory we see an 
appreciation that scientific work is about more than laboratory experiments. This 
does not simply mean that researchers are moving from the bench to the office and 
the ever increasing demands of computer based analysis, rather that they are moving 
into other areas outside the traditional research space.  
 
The requirement for laboratory workers to engage with the regulatory system is 
another example of scientists moving outside the laboratory, where scientists are 
increasingly finding that they are required to gain expertise in understanding the 
regulatory implications of their projects. This expertise is by no means trivial, with 
many of the researchers articulating that they do not have the time or background 
knowledge to engage fully with the regulatory documents. The findings presented 
here regarding the importance of expertise in the regulatory arena highlight the 
changing nature of laboratory work, and promote an increased awareness of the 
importance of scientists engaging with the regulatory documents. The BloodPharma 
team have been able to delegate this responsibility to a dedicated member of staff, 
but it is becoming apparent that younger researchers will be increasingly required to 
develop knowledge of the regulatory factors surrounding their research.  
 
For many of the BloodPharma team the use of public engagement represented 
another area of work with which they had to engage, and many found new or 
previously undeveloped skill sets in dealing with the public and in explaining their 
work to those outside the research sphere. The input of the Wellcome Trust and 
Edinburgh and Glasgow Universities in supporting such outreach mirrors a wider 
trend amongst research councils to encourage scientists to move out of the 
laboratories. What can be seen from the BloodPharma case study is that, in addition 
to requiring new skill sets, public outreach requires a large time commitment and 
financial investment. As a consequence of the outreach work some members of the 




ambassadors for STEMNET. This demonstrates that an appreciation of the role of 
public outreach, and the opportunity to carry this out in a supported way, has the 
potential to be developed by a scientist throughout their career. As interactions with 
lay audiences become increasingly required in large research projects the skills 
developed here will hopefully be of increased use to such scientists in the future. 
EuroStemCell (an organisation supplying information and educational resources 
about stem cells) have already expressed interest in the findings of this thesis and the 
lessons which can be learnt from the BloodPharma public outreach activities, 
particularly the unusual position of the team as a dual promoter of both a novel and 
an existing technology.  
 
This thesis is an in-depth case study of a ‘beyond-lab’ project, a study of scientific 
work moving outside the laboratory space. The BloodPharma project is an example 
of a scientific team engaging with a research, innovation and public outreach triangle 
in a way which emphasises the importance of this scientific work which takes place 
outside the laboratory. The triangle often includes the influence of policy on the 
translation of innovations to new therapies, and whilst it is a little early in the 
developmental pathway for policy to have been directly considered in relation to the 
cultured blood product, we can consider the use of public outreach as the first stages 
of engaging with public and policy influences outside the scientific community. The 
BloodPharma project represents a study in which the regulatory, innovation and 
public spheres have been considered as important influences since the inception of 
the project. In this way the project team has the opportunity to engage in two-way 
dialogue with the regulators and future policy makers, not simply being constrained 
by regulations but by having the opportunity to present the cultured blood project as 
a technology worthy of future regulatory discussion. The findings from this thesis 
should therefore act as an example of good working amongst an interdisciplinary 
team, who recognise the importance of all three points on the innovation triangle and 
seeks to build it into its everyday work. This is not to say that the BloodPharma 
project is an example of ‘perfect’ interdisciplinary work, however this case study acts 
as an example of a team carrying out an extremely ambitious project.  As large 




can be learnt from the BloodPharma team, with the aim of developing a smoother 
translation pathway for future stem cell therapies.  
 
The use of interdisciplinary working and expectations highlight the hurdles to be 
faced in the translation of such a large project into a clinically based stem cell 
therapy. Only the future will tell if the scale-up, regulatory and research streams of 
the project come together successfully to produce a cultured blood product for target 
markets, and eventually for the entire population.  
 
SUGGESTIONS FOR FURTHER WORK 
The findings from this in-depth case study of the BloodPharma project have shed 
new light on the innovation of a novel stem cell therapy and the potential challenges 
for translation, and these findings can contribute to further work in the area.   
 
Public acceptance for the project has so far been gathered through broad reaching 
outreach activities, however there is scope for a more detailed analysis of specific 
target groups. This would include patient groups such as thalassemia or sickle cell 
anaemia sufferers, who are expected to be the first target markets for the cultured 
blood product. Dialogue with these groups would provide further understanding of 
potential concerns about the BloodPharma product. These concerns could then be fed 
into further public outreach work in an effort to make the wider public more aware of 
Figure 11: Innovation/Regulation/Policy triangle 
 
The Innovation/Regulation/Policy 
triangle helps to explain the interlinked 
nature of translation for new 
bioscience innovations.  
This triangle is used to explain the 
outside influences which can impact 
on the development of new 
innovations, although the three 
corners of the triangle are sometimes 
labelled differently, for example 





the cultured blood product, and to attempt to allay concerns. Such a project is already 
being undertaken by myself, with other researchers at the ESRC Innogen Centre, as 
part of the continued funding for the BloodPharma project which is being supplied 
by the Scottish Funding Council. The natural/unnatural/synthetic distinction 
discussed in this thesis has already been highlight by the BloodPharma team as an 
important area of research to carry forward, in the context of the wording used to 
explain this cultured blood technology to the wider public.  
 
The use of tacit knowledge within stem cell work has been discussed in previous 
literature but this case study has contributed some practical examples of teams 
working to standardise work across different laboratory spaces. More work could be 
done gathering examples of standardisation methods from other projects, such as the 
use of pictures given in this thesis to help the researchers differentiate different types 
of cells. This could also be augmented by looking at incidences where 
standardisation has either worked well, or failed, and assessing how the expertise of 
the researchers has contributed to this. One example from the BloodPharma project 
would be the student who mistakenly identified mould patches as balls of cells. 
 
The BloodPharma project represents a niche case study within stem cell research and 
has contributed to a wider understanding of the field because it highlights 
exceptional considerations and risk profiles. The use of the ReNeuron study as an 
example of a stem cell therapy slightly further down the regulatory pathway has also 
allowed a view of what may be in store for the future of the BloodPharma project. As 
more therapies start to be developed there will be the ability to add more case studies 
to this project, and also to revisit the BloodPharma project further down the line. 
This will allow us to see whether the speculation of the researchers about future 
regulatory concerns came true, and how the regulators responded to the unique risk 
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Figure 12: Interim regulatory route map for stem cell research and manufacture  
Showing the complexity of the regulatory system in the UK. This version of the map has now been 












Figure 13: Additional outreach work  
Detailing some of my additional outreach work in my role as an Ambassador for STEMNET 
01/11/11 
Spoke about the cultured blood 'Vampires and 
Vegetarianism in the 21st Century' at the ESRC 
festival of social science. 
 
March 2011 
Took part in 'I'm a Scientist Get Me Out of Here' in the 
Stem Cells section. 
29/01/11 
Internal SSU seminar on the history of blood transfusion 
and its development into a stem cell derived product. 
 
Autumn 2010/Spring 2011 
Assisted a 6th form student doing a Baccalaureate 
project on public reactions to embryonic stem cell use. 
 
04/11/10 
I went to speak to a small group of medicinal students at 
the University of Edinburgh about ethics of stem cells as 
part of a wiki based project on stem cell therapies. 
 
02/11/10 
Organised a lesson for a local school about stem 
cell research, ethics, regulation and the BloodPharma 
project, along with one of the lab based post-docs. 
 
Other: A career day with a school in Edinburgh, and helped at a 
‘Dance your Genome’ workshop 
